,headlines,raw_links
0,Moderna looks to scale back COVID vaccine manufacturing: report,https://www.fiercepharma.com/pharma/moderna-looks-scale-back-manufacturing-covid-booster-cope-falling-demand-reuters
1,CDC starts push to reverse falling flu vaccine use in key groups, https://www.fiercepharma.com/pharma/cdc-starts-wild-mild-campaign-reverse-falling-flu-vaccine-use-key-groups
2,Japan awarded $115M to Arcturus JV to boost mRNA manufacturing, https://www.fiercepharma.com/manufacturing/japan-awards-115m-arcturus-jv-boost-mrna-manufacturing
3,"BioNTech, Twitter warned for trying to duck vaccine debate", https://www.fiercepharma.com/marketing/biontech-and-x-warned-pr-body-trying-duck-covid-19-vaccine-debate
4,AstraZeneca signs mRNA manufacturing deal with China's CanSino, https://www.fiercepharma.com/manufacturing/astrazeneca-commits-mrna-signs-vaccine-manufacturing-deal-chinas-cansino
5,BioNTech 'carefully watching' costs as COVID vaccine sales sink, https://www.fiercepharma.com/pharma/echoing-pfizer-biontech-carefully-watching-cost-amid-declining-covid-vaccine-sales
6,UPDATED: Takeda yanks FDA application for dengue vaccine Qdenga, https://www.fiercepharma.com/pharma/takeda-yanks-fda-application-dengue-vaccine-citing-data-collection-disagreement
7,Canada pays Novavax $350M for canceled COVID shot orders, https://www.fiercepharma.com/manufacturing/novavax-receive-350m-canada-canceled-covid-vaccine-orders
8,"Fingerpaint buys MYND for market access skills, vaccine pedigree", https://www.fiercepharma.com/marketing/fingerprint-spying-growing-vaccine-market-buys-mynd-expand-market-access-capabilities
9,Sanofi begins construction of another flu vaccine plant, https://www.fiercepharma.com/manufacturing/sanofi-barda-break-ground-another-flu-shot-plant-swiftwater-pa-campus
10,Pfizer wants payment from EU for undelivered vaccine doses: FT, https://www.fiercepharma.com/pharma/pfizer-adjusts-eu-vaccine-deal-still-wants-payment-undelivered-doses-ft
11,Pfizer enlists yet another celeb for its latest COVID vaccine ad, https://www.fiercepharma.com/marketing/pfizer-targeting-younger-demographic-enlists-yet-another-celeb-its-latest-covid-vaccine
12,NYT sues EC for failing to reveal texts with Pfizer CEO Bourla, https://www.fiercepharma.com/pharma/new-york-times-sues-ec-over-failure-reveal-text-messages-pfizer-ceo-bourla
13,"JPM: GSK's Miels talks RSV and mRNA vaccines, oncology setbacks", https://www.fiercepharma.com/pharma/jpm23-conversation-gsks-luke-miels-rsv-and-mrna-vaccines-blenrep-and-zejula-withdrawals-plus
14,2022 drug approvals: Biopharma delivered 37 new drugs, https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
15,"Vaccine patch passes clinical test, supporting further trials", https://www.fiercepharma.com/pharma/vaxess-flu-vaccine-patch-passes-early-clinical-test-clearing-path-further-development
16,Vaxxas raises $23M to fund needle-free COVID-19 vaccine trial, https://www.fiercepharma.com/pharma/vaxxas-raises-23m-fund-needle-free-covid-19-vaccine-trial
17,LTS Lohmann leads investment in needle-free delivery specialist, https://www.fiercepharma.com/pharma/lts-lohmann-leads-investment-needle-free-delivery-specialist
18,Moderna pads the case for its bivalent COVID-19 booster, https://www.fiercepharma.com/pharma/modernas-omicron-busting-covid-19-booster-holds-its-own-against-latest-variant-bq11
19,Novartis sells Singapore plant to BioNTech for vax production, https://www.fiercepharma.com/manufacturing/biontech-acquires-novartis-plant-singapore-will-retrofit-mrna-vaccine-production
20,Healthcare Twitter influencers beam over Pfizer's RSV shot data, https://www.fiercepharma.com/marketing/healthcare-twitter-influencers-beam-over-pfizers-rsv-shot-data
21,"Pfizer, GSK prep for battle in the world's first RSV vax market", https://www.fiercepharma.com/marketing/pfizer-gsk-prep-battle-they-look-create-worlds-first-ever-rsv-vaccine-market
22,FDA signs off on Novavax COVID-19 shot for booster use, https://www.fiercepharma.com/pharma/novavax-scores-covid-19-booster-nod-key-eligibility-mrna-vax-recipients
23,FDA approves single-vial version of GSK's Menveo vaccine, https://www.fiercepharma.com/pharma/fda-approves-single-vial-version-gsks-menveo-vaccine-ending-need-reconstitution
24,The top 10 vaccine companies worldwide, https://www.fiercepharma.com/pharma/top-10-vaccine-companies-worldwide
25,"Pfizer, BioNTech enlist Marvel's Avengers in COVID booster push", https://www.fiercepharma.com/marketing/pfizer-biontech-enlist-marvels-avengers-latest-covid-19-vaccine-booster-push
26,"Valneva, IDT Biologika end COVID vaccine deal as demand slides", https://www.fiercepharma.com/manufacturing/valneva-idt-biologika-end-covid-vax-deal-demand-slides
27,Moderna is seeking manufacturing site in Japan: report, https://www.fiercepharma.com/manufacturing/moderna-ceo-bancel-wants-build-plant-japan-pending-long-term-vaccine-deal-report
28,Biovac produces first batch of Pfizer vaccine doses: report, https://www.fiercepharma.com/vaccines/south-africas-biovac-produces-first-pfizer-covid-19-doses-bloomberg-reports
29,Takeda's dengue vaccine nod in Indonesia is the first of many, https://www.fiercepharma.com/vaccines/watershed-moment-takeda-first-dengue-fever-approval-after-over-decade-research
30,AstraZeneca CEO Soriot questions value of boostersâ€”for some, https://www.fiercepharma.com/pharma/astrazeneca-ceo-soriot-says-covid-booster-shots-are-not-good-use-taxpayer-money
31,Takeda's dengue fever vaccine approved in Indonesia, https://www.fiercepharma.com/vaccines/takedas-dengue-fever-vaccine-picks-first-nod-indonesia
32,US adds monkeypox meds while Bavarian Nordic ups capacity, https://www.fiercepharma.com/pharma/us-increases-supply-monkeypox-meds-while-bavarian-nordic-bolsters-supply-capability-through
33,"Pfizer shows key data, setting up pediatric nod for Prevnar 20", https://www.fiercepharma.com/pharma/playing-catch-merck-pfizer-shows-data-could-fetch-prevnar-20-key-approval-babies
34,GSK to supply 12 European countries with pandemic influenza shot, https://www.fiercepharma.com/pharma/latest-pandemic-preparedness-move-gsk-inks-deal-ec-supply-12-european-countries-85-million
35,Bavarian Nordic gets regulatory nods to make monkeypox vax, https://www.fiercepharma.com/manufacturing/bavarian-nordic-gets-regulatory-nods-make-monkeypox-vax-danish-facility
36,Valneva shares slide in wake of EU COVID contract vax slash, https://www.fiercepharma.com/manufacturing/valneva-shares-slide-wake-eu-covid-contract-vax-slash
37,Bavarian Nordic inks yet another Jynneos deal, https://www.fiercepharma.com/vaccines/bavarian-nordic-secures-another-deal-undisclosed-european-country-15-million-jynneos-doses
38,U.S. orders another 2.5 million doses of Jynneos vaccine, https://www.fiercepharma.com/vaccines/bavarian-nordic-inks-another-deal-supply-us-25-more-jynneos-doses
39,Novavax's U.S. COVID-19 vaccine authorization has arrived, https://www.fiercepharma.com/pharma/novavax-long-last-clinches-fda-emergency-nod-protein-based-covid-shot
40,"Alnylam accuses Pfizer, Moderna of infringing a second patent", https://www.fiercepharma.com/pharma/same-day-patent-was-granted-alnylam-claims-pfizer-moderna-infringed-it-making-covid-19
41,CureVac sues BioNTech for infringement on its mRNA technology, https://www.fiercepharma.com/pharma/after-its-own-vaccine-flop-curevac-sues-biontech-infringement-its-development-comirnaty
42,BioNTech opens ambitious African manufacturing push, https://www.fiercepharma.com/pharma/rwanda-biontech-begins-construction-vaccine-manufacturing-initiative-africa
43,Merck's Prevnar rival snags key pediatric nod, https://www.fiercepharma.com/pharma/key-pediatric-nod-mercks-vaxneuvance-its-game-pfizer
44,Both sides blast WTO's patent waiver for COVID vaccines, https://www.fiercepharma.com/pharma/wtos-patent-waiver-covid-vaccines-political-stunt-phrma-says
45,"Moderna, Pfizer vaccines score FDA nod for kids 6 months and up", https://www.fiercepharma.com/pharma/fda-signs-pfizer-moderna-covid-19-vaccines-kids-6-months-and-older
46,A lack of African J&J vaccine orders marks a 'financial failure', https://www.fiercepharma.com/pharma/jjs-production-partner-aspen-no-orders-its-covid-19-shot-warns-lack-demand-sends-incredibly
47,Merck appeals to parents of 9-year-olds in latest HPV ad, https://www.fiercepharma.com/marketing/gardasil-vaccine-maker-merck-appeals-parents-9-year-olds-latest-hpv-awareness-ad
48,"Europe delays Pfizer, BioNTech COVID vaccine deliveries", https://www.fiercepharma.com/pharma/pfizer-biontech-tweak-covid-shot-delivery-timing-europe-bloc-gears-potential-booster
49,Low COVID shot demand is weighing on a Pfizer partner: report, https://www.fiercepharma.com/pharma/another-covid-19-manufacturing-partner-time-pfizers-biovac-warns-production-slump-amid-low
50,Moderna hits back in one of several COVID vaccine patent suits, https://www.fiercepharma.com/pharma/moderna-mounts-defense-covid-19-vaccine-patent-feud-arbutus-genevant
51,COVID vaccine prospects in the back half of 2022 remain unclear, https://www.fiercepharma.com/pharma/biontech-trumpets-strong-first-quarter-pandemic-uncertainty-still-suggests-revenue-decline
52,FDA limits the use of the J&J vax because of blood clot threat, https://www.fiercepharma.com/pharma/back-where-it-started-fda-restricts-use-johnson-johnson-covid-19-vaccine-because-blood-clot
53,Moderna warns people may be under-vaccinated against COVID-19, https://www.fiercepharma.com/pharma/moderna-tunes-booster-pitch-ahead-potential-shift-endemic-covid-19-market-fall
54,Astorg has picked up ascendant manufacturer CordenPharma, https://www.fiercepharma.com/pharma/cordenpharma-part-germanys-mrna-contingency-plan-sold-private-equity-outfit-astorg
55,"GSK soars on Shingrix, COVID-19 antibody", https://www.fiercepharma.com/pharma/glaxosmithkline-soars-shingrix-covid-19-antibody-oncology-lags
56,Analysts expect an autumn rebound after COVID vax sales slump, https://www.fiercepharma.com/pharma/after-slump-covid-19-vaccine-market-will-regain-its-legs-later-year-analysts
57,Sanofi tees off work on its next-gen vaccine plant in Singapore, https://www.fiercepharma.com/pharma/sanofi-revs-work-eu400m-vaccine-factory-future-just-one-two
58,Novavax could still reap $5B in 2022: analyst, https://www.fiercepharma.com/pharma/novavax-fashionably-late-covid-19-vaccine-party-could-still-hit-5b-sales-forecast-2022
59,"J&J reduces revenue forecast for 2022, dropping vaccine sales", https://www.fiercepharma.com/pharma/johnson-johnson-after-weak-quarter-vaccine-sales-will-no-longer-include-it-guidance
60,COVAX countries are rejecting AstraZeneca COVID vaccines, https://www.fiercepharma.com/pharma/poor-countries-are-declining-covid-19-vaccines-astrazeneca-because-shorter-shelf-life
61,Valneva wins nod in U.K. for its COVID-19 vaccine, https://www.fiercepharma.com/pharma/latecomer-valneva-scores-approval-covid-19-vaccine-uk-can-shot-find-its-niche
62,Merck escapes marketing complaints on shingles shot Zostavax, https://www.fiercepharma.com/pharma/merck-evades-aggressive-marketing-claims-tied-once-dominant-shingles-vaccine-zostavax
63,Analysts dial back Pfizer COVID-19 sales estimates for Q1, https://www.fiercepharma.com/pharma/pfizers-first-quarter-haul-could-come-light-analysts-flag-overambitious-paxlovid-and
64,Moderna and Rovi face fresh COVID-19 vaccine contamination woes, https://www.fiercepharma.com/pharma/moderna-recalls-covid-19-vaccine-batch-over-foreign-body-found-cdmo-made-vial-again
65,Catalent to spend $160M to finish building UK facility, https://www.fiercepharma.com/pharma/catalent-spending-160m-complete-construction-uk-biologics-plant
66,Pfizer and Moderna's execs split on need for 4th dose, https://www.fiercepharma.com/pharma/top-pfizer-moderna-execs-odds-need-fourth-covid-19-vaccine-dose
67,Moderna CEO Bancel has a separation package worth $926 million, https://www.fiercepharma.com/pharma/moderna-ceo-bancel-will-have-soft-landing-his-golden-parachute-926-million
68,Curia inks deal with US agencies to supply injectables, https://www.fiercepharma.com/manufacturing/curia-inks-deal-us-agencies-supply-injectables
69,"Cytiva opens Welsh production plant, part of $1.5B expansion", https://www.fiercepharma.com/manufacturing/cytiva-opens-welsh-production-plant-part-15b-expansion-plans
70,Former Warp Speed official Mango talks vaccine manufacturing, https://www.fiercepharma.com/pharma/upcoming-insider-book-operation-warp-speed-mango-discusses-why-vaccine-manufacturing-goal
71,Aspen clinches deal to make and deploy J&J COVID shot in Africa, https://www.fiercepharma.com/pharma/johnson-johnson-locks-vaccine-licensing-deal-aspen-teeing-africas-first-local-covid-19-shot
72,Moderna will enforce mRNA patents in high-income countries, https://www.fiercepharma.com/pharma/moderna-will-provide-access-technology-spikevax-high-income-countries-will-have-pay
73,Moderna faces a patent infringement suit tied to its COVID shot, https://www.fiercepharma.com/pharma/moderna-headed-court-after-arbutus-genevant-call-infringement-patents-related-covid-19
74,2021 drug approvals: Biopharma delivered 55 new drugs, https://www.fiercepharma.com/special-report/2021-s-new-drug-approvals
75,CDC vaccine advisers recommend mRNA vaccines over J&J shot, https://www.fiercepharma.com/pharma/citing-risk-potentially-deadly-blood-clots-cdc-vaccine-advisors-recommend-mrna-pandemic
76,Pfizer's COVID vaccine set to pump $25B sales as late as 2027, https://www.fiercepharma.com/pharma/peak-sales-for-pfizer-s-covid-19-franchise-now-between-50b-60b-2027-vax-sales-at-25b
77,FDA approves AstraZeneca antibody for COVID-19 prevention, https://www.fiercepharma.com/pharma/astrazeneca-scores-approval-for-its-covid-19-antibody-cocktail-a-substitute-for-vaccination
78,"Omicron can partially evade Pfizer, BNT vaccine, companies say", https://www.fiercepharma.com/pharma/pfizer-biontech-say-vax-less-resistant-to-omicron-but-booster-can-restore-protection
79,Hilleman unveils vaccine R&D and manufacturing hub in Singapore, https://www.fiercepharma.com/manufacturing/merck-s-hilleman-laboratories-tees-up-58m-investment-at-new-singapore-vaccine-hub
80,"With omicron fears rising, BioNTech CEO Sahin urges for calm", https://www.fiercepharma.com/pharma/biontech-ceo-sahin-urges-calm-while-saying-much-remains-unknown-about-covid-omicron-variant
81,Sanofi aims to double vaccine sales by 2030, https://www.fiercepharma.com/vaccines/sanofi-aims-to-double-vaccine-sales-by-2030-citing-rsv-and-flu-market-expansion-as-key
82,FDA approves VBI's PreHevbrio just as HBV market is set to grow, https://www.fiercepharma.com/pharma/for-vbi-vaccines-timing-right-as-fda-nod-for-its-hepatitis-b-shot-comes-as-market-set-to
83,"Moderna, Regeneron warn new meds may be needed against omicron", https://www.fiercepharma.com/pharma/regeneron-moderna-warn-their-covid-19-treatments-may-not-work-against-omicron-variant
84,"T-cells give AZ's vax longer duration of protection, CEO says", https://www.fiercepharma.com/pharma/astrazeneca-ceo-soriot-says-its-covid-19-vaccine-superior-to-mrn-shots-preventing
85,Pfizer COVID-19 shot aces long-term test in 12-15 year-olds, https://www.fiercepharma.com/pharma/pfizer-biontech-ace-long-term-test-covid-19-shot-kids-12-15-setting-up-full-approval
86,Pfizer projects 2021 revenue at $81-$82 billion this year, https://www.fiercepharma.com/pharma/pfizer-ups-2021-covid-19-vaccine-sales-projection-to-36-billion-remains-coy-about-future
87,Lilly reveals $1.3B supply deal with US for COVID antibodies, https://www.fiercepharma.com/pharma/once-sidelined-eli-lilly-s-covid-19-antibody-treatment-comeback-trail-supply-agreement-u-s
88,FDA authorizes Pfizer COVID-19 vaccine for kids 5-11 years, https://www.fiercepharma.com/pharma/fda-approves-pfizer-covid-19-vaccine-for-kids-age-5-11-cdc-will-meet-next-week-to-sign-off
89,Takeda's Japan plant reemerges from FDA warning letter, https://www.fiercepharma.com/pharma/takeda-s-japan-plant-reemerges-fda-warning-letter-covid-vaccine-pharma-pipeline-setbacks
90,FDA panel sets up Pfizer's COVID-19 vaccine for approval in kids, https://www.fiercepharma.com/pharma/fda-panel-recommends-pfizer-covid-19-vaccine-for-kids-5-11-setting-it-up-for-approval
91,Pfizer COVID-19 vax data sets shot up for approval in kids 5-11, https://www.fiercepharma.com/pharma/pfizer-biontech-covid-19-vaccine-data-shows-shot-safe-effective-kids-age-5-11-setting-up
92,"Boosters a go for Moderna, J&J; FDA also backs mix and match", https://www.fiercepharma.com/pharma/fda-approves-moderna-johnson-johnson-covid-19-boosters-also-backs-mixing-and-matching
93,"Stelara, Tremfya, Darzalex fuel strong 3rd quarter for J&J", https://www.fiercepharma.com/pharma/johnson-johnson-ups-annual-guidance-strength-oncology-immunology-drug-sales
94,FDA set to endorse the interchangeability of COVID-19 boosters, https://www.fiercepharma.com/pharma/fda-ready-to-bless-mixing-and-matching-covid-19-vaccines-as-boosters-report
95,"FDA delays Moderna shot for 12-17 year-olds, report says", https://www.fiercepharma.com/pharma/fda-delays-nod-for-moderna-s-covid-19-vaccine-12-17-year-olds-because-myocarditis-concerns
96,"COVID vax market will reach $124 billion in 2022, says Airfinity", https://www.fiercepharma.com/pharma/pfizer-moderna-will-rake-a-combined-93-billion-next-year-covid-19-sales-says-analytics-group
97,FDA advisors conclude J&J vaccine should be a two-shot series, https://www.fiercepharma.com/pharma/fda-panel-backs-a-second-shot-johnson-johnson-s-covid-19-vaccine-but-don-t-call-it-a-booster
98,Moderna recommendation mirrors Pfizer booster EUA last month, https://www.fiercepharma.com/pharma/fda-advisors-recommend-moderna-vaccine-to-be-used-as-a-booster-for-elderly-immuno
99,J&J vax recipients see higher antibody counts with mRNA shots, https://www.fiercepharma.com/pharma/johnson-johnson-covid-19-vax-recipients-get-more-protection-from-moderna-pfizer-boosters
100,Moderna says it won't share vaccine recipe with poor nations, https://www.fiercepharma.com/pharma/once-a-feel-good-story-moderna-now-facing-criticism-for-covid-19-vaccine-strategy
101,Pfizer asks for FDA authorization of COVID shot for kids 5 to 11, https://www.fiercepharma.com/pharma/pfizer-requests-nod-for-covid-19-shot-kids-5-11-but-convincing-parents-might-be-a-tough-sell
102,Trial gives further support for co-administration of vaccines, https://www.fiercepharma.com/pharma/trial-shows-sanofi-s-fluzone-and-moderna-s-covid-19-shot-perform-same-when-given-same-doctor
103,Merck's antiviral for COVID won't affect vaccines in short term, https://www.fiercepharma.com/pharma/merck-s-molnupiravir-will-be-complementary-but-not-a-competitor-to-covid-19-vaccines-analyst
104,Merck's Vaxneuvance makes its case for FDA approval in children, https://www.fiercepharma.com/pharma/trial-data-could-push-merck-s-next-gen-vaxneuvance-closer-to-approval-for-kids-and-pose-a
105,Pfizer's Prevnar 20 can be administered with a flu shot: study, https://www.fiercepharma.com/vaccines/pfizer-s-next-gen-prevnar-20-can-be-administered-a-flu-shot-study-finds
106,Pfizer subsidiary says material is undissolved vax substance, https://www.fiercepharma.com/pharma/floating-material-found-pfizer-covid-19-vaccine-vials-japan-but-company-says-it-s-not
107,J&J's Ebola shot excels as part of vaccine combo in trial, https://www.fiercepharma.com/pharma/strong-trial-data-johnson-johnson-bavarian-nordic-a-step-closer-to-who-approval-for-ebola
108,Sinovac said in talks to build vaccine facility in South Africa, https://www.fiercepharma.com/manufacturing/sinovac-said-talks-to-build-vaccine-facility-south-africa
109,"Key FDA officials, global scientists refute COVID booster need", https://www.fiercepharma.com/pharma/two-key-departing-fda-officials-who-refute-need-for-covid-19-boosters-as-white-house-plans
110,EMA warns of rare nerve disorder as side effect of AZ vaccine, https://www.fiercepharma.com/pharma/astrazeneca-s-covid-19-shot-joins-list-vaccines-flagged-for-rare-guillain-barre-syndrome
111,"GSK, Pfizer and J&J race toward $10B-plus RSV market: analyst", https://www.fiercepharma.com/vaccines/gsk-pfizer-and-johnson-johnson-race-toward-10b-rsv-vaccine-market-analyst
112,Moderna taps National Resilience for COVID vax production duties, https://www.fiercepharma.com/pharma/moderna-taps-national-resilience-s-new-canadian-manufacturing-site-for-covid-19-vaccine
113,Novavax-Takeda reveal plans to provide 150M doses to Japan, https://www.fiercepharma.com/pharma/confidence-waning-moderna-vaccine-japan-takeda-reveals-plans-vaccine-partnership-novavax
114,AstraZeneca strikes COVID-19 vaccine delivery deal with EU, https://www.fiercepharma.com/pharma/astrazeneca-strikes-covid-19-vaccine-delivery-deal-europe-ending-month-s-long-legal-battle
115,U.S. will spend $2.7 billion to bolster vaccine manufacturing, https://www.fiercepharma.com/pharma/response-to-recent-criticism-u-s-will-spend-2-7-billion-vaccine-manufacturing
116,J&J doses shipped from South Africa to Europe will be sent back, https://www.fiercepharma.com/pharma/j-j-covid-19-vaccines-shipped-from-south-africa-to-europe-to-be-sent-back-as-aspen-looks-to
117,Moderna IDs source of particulates amid new contamination report, https://www.fiercepharma.com/pharma/amid-another-report-contaminants-japan-moderna-s-covid-19-vaccine-faces-increased-scrutiny
118,"Merck, Amgen test double-digit drug price hikes: analysts", https://www.fiercepharma.com/pharma/merck-amgen-adopt-double-digit-price-hikes-test-to-pharma-s-drug-cost-limits-analysts
119,Japan halts more Moderna vaccine doses after 2 deaths, https://www.fiercepharma.com/pharma/moderna-suspends-1m-more-vaccine-doses-after-death-2-japan-and-more-contaminants-found
120,"BioNTech eyes Rwanda, Senegal for malaria, TB vaccine production", https://www.fiercepharma.com/pharma/biontech-selects-rwanda-senegal-for-potential-malaria-and-tuberculosis-mrna-vaccine
121,Brazil company to produce Pfizer-BioNTech COVID-19 vaccines, https://www.fiercepharma.com/pharma/pfizer-biontech-sign-eurofarma-brazil-for-covid-19-vaccine-production
122,Pfizer backs up its COVID-19 booster boast with positive data, https://www.fiercepharma.com/pharma/pfizer-biontech-reveal-late-stage-data-to-support-value-covid-19-booster-shots
123,Moderna investigating contamination of COVID-19 shots in Japan, https://www.fiercepharma.com/pharma/moderna-investigating-reports-contamination-covid-19-vaccines
124,"EU blesses Catalent, Delpharm sites to produce mRNA COVID shots", https://www.fiercepharma.com/pharma/catalent-delpharm-manufacturing-sites-win-eu-s-blessing-to-produce-millions-pfizer-moderna
125,"Sanofi, GSK and Seqirus prep for near-record flu shot sales", https://www.fiercepharma.com/pharma/recipe-for-disaster-sanofi-gsk-and-seqirus-prep-for-near-record-flu-shot-deliveries-as-delta
126,EMA examining link between mRNA vaccines and 3 disorders, https://www.fiercepharma.com/pharma/europe-probing-link-between-pfizer-biontech-moderna-covid-vaccines-and-skin-condition-2
127,Moderna outlines plans for new Canadian mRNA manufacturing site, https://www.fiercepharma.com/manufacturing/moderna-scouts-plans-for-new-canadian-mrna-vaccine-manufacturing-site-and-more-could
128,Novavax deal helps Europe diversify its COVID-19 vaccine stock, https://www.fiercepharma.com/pharma/supply-problems-solved-novavax-completes-deal-europe-to-supply-200m-covid-19-vaccine-doses
129,Full endorsement for Pfizer COVID shot could come by Labor Day, https://www.fiercepharma.com/pharma/delta-variant-surging-fda-a-sprint-to-grant-full-approval-to-pfizer-biontech-vaccine
130,"Shots delivered to Mexico, Canada were not properly vetted", https://www.fiercepharma.com/pharma/u-s-supplied-mexico-canada-astrazeneca-covid-19-vaccines-had-not-been-properly-sanctioned
131,Merck earnings up 22% fueled by Gardasil's rebound, https://www.fiercepharma.com/pharma/gardasil-bounces-back-even-better-than-expected-fueling-a-strong-earnings-quarter-for-merck
132,Pfizer expects 2021 COVID-19 vax sales of $33.5B, https://www.fiercepharma.com/pharma/pfizer-now-expects-covid-19-vaccine-sales-33-5b-a-7-5b-increase-from-3-months-ago
133,FDA nod opens GSK's Shingrix to new patient population, https://www.fiercepharma.com/vaccines/as-glaxosmithkline-works-to-get-shingrix-back-track-fda-approval-increases-key-vaccine-s
134,"COVID booster? Leave that to the FDA for now, CDC says", https://www.fiercepharma.com/pharma/j-j-s-covid-19-shot-scores-safety-backing-from-cdc-experts-but-need-for-boosters-left
135,New U.S. deal brings Pfizer-BioNTech vaccine supply to 500M, https://www.fiercepharma.com/pharma/pfizer-biontech-sign-u-s-to-provide-200-million-more-covid-19-vaccine-doses
136,$200M from U.S. boosts Aspen's vax production in South Africa, https://www.fiercepharma.com/pharma/a-200m-injection-from-u-s-will-allow-aspen-to-produce-more-johnson-johnson-covid-19-vaccines
137,Pfizer-BioNTech set to produce shots in Africa by end of 2021, https://www.fiercepharma.com/pharma/agreement-biovac-pfizer-biontech-extend-their-covid-19-vaccine-manufacturing-network-to
138,"With Vaxneuvance nod, Merck set to challenge Pfizer's dominance", https://www.fiercepharma.com/pharma/next-gen-pneumococcal-vaccine-race-as-merck-answers-pfizer-s-approval-one-its-own
139,"Pfizer pushing for booster approval, but is effort premature?", https://www.fiercepharma.com/pharma/pfizer-pushing-for-booster-approval-fda-but-will-u-s-be-board
140,"Pfizer, CDC send mixed messages on COVID-19 boosters", https://www.fiercepharma.com/pharma/staying-vigilant-pfizer-and-biontech-plot-delta-busting-covid-19-booster-shot
141,"Lawsuit targets Emergent CEO, others for alleged insider trading", https://www.fiercepharma.com/pharma/latest-lawsuit-aimed-at-emergent-targets-7-for-insider-trading-including-ceo-kramer-who-made
142,Pfizer and CDC panel at odds over when COVID boosters needed, https://www.fiercepharma.com/pharma/pfizer-sees-boosters-as-a-way-to-stop-covid-s-spread-although-a-key-cdc-panel-doesn-t-see-it
143,"Warning label coming for Pfizer, Moderna COVID-19 vaccines", https://www.fiercepharma.com/pharma/fda-says-label-warning-coming-for-heart-inflammation-pfizer-bnt-moderna-covid-19-vaccines
144,Moderna banks $3.3B in latest US COVID-19 vaccine supply deal, https://www.fiercepharma.com/pharma/moderna-banks-3-3b-latest-covid-19-vaccine-supply-deal-us-rounding-out-government-s
145,"Novavax can forget U.S., but shot can still be a global force", https://www.fiercepharma.com/pharma/novavax-covid-19-vaccine-delays-will-impact-u-s-uptake-but-big-global-market-still-awaits
146,AstraZeneca scores a win in COVID-19 vaccine lawsuit with EU, https://www.fiercepharma.com/pharma/astrazeneca-scores-a-win-lawsuit-over-covid-19-vaccine-supply-shortcomings-europe
147,"GSK, Bayer stand by CureVac after COVID vaccine trial shortfall", https://www.fiercepharma.com/pharma/gsk-bayer-stand-by-curevac-for-now-following-disappointing-covid-19-vaccine-trial-flow
148,"GSK, Sanofi vaccines safe from an mRNA downfall, analysts argue", https://www.fiercepharma.com/pharma/while-mrna-saved-covid-19-day-gsk-and-sanofi-vaccines-likely-safe-beyond-pandemic-analysts
149,"Pfizer, AZ shots effective vs. Delta variant: real-world study", https://www.fiercepharma.com/pharma/two-shots-pfizer-astrazeneca-vaccine-effective-against-delta-variant-says-u-k-real-world
150,"With expiration near, FDA extends J&J COVID shot shelf life", https://www.fiercepharma.com/pharma/j-j-s-covid-19-vaccine-cleared-by-fda-for-more-time-shelf-just-as-millions-doses-were-set-to
151,U.S. to buy 500 million Pfizer COVID-19 shots for donation, https://www.fiercepharma.com/pharma/u-s-will-purchase-500-million-pfizer-covid-19-vaccine-doses-to-distribute-to-needy-countries
152,Pfizer nabs next-gen pneumococcal vaccine nod before rival Merck, https://www.fiercepharma.com/pharma/a-vaccine-roll-pfizer-gains-fda-nod-for-its-20-valent-pneumococcal-follow-to-prevnar-13
153,Moderna could bring in $15B in 2022 COVID-19 sales: analysts, https://www.fiercepharma.com/pharma/optimistic-about-future-need-for-covid-19-vaccines-moderna-could-bring-about-15b-2022-sales
154,Valneva COVID-19 shot sales could hit $1.1B next year: analysts, https://www.fiercepharma.com/pharma/it-s-not-too-late-for-valneva-analysts-eye-1-1b-covid-19-vaccine-sales-next-year
155,Samsung beefs up capacity for mRNA vaccine production, https://www.fiercepharma.com/pharma/samsung-adds-mrna-vaccine-substance-capacity-will-have-one-stop-site-for-manufacture-moderna
156,Moderna to launch single-dose COVID-19 vax next year in India, https://www.fiercepharma.com/pharma/moderna-will-launch-a-single-dose-covid-19-vaccine-next-year-india-report-says
157,"Moderna's COVID-19 vaccine aces trial in teens, teeing up filing", https://www.fiercepharma.com/pharma/moderna-s-covid-19-vaccine-aces-trial-teens-teeing-up-filing-age-group-next-month
158,"Looking for edge vs. Merck, Pfizer kicks off two-vaccine trial", https://www.fiercepharma.com/pharma/pfizer-begins-testing-elderly-co-administered-covid-19-booster-and-prevnar-20-vaccines
159,Done deal: Pfizer-BioNTech to supply 1.8B vaccine doses to EU, https://www.fiercepharma.com/pharma/it-s-official-pfizer-biontech-ink-enormous-deal-europe-to-provide-1-8b-covid-19-vaccine
160,IFPMA details plan to solve inequities in vaccine availability, https://www.fiercepharma.com/pharma/industry-trade-association-lays-out-five-step-plan-to-solve-inequities-covid-19-vaccine
161,"In study, mRNA vaccines showed effectiveness against variants", https://www.fiercepharma.com/pharma/study-shows-covid-19-vaccines-from-moderna-pfizer-biontech-are-effective-vs-variants
162,CDC rids COVID vaccine coadministration rule to pharma's benefit, https://www.fiercepharma.com/pharma/cdc-throws-out-covid-19-vaccine-coadministation-rule-to-boost-routine-immunizations-but
163,"Pfizer, Regeneron CEOs see extended need for COVID shots, drugs", https://www.fiercepharma.com/pharma/pfizer-s-covid-19-vaccine-could-reap-36b-2021-sales-analysts-predict
164,AstraZeneca investors approve Soriot's 2021 pay despite concerns, https://www.fiercepharma.com/pharma/as-astrazeneca-faces-another-eu-legal-challenge-shareholders-approve-ceo-soriot-s-2021-pay
165,"Lilly to welcome employees back in June, fully open in July", https://www.fiercepharma.com/pharma/pandemic-easing-up-lilly-will-welcome-employees-back-to-headquarters
166,Lifting IP protection of COVID-19 vaccines? It's complicated, https://www.fiercepharma.com/pharma/don-t-expect-lifting-covid-19-vaccine-patents-to-happen-quickly-if-at-all-analysts
167,EU regulator requests more safety data from COVID vaccine makers, https://www.fiercepharma.com/pharma/europe-s-drug-regulator-evaluates-reports-heart-inflammation-rare-nerve-disorder-covid-19
168,Moderna CEO says he's not concerned about Biden-backed IP waiver, https://www.fiercepharma.com/pharma/moderna-ceo-says-he-s-not-losing-any-sleep-over-biden-s-endorsement-for-covid-19-ip-waiver
169,"Moderna posts $1.7B in COVID-19 vaccine sales, ups 2021 outlook", https://www.fiercepharma.com/pharma/moderna-posts-massive-year-over-year-growth-thanks-to-1-7b-covid-19-vaccine-sales
170,Moderna to expand Massachusetts-based manufacturing site, https://www.fiercepharma.com/pharma/moderna-plans-major-expansion-at-massachusetts-based-manufacturing-site-to-help-grow-covid
171,BioNTech chief ups COVID-19 vaccine supply near 3B for 2021, https://www.fiercepharma.com/pharma/thanks-to-revved-up-manufacturing-biontech-ceo-estimates-3b-covid-vaccine-doses-2021
172,Novavax closing in on COVID-19 vaccine supply deal with Europe, https://www.fiercepharma.com/pharma/supply-timelines-more-certain-novavax-closing-covid-19-vaccine-deal-europe
173,"With vax success, Novavax execs rack up $106M in stock options", https://www.fiercepharma.com/pharma/novavax-hands-top-execs-100m-stock-options-as-covid-19-vaccine-nears-starting-line
174,"Lots of questions, few answers during Emergent earnings call", https://www.fiercepharma.com/pharma/lots-questions-but-not-many-answers-by-ceo-during-emergent-s-earnings-call
175,$157B in COVID-19 vaccine sales expected through 2025: analyst, https://www.fiercepharma.com/pharma/how-much-covid-19-vaccine-money-table-157b-through-2025-analyst
176,Pfizer discovers knock offs of its COVID-19 vaccine, https://www.fiercepharma.com/pharma/counterfeit-versions-pfizer-covid-19-vaccine-found-poland-mexico
177,Shareholders make push for clearer COVID-19 pricing strategies, https://www.fiercepharma.com/pharma/shareholders-to-push-for-detailed-covid-19-pricing-strategies-from-pfizer-j-j-and-merck-at
178,"J&J sees 'very viable path forward' for COVID shot, CFO says", https://www.fiercepharma.com/pharma/johnson-johnson-sees-very-viable-path-forward-for-its-covid-19-vaccine-despite-safety
179,Bharat lays out a major boost to its COVID shot production, https://www.fiercepharma.com/manufacturing/bharat-biotech-government-cash-hand-aims-for-700-million-covid-19-vaccines-per-year
180,"Pfizer vaccine sales could reach $24B, Moderna's $14B this year", https://www.fiercepharma.com/pharma/competition-struggling-pfizer-s-vaccine-sales-could-hit-24b-moderna-s-14b-year-analyst
181,FDA shuts off J&J vaccine production at troubled Emergent plant, https://www.fiercepharma.com/pharma/at-request-fda-emergent-s-troubled-baltimore-plant-suspends-j-j-vaccine-production
182,Decision on J&J COVID shot's return due by week's end: Fauci, https://www.fiercepharma.com/pharma/johnson-johnson-covid-shot-could-be-back-menu-come-friday-some-extra-safety-warnings-fauci
183,Moderna cuts COVID-19 vaccine deliveries after supply woes, https://www.fiercepharma.com/pharma/moderna-cuts-covid-19-vaccine-deliveries-to-canada-u-k-amid-european-supply-struggles
184,J&J asked COVID-19 vaccine rivals to team up on safety: WSJ, https://www.fiercepharma.com/pharma/as-blood-clot-concerns-mounted-j-j-reached-out-to-rival-covid-19-vaccine-makers-to-form
185,Pfizer CEO says we'll probably need annual COVID shots, https://www.fiercepharma.com/pharma/pfizer-chief-bourla-raises-likely-need-for-annual-covid-vaccinations-teeing-up-comirnaty
186,"With J&J vaccine in limbo, edge goes to Pfizer, Moderna: analyst", https://www.fiercepharma.com/pharma/safety-concerns-j-j-covid-19-vaccine-present-a-big-opportunity-for-pfizer-biontech-and
187,CDC discusses options for troubled Johnson & Johnson vaccine, https://www.fiercepharma.com/pharma/cdc-working-group-discusses-options-for-troubled-johnson-johnson-vaccine
188,"In Europe, Pfizer steps in to compensate for J&J vaccine pause", https://www.fiercepharma.com/pharma/after-j-j-announces-vaccine-supply-delay-to-europe-pfizer-biontech-fill-void
189,"Europe won't renew AZ, J&J COVID vaccine contacts: report", https://www.fiercepharma.com/pharma/astrazeneca-j-j-covid-19-vaccine-contracts-won-t-be-renewed-europe-next-year-report
190,Plastic bag shortage a hefty problem for Novavax production, https://www.fiercepharma.com/manufacturing/lack-grow-bags-a-hefty-problem-for-novavax-s-covid-19-vaccine-production-push
191,Feds halt J&J's COVID vaccine rollout on clot concerns, https://www.fiercepharma.com/pharma/feds-call-for-halt-to-johnson-johnson-covid-19-vaccine-rollout-after-extremely-rare-blood
192,Sanofi outlines 'boundary-pushing' vaccine plant in Singapore, https://www.fiercepharma.com/manufacturing/sanofi-plugs-eu400m-into-singapore-vaccine-factory-bringing-total-shot-investment-up
193,J&J shot under EMA scrutiny after 4 'serious' blood clot cases, https://www.fiercepharma.com/pharma/johnson-johnson-s-covid-19-vaccine-spotlight-at-ema-after-4-serious-cases-unusual-blood
194,SII asks government for help in boosting vax production, https://www.fiercepharma.com/manufacturing/very-stressed-serum-institute-india-asks-government-for-vaccine-production-boost
195,Europe says AZ vaccine should come with side effect warning, https://www.fiercepharma.com/pharma/astrazeneca-s-covid-shot-should-list-blood-clots-as-rare-side-effect-ema-says
196,Catalent doubling capacity at Italian plant to produce J&J shot, https://www.fiercepharma.com/manufacturing/catalent-to-expand-plant-italy-to-produce-j-j-vaccine
197,"Pfizer eyes yearly COVID shots, higher prices post-pandemic: CFO", https://www.fiercepharma.com/pharma/pfizer-sees-need-for-annual-revaccinations-and-rationale-for-higher-prices-after-pandemic
198,"Germany, Ireland stop using AZ vaccine as supply woes mount", https://www.fiercepharma.com/pharma/astrazeneca-stands-by-covid-19-vaccine-safety-but-says-it-s-shipping-fewer-doses-than-hoped
199,Europe approves J&J's COVID-19 vaccine; deliveries set for April, https://www.fiercepharma.com/pharma/europe-approves-johnson-johnson-s-covid-19-vaccine-first-one-dose-option
200,Safety worries threaten AZ COVID vaccine rollout in Europe, https://www.fiercepharma.com/pharma/another-european-country-has-halted-its-astrazeneca-covid-19-vaccine-usage-what-s-going
201,Merck plant in N.C. upgrades for J&J vaccine production, https://www.fiercepharma.com/manufacturing/merck-plant-durham-n-c-set-to-produce-bulk-substance-for-j-j-vaccine
202,J&J to sell another 100M vaccine doses to U.S.: reports, https://www.fiercepharma.com/pharma/johnson-johnson-to-sell-another-100m-coronavirus-vaccine-doses-to-u-s-taking-america-s
203,Pfizer vaccine tackles 3 troubling COVID variants in lab study, https://www.fiercepharma.com/pharma/pfizer-biontech-vaccine-tackles-troubling-covid-variant-found-brazil-lab-study
204,"CureVac, Novartis team up in COVID vaccine production push", https://www.fiercepharma.com/pharma/curevac-novartis-team-up-latest-pandemic-vaccine-manufacturing-collaboration
205,Rejuvenated Novavax ramps up to produce billions of COVID shots, https://www.fiercepharma.com/vaccines/after-reversal-fortunes-novavax-ramping-up-produce-billions-covid-19-vaccine-doses
206,Here's what it takes to supply COVID-19 vaccines to the globe, https://www.fiercepharma.com/special-reports/vaccine-supply-chains-holding-line-against-covid-19
207,"Merck, J&J in 'wartime' COVID vaccine production pact: WaPo", https://www.fiercepharma.com/pharma/merck-j-j-to-strike-wartime-covid-19-vaccine-production-pact-wapo
208,"J&J COVID-19 vaccine wins FDA authorization, CDC backing", https://www.fiercepharma.com/pharma/johnson-johnson-s-covid-vaccine-fda-panel
209,Merck's ready to rival Pfizer in pneumococcal vaccine race: exec, https://www.fiercepharma.com/vaccines/seeking-to-challenge-pfizer-next-gen-pneumococcal-vaccine-market-merck-exec-embraces
210,Moderna tots up COVID vaccine orders worth a whopping $18B, https://www.fiercepharma.com/pharma/moderna-has-taken-orders-worth-18-4-billion-for-its-covid-19-vaccine-and-it-s-negotiating
211,Pfizer eyes higher prices for COVID-19 vaccine after pandemic, https://www.fiercepharma.com/pharma/pfizer-eyes-higher-covid-19-vaccine-prices-after-pandemic-exec-analyst
212,Novavax strikes massive COVID supply deal with global consortium, https://www.fiercepharma.com/pharma/novavax-heels-coronavirus-shot-data-enters-massive-supply-deal-global-vaccine-consortium
213,"Pfizer, Moderna COVID-19 vaccines less potent against SA strain", https://www.fiercepharma.com/pharma/bring-boosters-studies-show-pfizer-moderna-covid-vaccines-are-less-protective-against-south
214,India's Cadila sees demand for its COVID vaccine outstrip supply, https://www.fiercepharma.com/manufacturing/india-s-cadila-hit-more-covid-19-vaccine-orders-than-it-can-fill
215,Pfizer aims to cut its COVID shot production time by nearly 50%, https://www.fiercepharma.com/manufacturing/pfizer-to-nearly-halve-covid-19-vaccine-production-timeline-sterile-injectables-vp
216,Novartis eyes manufacturing tie-ups to help boost COVID supplies, https://www.fiercepharma.com/pharma/u-s-eyes-manufacturing-tie-ups-to-boost-covid-19-vaccine-supply-via-defense-production-act
217,AstraZeneca CEO plays defense amid COVID-19 vaccine shortfall, https://www.fiercepharma.com/pharma/astrazeneca-plays-defense-amid-covid-19-vaccine-shortfall-as-europe-presses-for-more-supply
218,Pfizer-BioNTech working on COVID- vaccine booster shot, https://www.fiercepharma.com/pharma/first-moderna-now-pfizer-biontech-also-working-booster-shot-amid-rise-covid-19-variants
219,"Sanofi, after R&D setback, will produce Pfizer's COVID-19 shots", https://www.fiercepharma.com/pharma/sanofi-after-r-d-setback-lends-a-hand-to-vaccine-rival-pfizer-for-coronavirus-shot
220,J&J 'comfortable' meeting its COVID shot delivery promises: CFO, https://www.fiercepharma.com/pharma/j-j-ahead-phase-3-covid-19-vaccine-data-release-comfortable-meeting-its-delivery-commitments
221,Regeneron's COVID antibodies promising for 'passive vaccination', https://www.fiercepharma.com/pharma/regeneron-pitches-covid-antibody-cocktail-for-passive-vaccination-fresh-trial-data
222,AstraZeneca's surprise COVID-19 vaccine shortfall, https://www.fiercepharma.com/pharma/astrazeneca-s-surprise-covid-19-vaccine-shortfall-prompts-europe-to-press-for-answers
223,Will Pfizer's 6-dose-vial OK actually hurt COVID shot supply?, https://www.fiercepharma.com/manufacturing/pfizer-s-six-dose-vial-counts-toward-company-s-elevated-production-spurring-supply
224,Novavax sees trial dropout amid COVID-19 vaccine rollout, https://www.fiercepharma.com/vaccines/novavax-sees-covid-vaccine-trial-dropout-as-pfizer-moderna-shots-rollout-gears-up
225,Warp Speed chief Slaoui resigns at Biden's request: report, https://www.fiercepharma.com/pharma/warp-speed-chief-slaoui-resigns-at-biden-s-request-as-covid-19-vaccines-are-unleashed-report
226,'Second wave' of COVID-19 shots could come with advantages, https://www.fiercepharma.com/pharma/as-first-covid-19-vaccines-roll-out-a-second-wave-candidates-waiting-wings
227,J&J chief to a world waiting on COVID vaccine data: 'Very soon', https://www.fiercepharma.com/pharma/jpm-j-j-hopes-to-share-phase-3-coronavirus-vaccine-data-very-soon-ceo-says
228,Pfizer partner BioNTech hikes COVID-19 vaccine output to 2B, https://www.fiercepharma.com/manufacturing/jpm-biontech-raises-covid-19-vaccine-output-to-2b-eyeing-label-extensions-and-higher
229,Pfizer-BioNTech COVID vax works against variants: study, https://www.fiercepharma.com/pharma/pfizer-biontech-covid-19-vaccine-works-more-contagious-coronavirus-variants-study
230,Latecomer CureVac taps Bayer to speed COVID-19 shot to market, https://www.fiercepharma.com/vaccines/mrna-latecomer-curevac-finds-bayer-as-covid-19-vaccine-partner
231,FDA warns of 'premature' changes to COVID vaccine dosing, https://www.fiercepharma.com/pharma/not-so-fast-fda-warns-premature-changes-to-covid-19-vaccine-dosing-clash-slaoui
232,Moderna expects to provide at least 600M COVID-19 shots in 2021, https://www.fiercepharma.com/manufacturing/moderna-dials-up-low-end-vaccine-supply-estimate-setting-sights-1-billion-doses-2021
233,AstraZeneca's pandemic shot wins 2nd U.K. vaccine nod, https://www.fiercepharma.com/pharma/astrazeneca-vaccine-wins-emergency-nod-at-two-full-doses-uk
234,AstraZeneca now has a 'winning formula' for its COVID shot: CEO, https://www.fiercepharma.com/pharma/astrazeneca-has-a-winning-formula-for-its-covid-19-vaccine-ceo-says
235,Which drugs and vaccines will wage war on the pandemic in 2021?, https://www.fiercepharma.com/pharma/targeted-delivery-oral-vaccines-and-mrna-2-0-next-generation-drugs-and-prophylactics-fight
236,"Pfizer, Moderna set for lion's share of $38B in COVID shot sales", https://www.fiercepharma.com/pharma/as-first-covid-19-vaccinations-near-leading-developers-set-to-reap-tens-billions-analysts
237,"Pfizer, BioNTech nab first COVID-19 vaccine authorization", https://www.fiercepharma.com/vaccines/pfizer-biontech-nabs-covid-vaccine-authorization-from-uk-for-first-ever-marketed-mrna-shot
238,Zeteo to test intranasal device with Iowa State's COVID-19 vax, https://www.fiercepharma.com/drug-delivery/iowa-state-taps-device-maker-zeteo-for-early-work-nasal-spray-covid-19-vaccine
239,Slaoui lays out timeline for Moderna and Pfizer shot reviews, https://www.fiercepharma.com/vaccines/moderna-to-file-covid-shot-for-emergency-nod-november-as-pfizer-rollout-pegged-for-early
240,Pfizer aims to ship vaccines 'within hours' of green lights: CEO, https://www.fiercepharma.com/pharma/pfizer-won-t-hesitate-to-ship-vaccine-doses-after-regulatory-nods-raising-prospect-a-race-to
241,"FDA's coronavirus vaccine reviews will take weeks, not days", https://www.fiercepharma.com/pharma/as-covid-vaccine-developers-post-impressive-data-fda-official-says-reviews-will-take-weeks
242,CureVac inks EU supply deal on mRNA coronavirus shot, https://www.fiercepharma.com/pharma/curevac-eu-ink-supply-deal-for-up-to-405m-doses-mrna-coronavirus-shot-reuters
243,Moderna's COVID shot is stable at refrigerated temps for 30 days, https://www.fiercepharma.com/pharma/along-promising-data-moderna-says-its-vaccine-stable-refrigerators-for-30-days
244,"CureVac's mRNA shot holds a storage edge over Pfizer, Moderna", https://www.fiercepharma.com/pharma/curevac-s-mrna-coronavirus-shot-holds-edge-over-pfizer-and-moderna-counterparts-refrigerated
245,Pfizer-BioNTech COVID-19 vax data 'open the floodgates' for mRNA, https://www.fiercepharma.com/pharma/pfizer-biontech-covid-vaccine-data-open-floodgates-for-mrna-infectious-disease-other-areas
246,Pfizer weighs powder-form vaccine to cut cold storage needs, https://www.fiercepharma.com/vaccines/amid-cold-chain-blues-pfizer-looks-to-powder-vaccine-formula-2021-report
247,Pfizer set to earn billions amid COVID vaccine launch: analyst, https://www.fiercepharma.com/pharma/pfizer-biontech-set-to-earn-billions-amid-fast-covid-19-vaccine-launch-analysts
248,"GSK vaccines typically drive growth. Amid COVID, they're a drag", https://www.fiercepharma.com/pharma/gsk-s-vaccines-typically-a-reliable-growth-driver-weigh-sales-amid-covid-19
249,The first generation of COVID shots may be less than optimal, https://www.fiercepharma.com/vaccines/scientists-warn-americans-are-expecting-too-much-from-a-vaccine
250,"Sanofi, GSK to provide 200M coronavirus vaccines to COVAX", https://www.fiercepharma.com/vaccines/sanofi-gsk-to-provide-200m-coronavirus-vaccines-to-covax-for-equitable-distribution
251,"Sanofi, SK flu shots halted in Singapore after deaths in Korea", https://www.fiercepharma.com/vaccines/sanofi-sk-flu-shots-halted-singapore-as-south-korea-post-vaccination-deaths-climb-to-59
252,Deaths rattle Korea's seasonal flu vaccination, https://www.fiercepharma.com/vaccines/deaths-rattle-south-korea-s-seasonal-flu-vaccination-but-authority-presses-ahead-free
253,Top takeaways from FDA's COVID-19 vaccine confab, https://www.fiercepharma.com/pharma/cdc-working-warp-speed-local-jurisdictions-nationwide-covid-19-vaccine-plan-official
254,"Azar, Hahn at odds after vaccine guidance showdown: Politico", https://www.fiercepharma.com/pharma/hhs-secretary-azar-discussed-firing-fda-commissioner-hahn-after-covid-19-vaccine-guidance
255,Leading contender Moderna wraps COVID vaccine trial enrollment, https://www.fiercepharma.com/pharma/moderna-completes-enrollment-for-late-stage-covid-19-vaccine-study
256,The top vaccine programs to watch in 2020, https://www.fiercepharma.com/special-report/top-vaccine-programs-to-watch-2020
257,EU progressing in COVID-19 vaccine talks with Novavax: report, https://www.fiercepharma.com/vaccines/europe-progressing-covid-19-vaccine-supply-talks-novavax-report
258,BioNTech eyes up to 750M COVID vaccine doses with Novartis buy, https://www.fiercepharma.com/manufacturing/biontech-buys-novartis-plant-for-covid-19-vaccine-eyes-capacity-up-to-750m-doses
259,Moderna expects to see COVID vaccine efficacy data in November, https://www.fiercepharma.com/vaccines/moderna-expects-to-see-covid-19-vaccine-efficacy-data-november-report
260,Pfizer sees 'mild to moderate' safety profile for COVID vaccine, https://www.fiercepharma.com/vaccines/pfizer-sees-mostly-mild-to-moderate-safety-profile-phase-3-covid-vaccine-study
261,Boosting Black enrollment in COVID-19 vaccine trials, https://www.fiercepharma.com/vaccines/covid-vaccine-trials-move-at-warp-speed-but-recruiting-black-volunteers-takes-time
262,Pfizer execs see blockbuster vaccines throughout pipeline, https://www.fiercepharma.com/vaccines/pfizer-execs-see-blockbuster-opportunities-throughout-vaccine-pipeline-even-excluding
263,AstraZeneca's clinical hold has triggered alarm bells at the NIH, https://www.fiercepharma.com/vaccines/nih-very-concerned-about-serious-side-effect-coronavirus-vaccine-trial
264,Analysts weigh in on COVID-19 vaccine race after AZ trial pause, https://www.fiercepharma.com/vaccines/how-does-astrazeneca-s-trial-pause-affect-other-covid-19-vaccines-analysts-weigh
265,Merck plots next-gen pneumococcal vaccine filing for 2020, https://www.fiercepharma.com/vaccines/merck-set-to-file-next-gen-pneumococcal-shot-2020-potentially-setting-up-clash-pfizer
266,"Pfizer, AZ, Moderna and more pledge not to rush COVID-19 shots", https://www.fiercepharma.com/vaccines/no-rushed-vaccine-covid-19-leaders-make-joint-safety-and-efficacy-pledge
267,"Moderna won't meet Wall Street's COVID estimates, analyst says", https://www.fiercepharma.com/vaccines/facing-high-expectations-and-competition-moderna-won-t-meet-wall-street-s-covid-estimates
268,A COVID vaccine in early November? 'Extremely unlikely': Slaoui, https://www.fiercepharma.com/vaccines/a-covid-vaccine-early-november-extremely-unlikely-but-not-impossible-warp-speed-head
269,Pfizer barreling toward COVID vaccine results next month: CEO, https://www.fiercepharma.com/vaccines/pfizer-could-see-early-efficacy-data-for-coronavirus-vaccine-late-october-ceo
270,CDC sets its sights on November COVID-19 vaccine deliveries, https://www.fiercepharma.com/vaccines/cdc-sets-its-sights-november-covid-19-vaccine-deliveries-report
271,An independent DSMB could push for a shot OK before election day, https://www.fiercepharma.com/vaccines/fauci-says-covid-vaccine-trials-could-end-early-if-results-are-overwhelming
272,MIT syringe tees up easier biologic injections under the skin, https://www.fiercepharma.com/drug-delivery/mit-researchers-develop-double-barreled-syringe-for-breezy-biologics-injections-0
273,FDA would consider COVID vaccines before phase 3 trials finish, https://www.fiercepharma.com/pharma/fiercepharmapolitics-fda-could-consider-covid-vaccines-before-phase-3-trials-finish
274,EU hands AstraZeneca $396M to secure 300M coronavirus shots, https://www.fiercepharma.com/manufacturing/az-nets-396m-downpayment-for-300m-plus-eu-vaccine-doses
275,Pfizer really could score an October COVID vaccine nod: analyst, https://www.fiercepharma.com/pharma/pfizer-could-score-fast-covid-vaccine-approval-as-fda-s-hahn-promises-october-review-analyst
276,COVID-19 vaccination wave will generate $20B in 2021: analyst, https://www.fiercepharma.com/vaccines/coming-covid-19-vaccination-wave-will-generate-20b-sales-next-year-analyst
277,CSL may tackle production under Australia's shot pact with AZ, https://www.fiercepharma.com/manufacturing/australia-s-csl-homes-astrazeneca-shot-production-deal
278,U.K. books 90M COVID-19 vaccine doses from J&J and Novavax, https://www.fiercepharma.com/pharma/uk-books-90m-covid-19-vaccine-doses-from-j-j-and-novavax-and-backs-new-clinical-trials
279,J&J advances COVID-19 vaccine talks with Europe, https://www.fiercepharma.com/pharma/heels-u-s-deal-johnson-johnson-strikes-covid-vaccine-supply-pact-europe
280,Moderna takes $1.5B coronavirus vaccine order from U.S., https://www.fiercepharma.com/pharma/after-nearly-1b-research-funding-moderna-takes-1-5b-coronavirus-vaccine-order-from-u-s
281,Novavax aims for billions of doses of COVID-19 vaccine capacity, https://www.fiercepharma.com/pharma/novavax-aims-for-billions-covid-19-vaccine-doses-2021-more-than-enough-to-supply-u-s
282,Russia skips ahead in COVID race with unproven 'Sputnik V' shot, https://www.fiercepharma.com/pharma/russia-skips-ahead-covid-vaccine-race-authorizing-unproven-shot
283,Takeda signs on to introduce Novavax's COVID-19 shot in Japan, https://www.fiercepharma.com/vaccines/novavax-takeda-team-up-to-introduce-covid-19-vaccine-to-japan
284,Japan will buy 120 million shots from AZ starting early in 2021, https://www.fiercepharma.com/manufacturing/astrazeneca-taps-jcr-pharmaceuticals-daiichi-sankyo-and-other-local-pharmas-to-supply
285,Moderna prices COVID-19 shot at $32 to $37 for small purchasers, https://www.fiercepharma.com/vaccines/moderna-prices-covid-19-vaccine-at-32-to-37-for-small-purchasers
286,"Pfizer, BioNTech score 120M-dose COVID vaccine pact in Japan", https://www.fiercepharma.com/vaccines/pfizer-and-biontech-keep-supply-deals-rolling-120m-dose-japan-pact
287,Sanofi touts Dupixent's 'resilience' as cost cuts add up, https://www.fiercepharma.com/pharma/sanofi-touts-resilience-dupixent-other-medicines-during-pandemic-as-cost-cuts-add-up
288,GSK's Shingrix crashes as vaccination slows amid COVID-19, https://www.fiercepharma.com/pharma/shingrix-crashed-for-glaxosmithkline-as-vaccination-slows-amid-covid-19
289,Experts fear politics will impede upon rigorous vaccine approval, https://www.fiercepharma.com/vaccines/public-health-experts-fear-a-hasty-fda-signoff-vaccine
290,Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst, https://www.fiercepharma.com/pharma/pfizer-could-see-15b-covid-19-vaccine-sales-analyst
291,"Novavax, Fujifilm lock up supply for phase 3 COVID-19 shot trial", https://www.fiercepharma.com/manufacturing/novavax-fujifilm-lock-up-clinical-supply-for-late-stage-covid-19-vaccine-trial
292,Novavax execs up for windfall as COVID-19 shot aims for phase 2, https://www.fiercepharma.com/pharma/novavax-execs-could-earn-millions-covid-19-vaccine-even-if-it-s-never-approved
293,Where do COVID-19 vaccine players stand on pricing?, https://www.fiercepharma.com/pharma/where-do-covid-19-vaccine-players-stand-pricing-no-profit-slight-profit-or-discussions
294,"COVID-19 vaccine hopeful Valneva, U.K. in R&D, production deal", https://www.fiercepharma.com/vaccines/valneva-united-kingdom-tie-up-covid-19-vaccine-r-d-and-manufacturing-deal
295,"For COVID-19 adoption, consumers need data transparency: experts", https://www.fiercepharma.com/vaccines/want-ideal-covid-19-vaccine-adoption-be-transparent-about-clinical-data-say-experts
296,FDA's emergency pathway for COVID shots remains a mystery: firm, https://www.fiercepharma.com/vaccines/even-after-fda-s-covid-19-vaccine-guidance-emergency-pathway-remains-a-mystery-expert
297,"Pfizer, BioNTech post positive COVID vaccine data, eye phase 3", https://www.fiercepharma.com/pharma/covid-19-vaccine-partners-pfizer-biontech-post-early-trial-win-eye-phase-3
298,FDA to require 50% efficacy for COVID-19 vaccines, https://www.fiercepharma.com/vaccines/fda-to-require-at-least-50-efficacy-for-covid-19-vaccines-wsj
299,"WHO, global partners launch $18B COVID-19 vaccine initiative", https://www.fiercepharma.com/vaccines/who-global-partners-launch-18b-covid-19-vaccine-initiative
300,Inovio scores $71M deal to scale up vaccine delivery devices, https://www.fiercepharma.com/pharma/inovio-scores-71m-department-defense-deal-to-scale-up-vaccine-delivery-devices
301,Merck's next-gen pneumococcal vaccine puts the heat on Pfizer, https://www.fiercepharma.com/vaccines/merck-posts-phase-3-trial-wins-amid-next-gen-pneumococcal-vaccine-race-pfizer
302,J&J in talks to supply COVID-19 vaccine in Europe: reports, https://www.fiercepharma.com/pharma/johnson-johnson-talks-to-supply-covid-19-vaccine-europe-reports
303,Howâ€”and whenâ€”can the coronavirus vaccine become a reality?, https://www.fiercepharma.com/vaccines/how-and-when-can-coronavirus-vaccine-become-a-reality
304,AstraZeneca chief: COVID-19 shot to protect for about a year, https://www.fiercepharma.com/vaccines/astrazeneca-s-covid-19-to-protect-for-about-one-year-ceo-says
305,Sinopharm touts 100% antibody response for COVID-19 vaccine, https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving
306,Vaccine heroes? COVID-19 expectations put pharma on the spot, https://www.fiercepharma.com/marketing/vaccine-heroes-pressure-pharma-and-covid-19-drugs-to-boost-industry-image-but-pitfalls
307,"Novavax raises another $200M on heels of CEPI, DOD deals", https://www.fiercepharma.com/pharma/novavax-raises-another-200m-heels-cepi-department-defense-deals
308,"AZ taps Catalent for COVID-19 shot finishing, packaging duties", https://www.fiercepharma.com/manufacturing/astrazeneca-taps-catalent-for-covid-19-vaccine-finishing-packaging-at-italian-plant
309,China's Sinovac eyes phase 3 COVID-19 vaccine trial, https://www.fiercepharma.com/vaccines/china-s-sinovac-says-covid-19-vaccine-shows-early-positive-results-phase-2
310,BioNTech scores â‚¬100M financing for COVID-19 vaccine production, https://www.fiercepharma.com/manufacturing/pfizer-partner-biontech-scores-eu100m-debt-financing-to-fund-european-covid-19
311,"BIO: Moderna, Merck execs talk challenges in COVID manufacturing", https://www.fiercepharma.com/manufacturing/bio-moderna-merck-execs-see-possible-speed-bumps-covid-19-vaccine-manufacturing
312,NIH preps late-stage studies of 3 coronavirus vaccines: WSJ, https://www.fiercepharma.com/vaccines/nih-preps-late-stage-studies-moderna-az-and-j-j-coronavirus-vaccines-wsj
313,FDA official quickly leaves 'Warp Speed' vaccine program, https://www.fiercepharma.com/pharma/fiercepharmapolitics-fda-official-leaves-warp-speed-to-preserve-independent-regulatory-power
314,Flu shots makers gear up for a critical vaccination season, https://www.fiercepharma.com/vaccines/flu-vaccines-take-even-more-importance-amid-covid-19-but-challenges-await-experts
315,Novavax scores $60M Department of Defense deal for COVID-19 shot, https://www.fiercepharma.com/manufacturing/novavax-scores-60m-department-defense-contract-for-u-s-covid-19-vaccine-manufacturing
316,U.K. grants new vaccine manufacturing center Â£131M, https://www.fiercepharma.com/manufacturing/u-k-grants-new-vaccine-manufacturing-center-ps131m-as-researchers-race-to-deliver-a
317,AstraZeneca scores $1.2B from U.S. for COVID vaccines, https://www.fiercepharma.com/pharma/astrazeneca-scores-1b-from-u-s-signs-up-to-deliver-hundreds-millions-covid-19-vaccines
318,AstraZeneca in talks to supply COVID-19 vaccine worldwide, https://www.fiercepharma.com/pharma/after-signing-up-to-deliver-u-k-shots-first-astrazeneca-talks-to-supply-covid-19-vaccines
319,Drugmakers tout COVID-19 vaccines to refurbish their image, https://www.fiercepharma.com/vaccines/drugmakers-tout-covid-19-vaccines-to-refurbish-their-public-image
320,Warp Speed head 'confident' in COVID-19 vaccine by year-end, https://www.fiercepharma.com/vaccines/after-sneak-peak-at-early-data-operation-warp-speed-head-slaoui-confident-covid-19-vaccine
321,Sanofi chairman steps in after CEO's COVID-19 vaccine comments, https://www.fiercepharma.com/pharma/sanofi-chairman-steps-after-ceo-says-u-s-set-to-get-first-covid-19-vaccines
322,HHS whistleblower doubts 18-month coronavirus vaccine timeline, https://www.fiercepharma.com/vaccines/hhs-whistleblower-bright-doubts-18-month-coronavirus-vaccine-timeline
323,Former GSK exec to lead 'Warp Speed' vaccine project: reports, https://www.fiercepharma.com/vaccines/trump-taps-former-gsk-vaccine-head-slaoui-to-lead-warp-speed-project-reports
324,"In the race for a COVID-19 vaccine, rivals cheer for each other", https://www.fiercepharma.com/vaccines/global-race-for-a-covid-19-vaccine-rivals-cheer-for-each-other
325,Sanofi CEO promises first COVID-19 vaccine doses to U.S.: report, https://www.fiercepharma.com/vaccines/thanks-to-early-investment-u-s-set-for-first-access-to-sanofi-s-covid-19-vaccine-report
326,Fauci 'cautiously optimistic' about COVID-19 vaccine success, https://www.fiercepharma.com/vaccines/multiple-shots-goal-niaid-director-anthony-fauci-cautiously-optimistic-about-covid-19
327,Novavax inks $384M deal with CEPI to fund coronavirus vaccine, https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work
328,Pfizer tags U.S. production sites for possible COVID-19 vaccine, https://www.fiercepharma.com/manufacturing/pfizer-to-incorporate-3-u-s-sites-for-possible-covid-19-vaccine-launch
329,U.S. 'Warp Speed' project shoots for coronavirus shot this year, https://www.fiercepharma.com/pharma/operation-warp-speed-aims-to-deliver-100-million-covid-19-vaccine-doses-by-end-year
330,J&J signs manufacturing deal for potential COVID-19 vaccine, https://www.fiercepharma.com/manufacturing/johnson-johnson-sets-stage-for-covid-19-vaccine-rollout-emergent-manufacturing-tie-up
331,Sanofi CEO touts manufacturing prowess amid heated vaccine race, https://www.fiercepharma.com/pharma/sanofi-gets-covid-19-stocking-boost-as-ceo-touts-manufacturing-ability-amid-heated-vaccine
332,"COVID-19 vaccine timelines are overly hopeful, analyst says ", https://www.fiercepharma.com/vaccines/a-bullseye-from-24-feet-covid-19-vaccine-timelines-are-overly-hopeful-analyst-says
333,It could take 5 years for leading COVID-19 vaccines to debut, https://www.fiercepharma.com/pharma/don-t-count-a-covid-19-vaccine-for-at-least-five-years-says-ai-based-forecast
334,Recovered Biogen staff give blood to aid coronavirus research, https://www.fiercepharma.com/pharma/biogen-employees-after-falling-ill-covid-19-give-to-biobank-to-help-coronavirus-r-d
335,"Multiple COVID vaccines? That's what it could take, GSK CEO says", https://www.fiercepharma.com/vaccines/multiple-covid-19-vaccines-s-what-it-could-take-gsk-ceo-walmsley-says
336,"Sanofi, HHS team up on vaccine work against novel coronavirus", https://www.fiercepharma.com/vaccines/sanofi-hhs-team-up-vaccine-work-against-novel-coronavirus
337,NIH hasn't found coronavirus vaccine manufacturing partner, https://www.fiercepharma.com/pharma/amid-deadly-outbreak-nih-hasn-t-found-its-pharma-partner-to-manufacture-coronavirus-vaccines
338,GSK cutting 720 jobs at massive Belgian vaccine hub, https://www.fiercepharma.com/vaccines/gsk-cutting-up-to-720-jobs-r-d-manufacturing-and-support-functions-at-massive-belgian
339,"HIV vaccine study of GSK, Sanofi components falls short", https://www.fiercepharma.com/vaccines/after-high-hopes-hiv-vaccine-study-gsk-sanofi-components-fails-south-africa
340,"Inovio, Moderna score CEPI funding for coronavirus work", https://www.fiercepharma.com/vaccines/inovio-moderna-score-cepi-funding-for-vaccine-work-against-deadly-coronavirus
341,Vaccine researchers kick off work against new coronavirus, https://www.fiercepharma.com/vaccines/vaccine-researchers-kick-off-work-against-new-coronavirus-cnn
342,JPM: Merck turns to CMOs to help with Gardasil supply, https://www.fiercepharma.com/manufacturing/jpm-merck-hires-contract-manufacturers-to-help-gardasil-supply-plans-2023-plant
343,GSK's Shingrix has only tapped part of a huge market: exec, https://www.fiercepharma.com/vaccines/jpm-gsk-s-shingrix-has-stormed-out-gate-despite-supply-limitations-but-there-s-plenty
344,Merck snags FDA approval for Ebola vaccine following EU nod, https://www.fiercepharma.com/vaccines/heels-european-nod-merck-scores-fda-approval-for-ebola-vaccine-ervebo
345,J&J deploys 200K Ebola vaccine doses to fortify Rwanda's border, https://www.fiercepharma.com/vaccines/johnson-johnson-to-deploy-200-000-doses-ebola-vaccine-to-rwanda
346,Gavi authorizes $178M to build Ebola vaccine stockpile, https://www.fiercepharma.com/vaccines/following-merck-approval-gavi-authorizes-178m-to-build-ebola-vaccine-stockpile
347,"GSK's Shingrix supply will leap up, CEO saysâ€”in 2024, that is", https://www.fiercepharma.com/pharma/gsk-s-shingrix-rollout-has-been-limited-by-supply-but-new-bioreactor-2024-will-bring-massive
348,Merck makes history with world's first Ebola shot approval, https://www.fiercepharma.com/vaccines/merck-s-ervebo-world-s-first-ebola-shot-wins-european-licensure
349,Cosette to add liquids to its mix with deal for 2nd plant, https://www.fiercepharma.com/vaccines/cosette-to-add-liquids-to-its-portfolio-deal-for-second-g-w-labs-plant
350,Takeda's dengue shot 80% effective in massive phase 3 test, https://www.fiercepharma.com/vaccines/takeda-s-dengue-shot-80-effective-massive-phase-3-test
351,GSK sells 2 vaccines to Bavarian Nordic in $1.1B deal, https://www.fiercepharma.com/vaccines/gsk-sells-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic-for-up-to-1-06b
352,AZ struggles to produce FluMist for upcoming shot season, https://www.fiercepharma.com/vaccines/after-efficacy-problems-az-runs-into-manufacturing-issues-for-inhaled-flu-vaccine-flumist
353,Merck says ex-employee bolted to Pfizer with key vaccine info, https://www.fiercepharma.com/pharma/amid-race-to-market-next-gen-pneumococcal-shots-merck-argues-ex-employee-bolted-to-pfizer
354,Bavarian Nordic scores FDA nod for smallpox and monkeypox shot, https://www.fiercepharma.com/vaccines/bavarian-nordic-scores-fda-nod-for-smallpox-and-monkeypox-vaccine-jynneos
355,Pfizer touts data for a next-gen vaccine racing Merck to market, https://www.fiercepharma.com/vaccines/pfizer-touts-latest-next-gen-pneumococcal-data-amid-race-to-market-merck
356,GSK commits $100M to vaccine manufacturing in Montana, https://www.fiercepharma.com/vaccines/gsk-commits-100m-for-expanded-vaccine-manufacturing-site-montana
357,China floats larger penalties for rogue vaccine makers, https://www.fiercepharma.com/vaccines/up-to-30-times-product-value-china-proposes-larger-penalties-rogue-vaccine-makers
358,Sanofi's Dengvaxia faces more restrictions after FDA panel vote, https://www.fiercepharma.com/vaccines/sanofi-s-dengvaxia-faces-even-more-restrictions-u-s-after-fda-panel-vote
359,Philippine DOJ to charge Sanofi officials in Dengvaxia disaster, https://www.fiercepharma.com/vaccines/philippine-prosecutors-find-probable-cause-to-indict-sanofi-officials-dengvaxia-deaths
360,Gottlieb throws his weight behind continuous manufacturing, https://www.fiercepharma.com/manufacturing/gottlieb-throws-fda-weight-behind-industry-move-to-continuous-manufacturing
361,Heplisav-B; Janssen and moreâ€”News of Note, https://www.fiercepharma.com/vaccines/news-note-heplisav-b-sales-janssen-s-therapeutic-hpv-vaccine-and-more
362,"CEPI, CureVac team up in $34M deal to advance RNA 'printer'", https://www.fiercepharma.com/vaccines/cepi-curevac-team-up-34m-deal-to-advance-rna-printer
363,Sinovac swallows poison pill to quash an investor coup, https://www.fiercepharma.com/vaccines/sinovac-swallows-a-poison-pill-to-defend-against-rebel-investors
364,Themisâ€™ chikungunya vaccine nabs fast FDA review, https://www.fiercepharma.com/vaccines/themis-chikungunya-vaccine-furthest-development-nabs-fast-fda-review
365,Emergex gains new R&D facility and CSO, https://www.fiercepharma.com/vaccines/emergex-preps-for-synthetic-vaccines-human-testing-new-r-d-facility-and-key-hire
366,"Facebook, flu vaccines and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-facebook-flu-vaccines-and-more
367,Philippine officials pull Sanofi's Dengvaxia license: report, https://www.fiercepharma.com/vaccines/philippine-officials-pull-dengvaxia-s-marketing-license-but-sanofi-asks-them-to-reconsider
368,GSK sells Indian vaccine unit to Bharat Biotech, https://www.fiercepharma.com/vaccines/bharat-biotech-buys-gsk-s-indian-vaccine-firm-to-become-largest-rabies-vaccine-producer
369,Novel pneumococcal vaccine enters human testing, https://www.fiercepharma.com/vaccines/astellas-and-affinivax-s-novel-pneumococcal-vaccine-enters-human-testing
370,"Moderna, Seqirus and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-moderna-s-combo-vaccine-seqirus-revenue-and-more
371,FluGen plans further development of 'universal' flu vaccine, https://www.fiercepharma.com/vaccines/flugen-plans-further-development-universal-flu-shot-after-phase-2-win
372,China punishes 48 officials in Changsheng vaccine scandal, https://www.fiercepharma.com/vaccines/china-punishes-48-officials-over-changsheng-vaccine-scandal
373,"GlaxoSmithKline, VLP Therapeutics and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-glaxosmithkline-vlp-therapeutics-and-more
374,Merckâ€™s Prevnar challenger nabs FDA â€˜breakthroughâ€™ tag, https://www.fiercepharma.com/vaccines/merck-s-prevnar-challenger-nabs-fda-breakthrough-tag-should-pfizer-be-worried
375,"TB shot, measles outbreak and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-heat-stable-tb-shot-measles-outbreak-and-more
376,ImmusanTâ€™s celiac disease vaccine nabs fast FDA review, https://www.fiercepharma.com/vaccines/immusant-s-celiac-disease-vaccine-nabs-fda-fast-review-to-help-patients-tolerate-gluten
377,Novavax's NanoFlu bests Sanofi's Fluzone HD in seniors, https://www.fiercepharma.com/vaccines/novavax-s-nanoflu-bests-sanofi-s-fluzone-hd-seniors-biotech-eyes-phase-3
378,"Emergent's new CEO, Valneva and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-emergent-s-new-ceo-valneva-s-chikungunya-vaccine-and-more
379,"Sanofi's learned Dengvaxia lessons, vaccines chief says", https://www.fiercepharma.com/vaccines/years-into-troubled-launch-sanofi-vaccine-head-shares-dengvaxia-lessons
380,"Sanofi, Merck win FDA nod for 6-in-1 pediatric vaccine", https://www.fiercepharma.com/vaccines/sanofi-merck-win-fda-nod-for-6-1-pediatric-vaccine-vaxelis
381,Emergent BioSolutions and GeoVaxâ€”News of Note, https://www.fiercepharma.com/vaccines/news-note-emergent-biosolutions-and-geovax
382,Valneva scores quick FDA review for chikungunya vaccine, https://www.fiercepharma.com/vaccines/valneva-scores-quick-fda-review-for-chikungunya-vaccine
383,Sanofi flu vaccine cleared in Hong Kong after impurities report, https://www.fiercepharma.com/vaccines/sanofi-s-flu-vaccine-cleared-hong-kong-after-impurities-report
384,"Drone deliveries, HIV vaccines and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-hiv-vaccine-canada-cepi-donation-and-more
385,Only active Lyme disease vaccine program moves to phase 2, https://www.fiercepharma.com/vaccines/only-active-lyme-disease-vaccine-program-by-valneva-now-phase-2
386,Flu vaccination rates better so far this season: CDC, https://www.fiercepharma.com/vaccines/flu-vaccination-rates-better-so-far-season-cdc-says
387,Merck teams with Brazilian vaccine institute for dengue work, https://www.fiercepharma.com/pharma/merck-teams-brazilian-vaccine-institute-for-dengue-work
388,"Inovio-AZ, Changsheng and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-inovio-astrazeneca-hpv-study-changsheng-and-more
389,"Merckâ€™s Ebola vaccine has 'major impact,' but more help needed", https://www.fiercepharma.com/vaccines/merck-s-ebola-vaccine-has-major-impact-but-u-s-should-help-as-outbreak-worsens-experts
390,Shingrix shortage to persist 'throughout 2019', https://www.fiercepharma.com/pharma/glaxosmithkline-shingrix-shortage-expected-to-persist-throughout-2019-cdc-says
391,Global coalition backs RNA vaccine platform to fight â€˜Disease Xâ€™, https://www.fiercepharma.com/vaccines/global-coalition-invests-imperial-college-london-s-rna-vaccine-platform-to-fight-disease-x
392,"Gardasil-Cervarix, flu vaccines and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-gardasil-cervarix-divide-flu-vaccines-and-more
393,WHO worries Merck's Ebola vaccine will run short: report, https://www.fiercepharma.com/vaccines/who-concerned-about-supplies-merck-s-ebola-vaccine-amid-outbreak-report
394,"J&J, Merck chip in for $100M U.K. vaccine center", https://www.fiercepharma.com/vaccines/janssen-merck-chip-for-100m-u-k-vaccine-center-to-help-fight-epidemics
395,"Citing low vaccine trust, experts warn of measles in Philippines", https://www.fiercepharma.com/vaccines/after-dengvaxia-scandal-experts-warn-measles-threat-philippines
396,Merck quadruples Gardasil supply in China contract, https://www.fiercepharma.com/vaccines/merck-quadruples-gardasil-supply-china-contract-but-still-might-not-meet-full-demand
397,Themis eyes phase 3 for chikungunya vaccine, https://www.fiercepharma.com/pharma/themis-eyes-phase-3-for-chikungunya-vaccine-after-passing-midstage-test
398,"Pfizer results, GSK shortage and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-pfizer-results-gsk-shortage-and-more
399,"Rolling with RotaTeq in China, Merck to phase out Gavi doses", https://www.fiercepharma.com/pharma/amid-china-launch-merck-cites-supply-limits-plan-to-scale-down-rotateq-shipments-africa
400,GSK's Shingrix zooms ahead in U.S. despite tight supply, https://www.fiercepharma.com/pharma/despite-tight-supply-gsk-s-shingrix-zooms-to-blockbuster-status
401,Dupixent and vaccines bring Sanofi back to growth, https://www.fiercepharma.com/pharma/as-promised-dupixent-and-vaccines-reboot-sanofi-back-to-growth
402,"Flu vaccines, CureVac and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-flu-vaccines-curevac-and-more
403,Sanofi's controversial Dengvaxia picks up FDA priority review, https://www.fiercepharma.com/vaccines/sanofi-s-dengvaxia-wins-fda-priority-review-despite-controversial-past
404,Invectys raises â‚¬15M for DNA cancer vaccine study in CLL, https://www.fiercepharma.com/vaccines/invectys-raises-eu15-million-series-a-to-fund-dna-cancer-vaccine-study-cll
405,Merck's Gardasil turns in $1B in monster Q3, https://www.fiercepharma.com/vaccines/merck-s-gardasil-has-a-monster-q3-unprecedented-global-demand-driving-growth
406,J&J opens â‚¬72M vaccine plant for stepped-up R&D, https://www.fiercepharma.com/vaccines/johnson-johnson-opens-eu72m-vaccine-plant-to-support-larger-clinical-trials-possible
407,"Altimmune, Ebola outbreak and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-altimmune-ebola-and-more
408,J&J touts new immune response data for HIV vaccine, https://www.fiercepharma.com/vaccines/j-j-touts-latest-immune-response-data-for-mosaic-hiv-vaccine-program
409,Seqirus' cell-based Flucelvax nears first-ever EU approval, https://www.fiercepharma.com/vaccines/seqirus-flucelvax-nears-europe-s-first-approval-for-cell-based-flu-vaccine
410,NIH grants IDT 10-year vaccine manufacturing contract, https://www.fiercepharma.com/vaccines/nih-grants-idt-biologika-10-year-contract-for-vaccines-and-biologics-manufacturing
411,Officials deny shortage of Seqirus' Fluad in the U.K., https://www.fiercepharma.com/vaccines/officials-deny-shortage-seqirus-fluad-u-k-as-season-nears
412,"Sanofi's Dengvaxia, HPV vaccine and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-sanofi-s-dengvaxia-hpv-vaccine-and-more
413,China slaps $1.3B penalty on vaccine scandal culprit, https://www.fiercepharma.com/vaccines/china-slaps-monstrous-1-3b-penalty-vaccine-scandal-culprit-changsheng
414,U.S. vaccination rates in children keep dropping: CDC, https://www.fiercepharma.com/vaccines/worrying-trend-vaccination-rates-u-s-children-keep-dropping-cdc-reports
415,"TapImmune, IAVI and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-tapimmune-s-breast-cancer-combo-iavi-s-hiv-vaccine-and-more
416,"Novavax, Walter Reed and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-novavax-walter-reed-and-more
417,GSK fails to warn of pandemic flu vaccineâ€™s safety problem: BMJ, https://www.fiercepharma.com/vaccines/glaxosmithkline-fails-to-warn-pandemic-flu-vaccine-s-alarming-safety-signal-bmj-report
418,Pfizer wins 'breakthrough' tag for next pneumococcal vaccine, https://www.fiercepharma.com/vaccines/racing-merck-pfizer-wins-fda-breakthrough-tag-for-20-valent-pneumococcal-vaccine
419,"Bavarian Nordic, FluGen and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-flugen-sinovac-and-more
420,Scientists weigh Zika challenge study: report, https://www.fiercepharma.com/vaccines/seeking-efficacy-data-scientists-weigh-zika-challenge-study-report
421,Pfizer 'all in' on next-gen pneumococcal vaccine candidate: CFO, https://www.fiercepharma.com/vaccines/pfizer-all-advancing-next-gen-pneumococcal-vaccine-candidate-cfo
422,"Sanofi, ImmusanT and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-imv-combo-trial-immusant-and-more
423,"Needed vaccines unlikely at current funding levels, study says", https://www.fiercepharma.com/vaccines/needed-vaccines-against-hiv-malaria-and-tuberculosis-unlikely-to-launch-at-current-funding
424,45 Chinese vaccine makers cleared in sweeping inspections, https://www.fiercepharma.com/vaccines/china-s-drug-regulator-clears-45-vaccine-makers-scandal-triggered-sweeping-inspections
425,"With Advair generics looming, GSK sharpens ax for 650 job cuts", https://www.fiercepharma.com/pharma/gsk-to-cut-650-positions-450-sales-to-focus-new-launches-and-r-d
426,Moderna picks up FDA vaccine official Wellington Sun, https://www.fiercepharma.com/vaccines/moderna-picks-up-vaccine-exec-wellington-sun-from-fda
427,"Turnstone-La Jolla, Inovio-GeneOne and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-turnstone-la-jolla-pact-inovio-geneone-and-more
428,Group calls for flu shots over AstraZeneca's FluMist this year, https://www.fiercepharma.com/vaccines/pediatrics-group-calls-for-flu-shots-over-astrazeneca-s-flumist-year
429,Merckâ€™s Ebola vaccine widely used in latest outbreak: WHO official, https://www.fiercepharma.com/vaccines/merck-s-widely-used-vaccine-transforms-attitude-to-ebola-who-assistant-director-general
430,"Russian trolls, FluMist and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-russian-trolls-flumist-and-more
431,China has withheld deadly bird flu samples from U.S.: NYT, https://www.fiercepharma.com/pharma/china-hasn-t-shipped-h7n9-avian-influenza-samples-to-u-s-researchers-nyt
432,Two-thirds of U.S. teens have started HPV vaccine course: CDC, https://www.fiercepharma.com/vaccines/two-thirds-u-s-adolescents-have-started-hpv-vaccine-course-cdc
433,Flu-shot expert Seqirus swings to its first-ever profit, https://www.fiercepharma.com/vaccines/after-early-budget-woes-seqirus-swings-to-profitability-year-3
434,"Zika, VBI Vaccines and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-nih-zika-vaccine-trial-vbi-vaccines-and-more
435,CEPI awards IDT Biologika up to $36M for MERS research, https://www.fiercepharma.com/vaccines/idt-biologika-picks-up-cepi-deal-worth-up-to-36m-for-mers-vaccine-research
436,"Sanpower hands off Dendreon in $868M deal, its 3rd sale in 3 years", https://www.fiercepharma.com/pharma/dendreon-resold-by-sanpower-868m-deal-it-undesirable
437,The top 5 vaccine companies by 2017 revenue, https://www.fiercepharma.com/vaccines/top-5-vaccine-companies-by-2017-revenue
438,The top 5 vaccine companies by 2017 revenue, https://www.fiercepharma.com/special-report/top-5-vaccine-companies-by-2017-revenue
439,"Pfizer, Sanofi Pasteur and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-pfizer-sanofi-pasteur-and-more
440,Merck execs see 'significant' opportunity ahead for Gardasil, https://www.fiercepharma.com/vaccines/despite-high-flying-gardasil-sales-merck-execs-see-significant-opportunity-ahead
441,Sanofi ships first of 70M doses of flu shots for the 2018-19 season, https://www.fiercepharma.com/vaccines/sanofi-ships-first-70m-doses-flu-shots-for-2018-2019-season
442,Investigation finds systematic data fabrication at Changsheng, https://www.fiercepharma.com/vaccines/systematic-data-fabrication-chinese-police-seeks-to-arrest-18-over-vaccine-scandal
443,GSK's Shingrix beats expectations again in Q2, https://www.fiercepharma.com/vaccines/gsk-s-shingrix-beats-expectations-again-q2-despite-supply-constraint
444,"Ebola, GlaxoSmithKline and SK Bioscienceâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-glaxosmithkline-ebola-and-sk-bioscience
445,U.K. to offer Merck's Gardasil to boys after years of protests, https://www.fiercepharma.com/vaccines/u-k-to-offer-merck-s-gardasil-to-boys-after-years-protests
446,Immune responses from J&J's HIV shot last 1 year: study, https://www.fiercepharma.com/vaccines/immune-responses-from-j-j-s-hiv-shot-last-1-year-study
447,Chinaâ€™s latest vaccine scandal sparks fury and fear, https://www.fiercepharma.com/vaccines/chance-for-global-vaccine-makers-china-s-latest-vaccine-scandal-sparks-fury-and-fear
448,Univercells raises $18.8M for low-cost biologics manufacturing, https://www.fiercepharma.com/vaccines/univercells-raises-18-8m-to-commercialize-low-cost-biologics-manufacturing-platform
449,"MaxiVAX, PATH and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-maxivax-path-and-more
450,Top Chinese rabies vaccine maker mired in drug safety scandal, https://www.fiercepharma.com/vaccines/top-chinese-rabies-vaccine-maker-ordered-to-stop-production-over-forged-data
451,Moderna opens $110M manufacturing site for its mRNA program, https://www.fiercepharma.com/manufacturing/moderna-opens-110m-manufacturing-site-for-its-mrna-program
452,"Johnson & Johnson, Bavarian Nordic and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-johnson-johnson-mabvax-and-more
453,Seqirus joins universal flu vaccine partnership UIVI, https://www.fiercepharma.com/vaccines/seqirus-joins-universal-flu-vaccine-partnership-uivi
454,Sinovac aborts go-private deal amid bizarre fight for control, https://www.fiercepharma.com/vaccines/accusing-orbimed-as-co-conspirator-failed-coup-sinovac-aborts-go-private-process
455,Senators demand more from GSK to boost Shingrix supply, https://www.fiercepharma.com/senators-demand-more-from-gsk-to-boost-shingrix-supply
456,"Sanofi, Translate Bio ink mRNA vaccine R&D deal worth up to $805M", https://www.fiercepharma.com/vaccines/sanofi-translate-bio-ink-mrna-vaccine-r-d-deal-worth-up-to-805m
457,GSK bids adieu to vaccines President Luc Debruyne, https://www.fiercepharma.com/pharma/gsk-bids-adieu-to-vaccines-president-luc-debruyne-as-exec-overhaul-continues
458,GlaxoSmithKline to push past $10B in 2024 vaccine sales: report, https://www.fiercepharma.com/vaccines/sanofi-beats-pfizer-and-a-dark-horse-biotech-2024-vaccine-sales-rankings
459,"Emergent investing $50M, adding 60 jobs to fill-finish facility", https://www.fiercepharma.com/manufacturing/emergent-investing-50m-adding-60-jobs-to-fill-finish-facility
460,SutroVax targets vaccine market with Moncef Slaouiâ€™s help, https://www.fiercepharma.com/vaccines/eyeing-vaccine-industry-s-most-lucrative-market-sutrovax-pulls-85m-and-names-moncef-slaoui
461,Roche's multiple sclerosis drug Ocrevus lowers vaccine responses, https://www.fiercepharma.com/vaccines/roche-s-multiple-sclerosis-drug-ocrevus-may-reduce-response-to-vaccines-study
462,Sanofi hiked Flublok price 12.5% last season, https://www.fiercepharma.com/vaccines/citing-substantial-benefit-for-patients-sanofi-hiked-flublok-price-12-5-last-season
463,"U.K. research hub, Bavarian Nordic and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-u-k-research-hub-bavarian-nordic-and-more
464,GlaxoSmithKline sees some administration errors with Shingrix, https://www.fiercepharma.com/vaccines/early-its-shingrix-launch-glaxosmithkline-has-noticed-some-administration-and-storage
465,China's Gardasil approvals spawn new billionaires: Bloomberg, https://www.fiercepharma.com/vaccines/gardasil-franchise-creates-new-billionaires-china-bloomberg
466,Valneva seeking partner for $350M Lyme disease vaccine effort, https://www.fiercepharma.com/vaccines/valneva-investing-350m-lyme-disease-vaccine-ready-for-phase-2-h2-2018
467,"Ebola, flu vaccines and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-ebola-flu-vaccines-and-more
468,Doctors can change vaccine-hesitant minds with persistence: study, https://www.fiercepharma.com/vaccines/doctors-can-change-vaccine-hesitant-parents-minds-by-being-persistent-study
469,"Profectus, Emergent to work on Nipah vaccine under $25M CEPI deal", https://www.fiercepharma.com/vaccines/profectus-emergent-biosolutions-and-path-join-forces-search-for-a-nipah-vaccine
470,Gardasil 9 shortage hits Hong Kong as Chinese demand surges, https://www.fiercepharma.com/vaccines/growing-chinese-mainland-demand-paralyzes-gardasil-9-market-hong-kong
471,Pfizer steps up its RSV vaccine work with first human tests, https://www.fiercepharma.com/vaccines/pfizer-pushes-rsv-vaccine-into-human-testing
472,"Curevo, Merck, Inovio and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-curevo-merck-inovio-and-more
473,CEPI signs $54.9M Lassa vaccine deal with HIV organization, https://www.fiercepharma.com/vaccines/cepi-to-invest-up-to-54-9m-hiv-organization-s-lassa-fever-vaccine-effort
474,"ILiAD, Emergex and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-iliad-emergex-and-more
475,VBI Vaccines touts positive phase 1 data for CMV vaccine, https://www.fiercepharma.com/vaccines/vbi-eyes-1b-cmv-vaccine-market-positive-phase-1-data
476,"European Commission, Sinovac drama and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-european-commission-sinovac-drama-and-more
477,Pfizer's Trumenba shot nabs 'breakthrough' tag for new use, https://www.fiercepharma.com/vaccines/pfizer-nabs-fda-breakthrough-label-to-extend-trumenba-use-to-1-year-olds-but-s-about-far
478,Experts say next year's flu shot will only be 20% effective, https://www.fiercepharma.com/vaccines/2018-19-season-s-flu-shot-only-20-effective-under-egg-based-production-study
479,"Sanofi's Dengvaxia needs a diagnostic, stat, thanks to WHO", https://www.fiercepharma.com/pharma/sanofi-s-dengvaxia-should-be-used-after-a-point-care-diagnostic-who
480,"GSK's Mosquirix, Emergent BioSolutions and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-glaxosmithkline-s-mosquirix-emergent-biosolutions-and-more
481,Merck vaccine hopeful to battle Pfizer's Prevnar in phase 3, https://www.fiercepharma.com/vaccines/merck-charts-phase-3-development-path-for-15-valent-pneumococcal-shot
482,Merckâ€™s Ebola vaccine appears to provide long-term shield: study, https://www.fiercepharma.com/vaccines/antibody-response-to-merck-s-ebola-vaccine-could-last-for-at-least-2-years-study-finds
483,"Merck KGaA, Jenner hook up to improve vaccine manufacturing", https://www.fiercepharma.com/vaccines/milliporesigma-teams-jenner-institute-to-improve-vaccine-manufacturing
484,Merck's Gardasil 9 vaccine runs scarce in U.K., https://www.fiercepharma.com/vaccines/merck-reports-gardasil-9-shortage-for-u-k-private-clinics
485,Sanofi ups the ante in vaccines with new â‚¬350M plant, https://www.fiercepharma.com/manufacturing/sanofi-ups-ante-vaccines-new-eu350-million-canadian-plant
486,FDA launches criminal investigation into rogue herpes vaccine research, https://www.fiercepharma.com/vaccines/fda-launches-criminal-investigation-into-rogue-herpes-vaccine-research
487,Inovio nets $56M CEPI grant for Lassa fever and MERS vaccines, https://www.fiercepharma.com/vaccines/back-themis-deal-inovio-nabs-56m-cepi-grant-for-lassa-fever-and-mers-vaccines
488,"BiondVax, NIAID kick off phase 2 universal flu shot study in U.S.", https://www.fiercepharma.com/vaccines/biondvax-niaid-kick-off-phase-2-universal-flu-vaccine-study-u-s
489,GSKâ€™s Shingrix crowds out Merck in U.S. shingles vax market, https://www.fiercepharma.com/vaccines/merck-s-zostavax-slumps-as-glaxosmithkline-s-shingrix-steals-majority-u-s-share
490,"Merckâ€™s Zostavax, GeoVax and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-merck-s-zostavax-lawsuit-geovax-and-more
491,Families with alleged Dengvaxia deaths target Sanofi execs, https://www.fiercepharma.com/vaccines/more-alleged-deaths-and-more-requests-for-criminal-charges-filed-dengvaxia-mess
492,Pfizer R&D chief sees pipeline shots filling Prevnar decline, https://www.fiercepharma.com/vaccines/pfizer-r-d-chief-talks-vaccine-programs-at-analyst-meeting
493,"BMS' cancer vaccine, Bharat Biotech and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-bristol-myers-cancer-vaccine-bharat-biotech-and-more
494,BiondVax preps for phase 3 universal flu vaccine trial in Europe, https://www.fiercepharma.com/vaccines/biondvax-preps-for-phase-3-universal-flu-vaccine-trial-europe
495,"Male HPV vaccination rising, but still well below target: study", https://www.fiercepharma.com/vaccines/more-males-are-getting-hpv-vaccines-but-still-far-less-than-ideal-study
496,BN in $36M equine encephalitis vaccine deal with DOD, https://www.fiercepharma.com/vaccines/bavarian-nordic-wins-36m-dod-contract-to-develop-equine-encephalitis-vaccine
497,CVS pharmacies pick up GSK's Shingrix in a retail coup, https://www.fiercepharma.com/vaccines/cvs-stocks-glaxosmithkline-s-shingrix-thousands-pharmacies
498,FDA chief Gottlieb says universal flu shot is far from ready, https://www.fiercepharma.com/vaccines/after-a-rough-season-fda-head-says-universal-flu-shot-years-off
499,Participants in rogue herpes vaccine research take legal action, https://www.fiercepharma.com/vaccines/participants-rogue-herpes-vaccine-research-take-legal-action
500,"Meissaâ€™s chairman, Takeda and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-meissa-s-chairman-from-j-j-sanofi-s-dengvaxia-and-more
501,SK's Skyzoster grabs Korean market share from Merck's Zostavax, https://www.fiercepharma.com/vaccines/as-shingrix-competition-looms-u-s-zostavax-yields-market-share-korea-to-sk-s-skyzoster
502,Sanofi may seek Dengvaxia approval in the U.S., https://www.fiercepharma.com/vaccines/sanofi-may-file-dengvaxia-application-u-s-amid-philippine-mess-report
503,"Bavarian Nordic, universal flu vaccine and moreâ€”News of Note", https://www.fiercepharma.com/infectious-diseases/news-note-bavarian-nordic-universal-flu-vaccine-and-more
504,GSK's Fluarix protects young children in large phase 3 test, https://www.fiercepharma.com/vaccines/glaxosmithkline-s-fluarix-protects-young-children-large-phase-3-test
505,Modernaâ€™s vaccines head steps down as readouts near, https://www.fiercepharma.com/vaccines/moderna-s-vaccines-head-steps-down-as-multiple-programs-undergo-phase-1
506,CEPI grants Themis $37.5M for Lassa and MERS vaccines, https://www.fiercepharma.com/vaccines/themis-nabs-cepi-s-first-grant-37-5m-to-develop-lassa-and-mers-vaccines
507,Novavax posts positive early clinical data for flu vaccine, https://www.fiercepharma.com/vaccines/novavax-s-flu-vaccine-for-older-adults-shows-early-promise-against-sanofi-s-fluzone
508,"Sanofi, flu vaccines and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-sanofi-flu-vaccines-and-more
509,RFK Jr.'s plan for vaccine safety commission seems stalled, https://www.fiercepharma.com/vaccines/one-year-later-rfk-jr-s-plan-for-vaccine-safety-commission-seems-stalled
510,Prokarium raises $10M to develop thermostable oral vaccines, https://www.fiercepharma.com/vaccines/prokarium-raises-10m-for-development-thermostable-oral-vaccines
511,"Bavarian Nordic, AstraZeneca partner in CV301-Imfinzi combo", https://www.fiercepharma.com/vaccines/bavarian-nordic-s-cancer-vaccine-cv301-paired-imfinzi-its-third-pd-1-l1-combo
512,"AstraZeneca's FluMist wins CDC committee's backing, again", https://www.fiercepharma.com/vaccines/astrazeneca-s-flumist-wins-cdc-committee-s-backing-after-two-down-years
513,"FluMist, Heplisav-B and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-astrazeneca-s-flumist-dynavax-s-heplisav-b-head-into-acip
514,Sanofi denies Dengvaxia refund request; Philippines preps suit, https://www.fiercepharma.com/vaccines/sanofi-again-denies-dengvaxia-refund-request-as-philippine-officials-prep-lawsuit
515,"Flucelvax, Fluad propel Seqirus to 26% sales growth in H1", https://www.fiercepharma.com/vaccines/flucelvax-fluad-propel-seqirus-to-26-sales-growth-h1
516,Sanofi refuses to refund Philippines for used Dengvaxia, https://www.fiercepharma.com/vaccines/citing-bad-implication-sanofi-refuses-to-refund-philippines-for-used-dengvaxia
517,Early probe finds 'causal' link between Dengvaxia and deaths, https://www.fiercepharma.com/vaccines/preliminary-probe-philippines-finds-causal-association-between-sanofi-s-dengvaxia-and
518,"Pfizer's Prevnar posts big Q4, beating consensus by 10%", https://www.fiercepharma.com/vaccines/pfizer-s-prevnar-posts-1-53b-q4-sales-beating-consensus-by-10
519,"Vical, FluGen and moreâ€”News of Note", https://www.fiercepharma.com/deals/news-note-vical-flugen-and-more
520,Philippine DOH demands full Dengvaxia refund from Sanofi, https://www.fiercepharma.com/vaccines/philippine-health-authority-demands-full-dengvaxia-refund-from-sanofi
521,Bharat Biotech picks up WHO prequalification for Rotavac, https://www.fiercepharma.com/vaccines/bharat-biotech-picks-up-who-prequalification-for-rotavac-a-discounted-option-to-gsk-and
522,Takedaâ€™s Zika vaccine gets FDA fast track, https://www.fiercepharma.com/vaccines/takeda-s-zika-vaccine-gets-fda-fast-track-though-virus-no-longer-emergency
523,GlaxoSmithKline's Shingrix recommended in Europe, https://www.fiercepharma.com/vaccines/working-to-launch-its-shingles-vaccine-u-s-gsk-picks-up-shingrix-recommendation-europe
524,"Gritstone, Inovio and moreâ€”News of Note", https://www.fiercepharma.com/r-d/news-note-gritstone-oncology-inovio-pharmaceuticals-and-more
525,Seqirus boosting output and focusing on just a few vaccines, https://www.fiercepharma.com/vaccines/seqirus-boosting-output-and-focusing-just-a-few-vaccines-csl-ceo
526,Sanofi to pay for proven Dengvaxia adverse events in Philippines, https://www.fiercepharma.com/vaccines/sanofi-will-pay-for-dengvaxia-adverse-events-philippines-executive-says
527,Vicalâ€™s Astellas-partnered CMV vaccine falls short in phase 3, https://www.fiercepharma.com/vaccines/vical-s-astellas-partnered-cmv-vaccine-failed-phase-3
528,"GlaxoSmithKline's Fluarix, CureVac and moreâ€”News of Note", https://www.fiercepharma.com/regulatory/news-note-glaxosmithkline-s-fluarix-curevac-and-more
529,Sanofi to refund Philippines $28M for unused Dengvaxia doses, https://www.fiercepharma.com/vaccines/sanofi-to-refund-philippines-for-28m-unused-dengvaxia
530,Google backs universal flu vaccine developer Vaccitech, https://www.fiercepharma.com/vaccines/google-sequoia-back-oxford-universal-flu-vaccine-developer-vaccitech
531,Dynavax building out infrastructure for launch: CEO, https://www.fiercepharma.com/vaccines/dynavax-building-out-infrastructure-for-a-steady-heplisav-b-launch-ceo-says
532,"Dynavaxâ€™s Heplisav-B, Emergent and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-dynavax-s-heplisav-b-emergent-outlook-and-more
533,"Themis nabs â‚¬10M series C for chikungunya, Zika push", https://www.fiercepharma.com/vaccines/themis-nabs-eu10m-series-c-for-chikungunya-zika-push
534,Moderna unveils new infectious disease programs at JPM, https://www.fiercepharma.com/vaccines/moderna-updates-at-j-p-morgan-again-but-mostly-infectious-diseases
535,"Philippines suspends Dengvaxia, fines Sanofi $2,000", https://www.fiercepharma.com/vaccines/philippines-suspends-dengvaxia-approval-fines-sanofi-a-symbolic-2-000
536,Sanofi looks for path forward with Dengvaxia as challenges mount, https://www.fiercepharma.com/vaccines/sanofi-hasn-t-been-asked-for-a-dengvaxia-refund-official
537,"GlaxoSmithKline's Shingrix, Seqirus and moreâ€”News of Note", https://www.fiercepharma.com/r-d/news-note-glaxosmithkline-s-shingrix-seqirus-expansion-and-more
538,Serum Institute talks up plan to go after blockbuster vaccines, https://www.fiercepharma.com/vaccines/watch-out-pfizer-merck-and-glaxosmithkline-serum-institute-after-your-best-selling
539,Experts say flu vaccine might be just 10% effective this year, https://www.fiercepharma.com/vaccines/egg-based-production-at-fault-for-flu-shot-s-mere-10-effectiveness-year
540,"At Philippines hearing, Sanofi exec testifies to Dengvaxia's safety", https://www.fiercepharma.com/pharma/sanofi-official-responds-dengvaxia-probe-stopping-vaccinations-a-disservice-to-public
541,Philippines plans to sue over Dengvaxia safety scare: official, https://www.fiercepharma.com/vaccines/philippines-plans-legal-action-against-sanofi-over-dengvaxia-safety-scare-official
542,Sanofi's abandoned Zika vaccine shows early promise, https://www.fiercepharma.com/vaccines/regret-it-or-not-zika-vaccine-sanofi-walked-away-from-shows-early-promise
543,Immunovaccine's cancer vax shows early promise in small trial, https://www.fiercepharma.com/vaccines/immunovaccine-s-incyte-partnered-cancer-vaccine-combo-shows-early-work-ovarian-cancer
544,"GSK, Neon Therapeutics and moreâ€”News of Note", https://www.fiercepharma.com/r-d/news-note-glaxosmithkline-neon-therapeutics-and-more
545,Sanofi ordered to pull Dengvaxia in Philippines, https://www.fiercepharma.com/vaccines/sanofi-ordered-to-pull-dengvaxia-philippines-as-safety-episode-escalates
546,Philippines launches investigation into Dengvaxia, https://www.fiercepharma.com/vaccines/philippines-halts-sanofi-dengvaxia-vaccination-program-sets-probe-into-officials-conduct
547,Sanofi abandons C. diff shot after phase 3 failure, https://www.fiercepharma.com/pharma/sanofi-abandons-phase-3-c-diff-vaccine-right-after-dengvaxia-safety-issues-come-to-light
548,J&J launches efficacy study for a 'global' HIV vaccine, https://www.fiercepharma.com/vaccines/j-j-gates-foundation-and-niaid-launch-efficacy-study-for-their-global-hiv-vaccine
549,Sanofi to take â‚¬100M charge as Dengvaxia hits a snag, https://www.fiercepharma.com/vaccines/new-analysis-sanofi-moves-for-smaller-dengvaxia-label-and-plans-a-eu100m-charge
550,Pfizer's Prevnar 13 set for another price hike in 2018, https://www.fiercepharma.com/vaccines/pfizer-s-prevnar-13-set-for-another-price-hike-2018-as-u-s-price-per-dose-climbs-to-180
551,Merckâ€™s Gardasil protects over 10 years: study, https://www.fiercepharma.com/vaccines/merck-s-gardasil-protects-over-10-years-get-it-early-study
552,"MSF, HIV vaccines and moreâ€”News of Note", https://www.fiercepharma.com/regulatory/news-note-msf-hiv-vaccines-and-more
553,Takeda pushes U.S.-backed Zika vaccine into the clinic, https://www.fiercepharma.com/vaccines/takeda-pushes-u-s-government-backed-zika-vaccine-project-into-clinic
554,Herpes researcher experiments on people before heading abroad, https://www.fiercepharma.com/vaccines/before-heading-offshore-dubious-herpes-vaccine-trial-carried-out-people-u-s
555,"Bavarian Nordic, BiondVax and moreâ€”News of Note", https://www.fiercepharma.com/deals/news-note-bavarian-nordic-biondvax-and-more
556,Merck to miss 2017 filing target for Ebola vaccine, https://www.fiercepharma.com/vaccines/merck-to-miss-2017-filing-target-for-ebola-vaccine-spokesperson
557,Emergent BioSolutionsâ€™ Massachusetts plant wins FDA nod, https://www.fiercepharma.com/vaccines/canton-site-to-contribute-to-emergent-biosolutions-1b-sales-target
558,"Immunovaccine, Leidos extend malaria collaboration", https://www.fiercepharma.com/vaccines/immunovaccine-extended-malaria-vaccine-development-deal-leidos
559,Could RSV be Bavarian Nordic's savior after Prostvac flop?, https://www.fiercepharma.com/vaccines/as-hopes-prostvac-live-combo-therapy-bavarian-nordic-presses-rsv-vaccine
560,"ImmusanT, PaxVax and moreâ€”News of Note", https://www.fiercepharma.com/r-d/news-note-immusant-paxvax-and-more
561,"Merck, GSK face hep A vaccine shortage amid U.S. outbreaks", https://www.fiercepharma.com/vaccines/merck-glaxosmithkline-face-hepatitis-a-vaccine-shortage-amid-recent-u-s-outbreaks
562,Dynavax's twice-rejected hep B shot Engerix-B wins FDA nod, https://www.fiercepharma.com/vaccines/persistence-pays-off-for-dynavax-as-twice-rejected-hep-b-shot-wins-fda-nod
563,Egg-based flu shot production hurt efficacy last year: study, https://www.fiercepharma.com/vaccines/egg-based-flu-vaccine-manufacturing-came-up-short-last-year-study
564,"GeoVax, mumps outbreak and moreâ€”News of Note", https://www.fiercepharma.com/infectious-diseases/news-note-geovax-mumps-outbreak-and-more
565,"Takeda, Sanofi near dengue vaccine final showdown", https://www.fiercepharma.com/vaccines/takeda-s-interim-phase-2-dengue-vaccine-data-could-threaten-sanofi
566,Sanofi's vaccines pick up pharma's slackâ€”again, https://www.fiercepharma.com/vaccines/sanofi-s-vaccines-pick-up-pharma-s-slack-again-even-as-dengvaxia-languishes
567,"Pfizer, Serum Institute and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-pfizer-mumps-vaccines-and-more
568,Merck hack triggers Gardasil's Q3 sales shortfall, https://www.fiercepharma.com/vaccines/merck-hack-causes-gardasil-sales-miss-q3-as-drugmaker-borrows-from-cdc
569,"Aviragen, Vaxart merge to develop oral vaccines", https://www.fiercepharma.com/vaccines/aviragen-vaxart-merge-to-develop-oral-vaccines-for-influenza-norovirus-and-rsv
570,Sanofi inks AI pact to dig up biomarkers on flu vax response, https://www.fiercepharma.com/vaccines/new-berg-deal-sanofi-aims-to-understand-why-some-people-respond-better-to-flu-shots
571,CDC panel recommends GSK's Shingrix over older Merck shot, https://www.fiercepharma.com/vaccines/fresh-off-fda-approval-cdc-panel-recommends-glaxosmithkline-s-shingrix-over-older-merck
572,Inovio and malaria vaccinesâ€”News of Note, https://www.fiercepharma.com/r-d/news-note-inovio-and-malaria-vaccines
573,China approves self-developed Ebola vaccine, https://www.fiercepharma.com/vaccines/china-approves-self-developed-ebola-vaccine-from-2014-outbreak-virus-type
574,Bharat's typhoid vaccine can be used in young children: WHO, https://www.fiercepharma.com/vaccines/who-experts-endorse-bharat-biotech-s-conjugate-typhoid-vaccine-for-young-children
575,GlaxoSmithKline wins blockbuster green light with Shingrix, https://www.fiercepharma.com/vaccines/glaxosmithkline-wins-blockbuster-green-light-shingrix-its-new-shingles-vaccine
576,"Prevnar 13, leprosy vaccine and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-prevnar-13-leprosy-vaccine-and-more
577,Cancer vaccines really are poised for a leap onto market: expert, https://www.fiercepharma.com/vaccines/despite-past-failures-cancer-vaccines-are-poised-to-hit-market-coming-years-expert
578,GlaxoSmithKline lands first-ever approval for Shingrix, https://www.fiercepharma.com/vaccines/glaxosmithkline-secures-first-approval-for-shingrix-from-canadian-authorities
579,"Ebola vaccines from GSK, Merck elicit yearlong response", https://www.fiercepharma.com/vaccines/ebola-vaccines-from-gsk-merck-elicit-lasting-response-study-finds
580,RSV vaccine player Codagenix snags $3M investment, https://www.fiercepharma.com/vaccines/rsv-vaccine-new-player-codagenix-gets-3m-public-and-private-investment
581,Sanofi builds on its lead in flu vaccines with $200M investment, https://www.fiercepharma.com/pharma/sanofi-builds-its-top-spot-flu-vaccines-200m-plant-investment
582,Twitter is rife with antivaccine sentiment: study, https://www.fiercepharma.com/vaccines/social-media-infested-autism-related-antivaccine-messages-study
583,NIH Zika vaccine and moreâ€”News of Note, https://www.fiercepharma.com/infectious-diseases/news-note-nih-zika-vaccine-emergent-biosciences-and-more
584,Merck's HPV shot Gardasil 9 works for at least 6 years: study, https://www.fiercepharma.com/vaccines/new-phase-3-shows-efficacy-merck-s-gardasil-9-can-last-6-years
585,Dynavax and Hilleman Labsâ€”News of Note, https://www.fiercepharma.com/deals/news-note-dynavax-and-hilleman-labs
586,"Inovio, GeneOne to test MERS vaccine in South Korea", https://www.fiercepharma.com/vaccines/inovio-geneone-to-test-mers-vaccine-once-devastated-south-korea
587,"J&J, BARDA join forces to amp up pandemic flu prep", https://www.fiercepharma.com/vaccines/j-j-barda-partner-up-to-advance-pandemic-flu-preparedness
588,"Moderna updates info on Chikungunya, Zika vaccine programs", https://www.fiercepharma.com/vaccines/moderna-initiates-chikungunya-vaccine-human-test-replaces-backup-zika-candidate
589,FDA panel unanimously endorses Glaxo's Shingrix, https://www.fiercepharma.com/vaccines/fda-panel-unanimously-endorses-glaxo-s-shingrix-as-1b-market-duel-nears
590,Observers peg blockbusters as targets for tribal licensing, https://www.fiercepharma.com/vaccines/industry-watchers-peg-top-blockbusters-among-them-prevnar-13-as-targets-for-tribal
591,Seqirusâ€™ adjuvanted flu shot shows better for young children, https://www.fiercepharma.com/vaccines/seqirus-adjuvanted-quadrivalent-flu-vaccine-shows-better-protection-among-young-kids
592,"Lasker awards, Targovax and FluMistâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-lasker-awards-targovax-and-flumist
593,"WRAIR, PATH to test new regimen of GSK's malaria shot", https://www.fiercepharma.com/vaccines/path-walter-reed-to-test-modified-regimen-glaxosmithkline-s-malaria-shot
594,Gates Foundation commits $120M for PATH's vaccine work, https://www.fiercepharma.com/vaccines/gates-foundation-commits-120m-for-nonprofit-path-s-vaccine-work
595,"VBI Vaccines, BiondVax and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-vbi-vaccines-biondvax-and-more
596,Gaviâ€™s vaccine program to save 20M lives by 2020, https://www.fiercepharma.com/vaccines/gavi-s-vaccine-program-to-save-20-million-lives-350b-by-2020-study
597,St. Kitts probes unregulated herpes vaccine trial, https://www.fiercepharma.com/regulatory/island-government-probes-unregulated-herpes-vaccine-trial
598,Themis nabs U.K. funding for Chikungunya vaccine, https://www.fiercepharma.com/vaccines/themis-nabs-u-k-government-funding-for-chikungunya-vaccine-tests
599,Sanofi exits Zika collab as feds gut R&D contract, https://www.fiercepharma.com/vaccines/contract-revamp-sanofi-s-zika-collab-u-s-government-to-wind-down
600,"HPV vaccination rates ticking upward, CDC says", https://www.fiercepharma.com/vaccines/hpv-vaccination-rates-ticking-upward-cdc-says-as-it-urges-more-uptake
601,"Sanofi, FluMist and moreâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-sanofi-flumist-and-more
602,FDA seizes smallpox vaccine used in clinic's rogue cancer remedy, https://www.fiercepharma.com/vaccines/fda-finds-unregulated-use-smallpox-vaccine-stem-cell-concoction-for-cancer-patients
603,Peter Thiel backs unregulated offshore herpes vaccine trial, https://www.fiercepharma.com/vaccines/offshore-human-testing-herpes-vaccine-stokes-debate-over-u-s-safety-rules
604,Pfizer gains Indian patent to Prevnar 13, https://www.fiercepharma.com/vaccines/pfizer-gains-indian-patent-to-prevnar-13-draws-monopoly-criticism-from-msf
605,"Seqirus, VBI and Altimmuneâ€”News of Note", https://www.fiercepharma.com/vaccines/news-note-seqirus-vbi-and-altimmune
606,"MilliporeSigma, Baylor team up for neglected disease vax work", https://www.fiercepharma.com/vaccines/merck-kgaa-baylor-join-together-vaccine-work-against-neglected-diseases
607,J&J labs resident Meissa nabs funds to advance RSV vaccine, https://www.fiercepharma.com/vaccines/j-j-labs-resident-nabs-funds-from-vc-and-nih-to-advance-rsv-vaccine
608,Sanofi's Riboldi talks up new facility's role in flu-shot push, https://www.fiercepharma.com/vaccines/video-interview-sanofi-pasteur-s-ryan-riboldi-quality-testing-facility
609,FDA requires more time to finalize Heplisav-B postmarketing plan, https://www.fiercepharma.com/vaccines/dynavax-shares-roller-coaster-as-fda-requires-heplisav-b-postmarketing-details
610,"Valneva, Emergent BioSolutions to co-develop Zika shot", https://www.fiercepharma.com/pharma/valneva-emergent-biosolutions-to-co-develop-zika-shot
611,Sanders pushes for price limits on taxpayer-funded drugs, https://www.fiercepharma.com/pharma/sanders-pushes-for-u-s-price-limits-taxpayer-funded-medical-products
612,FDA AdCom in favor of Dynavaxâ€™s hep B vaccine on third try, https://www.fiercepharma.com/vaccines/heplisav-b-approval-highly-probable-as-adcom-voted-favor-dynavax-s-third-try
613,"Bavarian Nordic, J&J team up in $879M HIV and HBV vaccines deal", https://www.fiercepharma.com/vaccines/bavarian-nordic-j-j-join-forces-879m-hiv-and-hbv-vaccines-development
614,"FDA holds off on job cuts, assures workers fees to be authorized", https://www.fiercepharma.com/pharma/fda-holds-off-job-cuts-assures-workers-user-fees-will-get-authorized
615,"AZ-Daiichi, Padcev, AbbVieâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/az-daiichi-trop2-readout-padcev-bladder-cancer-win-abbvie-i-mab-cd47-breakup
616,"BeiGene, PeptiDream and Bioconâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/novartis-beigene-pd-1-breakup-genentech-1b-peptidream-deal-biocon-new-ceo
617,Takeda settles antitrust lawsuit over gout drug Colcrys, https://www.fiercepharma.com/pharma/takeda-settles-pay-delay-lawsuit-over-gout-drug-colcrys
618,Novartis returns PD-1 to BeiGene in another cancer drug divorce, https://www.fiercepharma.com/pharma/after-tigit-divorce-novartis-returns-tislelizumab-beigene-pd-1-gains-first-european-nod
619,"Otsuka, Astellas, Exelixis and Insilicoâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/otsuka-eye-disease-deal-astellas-354m-plant-exelixis-insilico-ai-drug-pact
620,"Astellas, Otsuka, Takedaâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astellas-brief-ira-fight-otsuka-psychedelic-buy-takeda-court-loss
621,"Vyvanse, Keytruda-Lenvima, Adagene-ADCâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/vyvanse-generics-another-lenvima-flop-adagene-adc-breakup
622,"Moderna, GSK and Glenmarkâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/moderna-vaccine-car-t-combo-plans-shingrix-100-efficacy-glenmark-doj-deal
623,"Carvykti, Sangon, China and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/carvyktis-momentum-novos-funding-sangon-chinas-call-foreign-investment
624,Japan awarded $115M to Arcturus JV to boost mRNA manufacturing, https://www.fiercepharma.com/manufacturing/japan-awards-115m-arcturus-jv-boost-mrna-manufacturing
625,"Astellas, Singapore biotechs, AZ-CanSinoâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astellas-eye-drug-nod-singapores-biotech-dream-astrazenecas-cansino-mrna-deal
626,AstraZeneca signs mRNA manufacturing deal with China's CanSino, https://www.fiercepharma.com/manufacturing/astrazeneca-commits-mrna-signs-vaccine-manufacturing-deal-chinas-cansino
627,"BMS-BeiGene, Sumitomo-Otsuka, AstraZenecaâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/fierce-pharma-asia-bms-beigene-deal-end-sumitomo-otsuka-schizophrenia-flops-astrazeneca-ceo
628,"BMS, BeiGene end legacy Celgene deal years after China ban", https://www.fiercepharma.com/pharma/bristol-myers-beigene-end-legacy-celgene-deal-settlement-years-after-china-ban
629,AstraZeneca CEO tries to clear the air on China spinoff plan, https://www.fiercepharma.com/pharma/astrazeneca-looks-stronger-china-sales-ceo-tries-clear-air-spinoff-plan
630,"Daiichi Sankyo, Astellas, Takedaâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/daiichi-leukemia-drug-nod-astellas-protein-degrader-pact-takeda-rare-disease-setback
631,"Eisai, Astellas, GSK and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/fierce-pharma-asia-eisais-subcutaneous-leqembi-study-astellas-ira-suit-gsks-taiwan-nucala
632,"BeiGene-Novartis, Takeda, Eisai and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/beigene-novartis-tigit-divorce-takedas-fda-withdrawal-departure-eisais-alzheimers-lead
633,"AZ-Daiichi, Moderna, Takeda and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/az-daiichi-adc-scare-moderna-china-investment-takeda-1b-f-star-deal
634,Korea's SK inks deal to support vaccine production in Thailand, https://www.fiercepharma.com/manufacturing/sk-bioscience-inks-deal-support-vaccine-manufacturing-thailand
635,"Shionogi, Takeda, AbbVie-BeiGeneâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/shionogi-qpex-buy-takeda-rare-disease-win-abbvie-patent-case-against-beigene
636,"AstraZeneca, Takeda, Dr. Reddy's and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astrazeneca-china-spinoff-report-new-rd-pact-takedas-vyvanse-shortage
637,AZ's China head refutes news report about potential spinoff, https://www.fiercepharma.com/pharma/misinformation-astrazenecas-china-head-refutes-spinoff-report
638,"FDA dings one Dr. Reddy's plant in India, clears another", https://www.fiercepharma.com/manufacturing/fda-inspections-ding-one-dr-reddys-facility-clears-another-india
639,"Astellas, Eisai and BeiGeneâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astellas-ceos-aggressive-strategy-leqembis-adcomm-win-abbvie-sues-beigene
640,"Leqembi, Enhertu, Samsung Biologicsâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/fierce-pharma-asia-eisai-and-biogens-leqembi-briefing-az-and-daiichis-enhertu-data-pfizer
641,Samsung Biologics reels in $411M Pfizer biosim production deal, https://www.fiercepharma.com/manufacturing/samsung-biologics-reels-411m-likely-make-pfizers-humira-copycat
642,FDA to allow temporary overseas production of chemo drugs, https://www.fiercepharma.com/manufacturing/fda-allow-temporary-overseas-production-shore-supplies-chemo-drug
643,"Sun Pharma, XtalPi, Yuhanâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/fierce-pharma-asia-suns-taro-buyout-eli-lillys-xtalpi-collaboration-yuhans-newly-bought
644,"Carvykti, Thermo Fisher, Celltrionâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/carvykti-eu-filing-thermo-fisher-singapore-expansion-celltrion-humira-biosim-nod
645,"Takeda, AstraZeneca, Astellas and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/takeda-challenging-year-az-new-adc-buy-astellas-menopause-drug-nod
646,"FibroGen, AZ's anemia drug Evrenzo finally chalks up a win", https://www.fiercepharma.com/pharma/fibrogen-azs-evrenzo-finally-chalks-win-chemo-induced-anemia-china
647,"Roche, Eisai, Takeda and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/chinese-biotechs-her2-deals-roche-eisai-takeda-us-layoffs
648,"Astellas, J&J, Sun and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astellas-59b-eye-drug-buy-jj-new-car-t-deal-sun-clinical-hold
649,"Daiichi Sankyo, Glenmark, Serum-Bioconâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/daiichi-leukemia-drug-delay-enhertu-growth-glenmark-merck-zetia-settlement
650,Sun Pharma pauses US drug exports from India plant, https://www.fiercepharma.com/manufacturing/sun-pharma-hits-pause-mohali-plant-response-fda-letter
651,Bluebird amends deal with Lonza to boost gene therapy capacity, https://www.fiercepharma.com/pharma/bluebird-taps-lonza-boost-manufacturing-capacity-its-gene-therapies-zynteglo-and-skysona
652,Novo Nordisk Foundation to set up cell therapy production 'hub', https://www.fiercepharma.com/pharma/novo-nordisk-foundation-pumps-136m-new-cell-therapy-manufacturing-hub-denmark
653,Catalent poaches Lonza's David McErlane to head up biologics, https://www.fiercepharma.com/pharma/after-lonza-ceo-departure-catalent-scoops-swiss-cdmos-bioscience-business-head-lead
654,"Otsuka, Astellas, Exelixis and Insilicoâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/otsuka-eye-disease-deal-astellas-354m-plant-exelixis-insilico-ai-drug-pact
655,New cell therapy manufacturer BlueWhale has emerged with $18M, https://www.fiercepharma.com/pharma/bluewhale-bio-breaches-cover-18m-mission-overhaul-cell-therapy-production
656,"Carvykti, Sangon, China and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/carvyktis-momentum-novos-funding-sangon-chinas-call-foreign-investment
657,J&J's myeloma bispecific not slowing Carvykti down: Legend exec, https://www.fiercepharma.com/pharma/jjs-bispecific-not-slowing-car-t-down-carvykti-gets-fda-regular-review-earlier-myeloma
658,"GeneFab debuts, acquires Senti Bio's production tech for $38M", https://www.fiercepharma.com/manufacturing/genefab-debuts-manufacturer-acquires-senti-bio-production-tech-38m
659,Thermo Fisher axes hundreds of jobs in Florida, https://www.fiercepharma.com/pharma/thermo-fisher-lays-200-clinical-stage-cell-and-gene-therapy-factory-fl
660,Bluebird touts gene therapy launches as cash remains tight, https://www.fiercepharma.com/pharma/bluebird-touts-zynteglo-skysona-launch-progress-fda-decision-scd-gene-therapy-draws-closer
661,J&J's myeloma bispecific not slowing Carvykti down: Legend exec, https://www.fiercepharma.com/pharma/jjs-bispecific-not-slowing-car-t-down-carvykti-gets-fda-regular-review-earlier-myeloma
662,"GeneFab debuts, acquires Senti Bio's production tech for $38M", https://www.fiercepharma.com/manufacturing/genefab-debuts-manufacturer-acquires-senti-bio-production-tech-38m
663,Thermo Fisher axes hundreds of jobs in Florida, https://www.fiercepharma.com/pharma/thermo-fisher-lays-200-clinical-stage-cell-and-gene-therapy-factory-fl
664,Bluebird touts gene therapy launches as cash remains tight, https://www.fiercepharma.com/pharma/bluebird-touts-zynteglo-skysona-launch-progress-fda-decision-scd-gene-therapy-draws-closer
665,Pair of future SCD gene therapies priced fair at $1.35M - $2.05M, https://www.fiercepharma.com/pharma/icer-updates-cost-effectiveness-threshold-bluebird-vertex-and-crisprs-dueling-sickle-cell
666,"BeiGene-Novartis, Takeda, Eisai and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/beigene-novartis-tigit-divorce-takedas-fda-withdrawal-departure-eisais-alzheimers-lead
667,"AZ-Daiichi, Moderna, Takeda and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/az-daiichi-adc-scare-moderna-china-investment-takeda-1b-f-star-deal
668,BioMarin lands FDA nod for hemophilia gene therapy Roctavian, https://www.fiercepharma.com/pharma/biomarins-hemophilia-gene-therapy-roctavian-lands-fda-nod-glimmers-enthusiasm-among-doctors
669,UPDATED: Sarepta prices DMD gene therapy at $3.2M, https://www.fiercepharma.com/pharma/sareptas-dmd-gene-therapy-finally-makes-it-accelerated-approval-finish-line-restricted
670,Andelyn debuts cell and gene manufacturing facility in Ohio, https://www.fiercepharma.com/manufacturing/andelyn-biosciences-debuts-cell-and-gene-manufacturing-headquarters
671,US oncologists: cost biggest barrier to new cancer drug uptake, https://www.fiercepharma.com/marketing/us-oncologists-see-cost-biggest-barrier-new-cancer-drug-uptake-cell-gene-therapy
672,BioMarin's hemophilia gene therapy may win over Europe: analysts, https://www.fiercepharma.com/marketing/biomarins-hemophilia-gene-therapy-may-have-chance-winning-over-europe-analysts
673,FDA clears BMS' cell therapy facility in Massachusetts, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says
674,Catalent expands its biologics services platform after setbacks, https://www.fiercepharma.com/manufacturing/catalent-tacks-more-biologic-services-its-onebio-platform
675,"ASCO: J&J, Legend's Carvykti stages stellar show in myeloma", https://www.fiercepharma.com/pharma/jj-legends-carvykti-stages-stellar-show-earlier-myeloma-has-car-t-reached-ceiling
676,ASCO: BMS pitches Breyanzi as the first CAR-T for CLL, https://www.fiercepharma.com/pharma/bms-pitches-breyanzi-first-car-t-cll-can-single-arm-trial-persuade-fda
677,Novartis targets new fieldsâ€”and CAR-Tâ€”for immunology growth, https://www.fiercepharma.com/pharma/next-immunology-growth-novartis-targets-atypical-areas-and-car-t-cosentyx-set-one-more-show
678,"Astellas, J&J, Sun and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astellas-59b-eye-drug-buy-jj-new-car-t-deal-sun-clinical-hold
679,Danaher's Aldevron unit plots mRNA manufacturing expansion, https://www.fiercepharma.com/manufacturing/danahers-aldevron-unit-expands-cell-and-gene-therapy-protein-production
680,BioMarin debuts â‚¬38M expansion of its Irish operations, https://www.fiercepharma.com/manufacturing/biomarin-debuts-eu38m-expansion-its-irish-manufacturing-operations
681,"J&J-Legend, BeiGene-Novartis and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/carvykti-massive-myeloma-win-extra-production-help-beigene-pd-1-comeback
682,"Leaked abstract shows massive benefit for J&J, Legend's Carvykti", https://www.fiercepharma.com/pharma/leaked-abstract-show-jj-legends-carvykti-reduce-progression-or-death-74-earlier-myeloma
683,"J&J, Legend tap Novartis to help make CAR-T therapy Carvykti", https://www.fiercepharma.com/manufacturing/jj-legend-tap-novartis-help-make-car-t-therapy-carvykti-amid-supply-constraint
684,"Takeda, Astellas, Eisaiâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/takeda-gene-therapy-pivot-new-pay-delay-lawsuit-astellas-write-offs
685,"Vertex, bluebird SCD gene therapies can cost $1.9M: ICER", https://www.fiercepharma.com/pharma/sickle-cell-disease-gene-therapies-vertex-crispr-bluebird-can-be-cost-effective-19m-icer
686,"Astellas depreciates FibroGen's Evrenzo, nixes cell therapy deal", https://www.fiercepharma.com/pharma/astellas-writes-340m-fibrogens-evrenzo-joins-gsk-nixing-cell-therapy-collab-adaptimmune
687,Sartorius buys Polyplus in $2.6B cell and gene therapy expansion, https://www.fiercepharma.com/manufacturing/26b-cell-and-gene-therapy-expansion-sartorius-buys-viral-vector-specialist-polyplus
688,"Takeda, Eisai, GSK and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/takeda-pdt-expansion-leqembi-sales-prospects-gsk-prep-generics-deals
689,Pharmaron charts upgrades at former AbbVie UK plant, https://www.fiercepharma.com/manufacturing/pharmaron-snares-prestigious-government-grant-scale-out-cell-and-gene-facility-it
690,J&J shelves Carvykti's UK launch amid manufacturing shortfalls, https://www.fiercepharma.com/pharma/johnson-johnson-scraps-carvykti-launch-plan-uk-car-t-manufacturing-remains-lacking
691,"'The Top Line': AI and machine learning, plus the headlines", https://www.fiercepharma.com/pharma/top-line-podcast-why-pharma-needs-ramp-its-use-ai-and-machine-learning-tools-stay-ahead
692,Bayer cuts 55 jobs at its rapidly growing Berkeley campus, https://www.fiercepharma.com/manufacturing/reorganization-bayer-lays-55-berkeley-campus
693,BMS details landmark Abecma myeloma data that ASH turned down, https://www.fiercepharma.com/pharma/bristol-meyers-landmark-abecma-earlier-multiple-myeloma-data-are-here-why-did-ash-turn-it
694,SK plots next growth phase with plans for $261M campus in Korea, https://www.fiercepharma.com/manufacturing/sk-plots-261m-vaccine-ecosystem-korea
695,Vertex teases launch plans for first CRISPR gene editing therapy, https://www.fiercepharma.com/marketing/vertex-teases-launch-plan-first-crispr-gene-editing-therapy-ahead-fda-decision
696,"Gene therapy costs, IRA model updates top ICER head's agenda", https://www.fiercepharma.com/pharma/icer-chiefs-agenda-surging-gene-therapy-cost-post-ira-drug-pricing-update-and-kudos
697,Catalent draws buyout interest from Danaher: Bloomberg, https://www.fiercepharma.com/manufacturing/catalent-covid-vaccine-contract-draws-buyout-interest-danaher-significant-premium
698,Sensorion taps Eveon to deliver gene therapy to inner ear, https://www.fiercepharma.com/pharma/seeking-improved-efficacy-sensorion-taps-eveon-deliver-gene-therapy-inner-ear
699,Vector BioMed debuts as viral vector CDMO with $15M funding, https://www.fiercepharma.com/manufacturing/vector-biomed-debuts-viral-vector-cdmo-15m-funding
700,"J&J, Legend's Carvykti hits goal in earlier myeloma", https://www.fiercepharma.com/pharma/jj-legends-carvykti-hits-goal-earlier-myeloma-escalates-car-t-showdown-bristol-myers-abecma
701,BMS makes case for Breyanzi in CLL. Will it make a difference?, https://www.fiercepharma.com/pharma/bristol-myers-makes-case-breyanzi-chronic-lymphocytic-leukemia-will-it-make-difference
702,England's NICE endorses Gilead's CAR-T Yescartaâ€”finally, https://www.fiercepharma.com/pharma/after-years-back-and-forth-gilead-and-kites-car-t-yescarta-woos-uk-cost-watchdog-nice
703,CRL inks pact to help develop liver cancer gene therapy, https://www.fiercepharma.com/manufacturing/crl-pact-south-korean-biopharma-develop-liver-cancer-therapy
704,Ipsen CEO 'not at all afraid' of Big Pharma in rare diseases, https://www.fiercepharma.com/pharma/ipsen-ceo-not-all-afraid-big-pharma-rare-disease-steers-clear-gene-therapy
705,EMA looks to warn doctors of Zolgensma's liver failure deaths, https://www.fiercepharma.com/marketing/ema-looks-warn-doctors-zolgensmas-liver-failure-deaths-amid-discussion-novartis
706,"JPM: Novartis CEO refutes respiratory, eye drug sell-off report", https://www.fiercepharma.com/pharma/novartis-weighing-respiratory-eye-drug-selloffs-after-sandoz-not-necessarily-says-ceo
707,Agilent to spend $725M to boost production for biologic APIs, https://www.fiercepharma.com/manufacturing/agilent-shell-out-725m-boost-production-capacity-biologic-apis
708,"Bluebird touts launch progress, extends cash runway to 2024", https://www.fiercepharma.com/pharma/jpm23-bluebird-touts-gene-therapy-launch-progress-extends-cash-runway-2024
709,Cancer center leaders lay bare CAR-T makers' struggles, https://www.fiercepharma.com/pharma/johnson-johnson-bristol-myers-kite-pharma-car-t-cell-therapy-struggle-sloan-kettering
710,Abecma's 3rd-line myeloma data not selected by ASH22, https://www.fiercepharma.com/pharma/where-are-abecmas-third-line-data-bristol-myers-renews-car-ts-pitch-earlier-myeloma
711,ASH: Bristol bolsters Breyanzi's case in earlier lymphoma, https://www.fiercepharma.com/pharma/bristol-myers-bolsters-breyanzis-earlier-lymphoma-case-elevated-car-t-fight-against-gilead-0
712,"'The Top Line': Biogen's new CEO, plus this week's headlines", https://www.fiercepharma.com/fierce-biotech-homepage/top-line-biogens-new-ceo-plus-weeks-headlines
713,Genentech starts phase 2 trial to optimize cell therapy delivery, https://www.fiercepharma.com/pharma/genentech-starts-phase-2-trial-optimize-delivery-eye-disease-cell-therapy
714,'The Top Line': Fierce Biotech's Cell & Gene Therapy Forum, https://www.fiercepharma.com/fierce-biotech-homepage/top-line-recap-fierce-biotechs-cell-and-gene-therapy-forum
715,Charles River cell therapy push powers on with latest expansion, https://www.fiercepharma.com/manufacturing/charles-river-cell-therapy-production-push-powers-latest-expansion
716,Vision loss cell therapy implant hits primary goals in phase 3, https://www.fiercepharma.com/pharma/neurotechs-vision-loss-cell-therapy-implant-hits-primary-goals-phase-3-trials
717,SK bioscience unveils strategy aimed at global market expansion, https://www.fiercepharma.com/manufacturing/sk-bioscience-unveils-strategy-aimed-global-market-expansion
718,ReiThera opens â‚¬15M bio production after regulatory signoff, https://www.fiercepharma.com/manufacturing/reithera-opens-eu15m-bio-production-expansion-after-italian-regulatory-sign
719,"Sumitomo-Myovant, Astellas-Taysha, Genentechâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/sumitomo-myovant-buy-astellas-taysha-gene-therapy-pact-trade-secret-theft-sentencing
720,Zolgensma decline unrelated to gene therapy deaths: Novartis CEO, https://www.fiercepharma.com/pharma/novartis-ceo-pins-zolgensma-decline-market-expansion-slowdown-unrelated-death-reports
721,VectorBuilder bags $57M to build out gene delivery capabilities, https://www.fiercepharma.com/pharma/vectorbuilder-bags-57m-build-out-gene-delivery-capabilities
722,"J&J, Legend's CAR-T nets $55M sales before key readout", https://www.fiercepharma.com/marketing/jj-legends-carvykti-nets-55m-sales-all-eyes-car-ts-earlier-myeloma-readout
723,"J&J, Legend double CAR-T manufacturing investment to $500M", https://www.fiercepharma.com/manufacturing/legend-jj-double-down-car-t-manufacturing-500m-carvykti-eyes-wider-myeloma-use
724,Cytiva expansion tear continues with CEVEC Pharma acquisition, https://www.fiercepharma.com/manufacturing/cytiva-expansion-tear-continues-cevec-pharma-acquisition
725,Gilead's Kite wins all-clear for viral vector production, https://www.fiercepharma.com/manufacturing/kites-commercial-viral-vector-ambitions-take-flight-gilead-cell-therapy-player-wins
726,"'The Top Line': The Fierce 15, Fierce Biotech Summit highlights", https://www.fiercepharma.com/pharma/top-line-fierce-15-honorees-are-announced-plus-fierce-biotech-summit-highlights
727,"As Keytruda's shine wanes, can Merck build a 2nd blockbuster?", https://www.fiercepharma.com/pharma/keytruda-taught-merck-how-build-blockbuster-manufacturing-second-lightning-bolt-easier-said
728,Bluebird's $3M gene therapy breaks drug price record, https://www.fiercepharma.com/pharma/3m-gene-therapy-bluebird-breaks-own-record-fda-approval-skysona
729,MeiraGTx shows off gene therapy manufacturing site in Ireland, https://www.fiercepharma.com/manufacturing/meiragtx-unveils-irelands-first-site-capable-commercial-stage-gene-therapy
730,"Under Biden's order, DOD and HHS earmark $1B for US boost", https://www.fiercepharma.com/manufacturing/under-bidens-us-biomanufacturing-order-hhs-and-dod-earmark-1b-domestic-production
731,"As gene therapies proliferate, a risk of 'cost shock' looms", https://www.fiercepharma.com/pharma/fierce-next-gen-cell-and-gene-therapy-payment-panel
732,BMS' CAR-T pressures Gilead in 2L lymphoma with broader nod, https://www.fiercepharma.com/marketing/bristol-myers-breyanzi-broader-fda-nod-brings-car-t-showdown-gilead-earlier-lymphoma
733,BioMarin's hemophilia gene therapy wins conditional EU backing, https://www.fiercepharma.com/pharma/biomarins-hemophilia-gene-therapy-roctavian-wins-conditional-eu-backing-fda-plan-delayed
734,"'The Top Line': 10 most profitable pharmas, bluebird and more", https://www.fiercepharma.com/pharma/top-line-podcast-top-10-list-pharma-profits-turns-some-surprises-bluebird-bios-gene
735,CSL clicks with photographer Rankin in hemophilia project, https://www.fiercepharma.com/marketing/csl-behring-clicks-photographer-rankin-history-hemophilia-project
736,Novartis' CAR-T Kymriah posts impressive survival data in ALL, https://www.fiercepharma.com/pharma/amid-struggles-car-t-kymriah-novartis-posts-strong-survival-data-all
737,Bluebird scores 2nd straight win at high-stakes FDA meeting, https://www.fiercepharma.com/pharma/bluebird-scores-second-straight-win-high-stakes-fda-gene-therapy-meeting
738,Astellas opens new $100M gene therapy production plant, https://www.fiercepharma.com/manufacturing/astellas-opens-new-100m-gene-therapy-production-plant
739,Sana Biotechnology inks deal for new manufacturing facility, https://www.fiercepharma.com/manufacturing/sana-biotechnology-inks-deal-new-manufacturing-facility-hires-execs
740,Novartis' Kymriah faces off against Yescarta with new nod, https://www.fiercepharma.com/marketing/novartis-kymriah-bags-fda-nod-face-gileads-yescarta-follicular-lymphoma
741,"J&J-Legend, Junshi, Vir-WuXi and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/jj-legends-new-car-t-data-junshis-antiviral-tops-pfizers-paxlovid-vir-wuxi-end-covid-pact
742,"ASCO: J&J, Legend reveal more CAR-T data from Carvykti", https://www.fiercepharma.com/pharma/asco-jj-legend-unfold-more-car-t-data-and-look-carvykti-earlier-myeloma-difficult-population
743,"Roche, bluebird settle gene therapy trademark suit", https://www.fiercepharma.com/marketing/roche-bluebird-bio-settle-gene-therapy-trademark-suit-around-spark-sickle-cell-disease
744,"AZ-Daiichi, Biogen-Eisai, Hutchmed, Junshiâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/enhertu-breast-cancer-nod-biogen-eisai-next-play-fda-snubs-2-china-made-cancer-drugs
745,"Astellas, BeiGene, Serum Instituteâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/astellas-gene-therapy-write-beigene-novartis-pd-1-win-serum-institutes-unused-covid-shots
746,WuXi teams with Singapore group on cell therapy production, https://www.fiercepharma.com/pharma/wuxi-advanced-therapies-teams-singapore-group-cell-therapy-production-tech
747,The FDA says Ocugen needs to hand over results from a 2019 study, https://www.fiercepharma.com/pharma/ocugen-stares-down-10000-fine-over-missing-clinical-trial-data-fda
748,BioMarin joins pharma's filmmaking push, https://www.fiercepharma.com/marketing/biomarin-gets-filmmaking-plots-patient-documentary-new-bleeding-disorder-campaign
749,"Daiichi-Seagen, Legend and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/daiichi-loses-seagen-patent-suit-cdmo-builds-500m-gene-therapy-plant-legend-lands-sec
750,Materials maker Akron beefs up plasmid DNA production in Florida, https://www.fiercepharma.com/pharma/akron-bio-debuts-new-plasmid-dna-plant-quest-ease-regenerative-medicine-bottlenecks
751,"Watch out, BMS. J&J, Legend's CAR-T is here", https://www.fiercepharma.com/pharma/johnson-johnson-legend-car-t-cilta-cel-myeloma-ring-fda-approval-rivaling-bristol-myers
752,"BioMarin eyes profit, though safety concerns cloud new launch", https://www.fiercepharma.com/pharma/biomarin-eyes-profit-as-dwarfism-drug-launch-underway-hemophilia-gene-therapy-refiling-nears
753,"Samsung Biologics, GSK, Fujifilm and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/samsung-biologics-mrna-ambition-gsk-covid-19-vaccine-supply-fujifilm-s-plant-buy
754,Roche loses one bid against bluebird's 'spark' DTC ad, https://www.fiercepharma.com/marketing/court-ruling-bluebird-bio-s-gene-therapy-marketing-campaign-does-not-spark-joy-at-roche-s
755,"Takeda-Denali, Daiichi Sankyo, J&J-Legendâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/takeda-denali-alzheimer-s-hiccup-daiichi-sankyo-r-d-reorg-j-j-legend-car-t-supply-prep
756,Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, https://www.fiercepharma.com/pharma/unfinished-business-bluebird-bio-ceo-wants-zynteglo-back-european-market
757,Selecta taps Ginkgo to improve gene therapy delivery , https://www.fiercepharma.com/drug-delivery/selecta-taps-ginkgo-to-create-better-capsids-for-gene-therapy-delivery
758,South Korea's SK commits $350M as part of CDMO plans, https://www.fiercepharma.com/manufacturing/south-korea-s-sk-commits-350m-to-cbm-as-part-cdmo-partnership
759,"2022 forecast: Cell, gene therapy makers have high hopes", https://www.fiercepharma.com/pharma/cell-and-gene-therapy-makers-push-past-regulatory-payer-hurdles-to-set-up-high-hopes-for
760,Gilead's Yescarta could get $1.5B sales in 2L lymphoma: analyst, https://www.fiercepharma.com/marketing/gilead-yescarta-1-5-billion-sales-earlier-lymphoma-game-changing-car-t-data-fast
761,Novartis has an idea why Kymriah failed in 2L lymphoma, https://www.fiercepharma.com/pharma/novartis-has-idea-why-kymriah-failed-lymphoma-shifts-focus-to-next-gen-car-t
762,"BMS, Gilead lock horns in CAR-T for 2L lymphoma", https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma
763,"Legend-J&J, BeiGene, Samsung Biologicsâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-legend-johnson-johnson-car-t-delay-beigene-brukinsa-samsung
764,"GenScript adopts automation at its new cell, gene therapy", https://www.fiercepharma.com/manufacturing/genscript-debuts-new-cell-and-gene-therapy-plant-new-jersey
765,Jaguar to pump $125M into NC gene therapy manufacturing site, https://www.fiercepharma.com/manufacturing/jaguar-to-pump-125m-into-north-carolina-gene-therapy-manufacturing-facility
766,"Takeda, GammaDelta, Fujifilm and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-gammadelta-buy-fda-warning-letter-removal-fujifilm-s
767,"Takeda, BMS-BeiGene, Samsung and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-cell-gene-therapy-deals-bms-beigene-abraxane-brawl
768,"Takeda, Moderna and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-narcolepsy-trial-problem-gene-therapy-pact-human-error
769,"Takeda, Astellas, Everest-Providence and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-lung-cancer-nod-4th-death-astellas-gene-therapy-trial
770,Eyevensys bags $12M to test non-viral gene therapy delivery tech, https://www.fiercepharma.com/drug-delivery/eyevensys-bags-12m-to-test-non-viral-gene-therapy-delivery-tech
771,Poseida partners with Cellares on cell therapy factory in a box, https://www.fiercepharma.com/manufacturing/cellares-welcomes-poseida-aboard-cell-shuttle-as-it-closes-out-early-access-program
772,Bluebird bio's Zynteglo bounces back in Europe, https://www.fiercepharma.com/pharma/after-5-month-hiatus-bluebird-bio-s-zynteglo-bounces-back-europe-all-clear-from-safety-group
773,NICE says no dice to Orchard's pricey therapy for rare disease, https://www.fiercepharma.com/pharma/england-s-price-watchdog-rejects-orchard-s-pricey-gene-therapy-for-metachromatic
774,Bluebird counters trademark suit from Roche's Spark, https://www.fiercepharma.com/marketing/bluebird-hits-back-at-roche-s-spark-accuses-trademark-lawsuit-as-attempt-to-silence
775,AGC is picking up a second commercial plant in CO, https://www.fiercepharma.com/manufacturing/agc-biologics-inks-deal-for-commercial-novartis-gene-therapies-plant-co
776,"Fujifilm is pumping $850M into its U.S., U.K. production", https://www.fiercepharma.com/manufacturing/fujifilm-keeps-expansion-spree-rolling-850m-to-grow-vaccine-and-gene-therapy-capacity
777,Viralgen is infusing $142M into its viral vector operations, https://www.fiercepharma.com/manufacturing/bayer-s-gene-therapy-cdmo-viralgen-cuts-ribbon-first-phase-142m-viral-vector
778,"Novartis, GBT anemia drugs face payer hurdles: survey", https://www.fiercepharma.com/pharma/novartis-gbt-sickle-cell-disease-drugs-face-coverage-hurdles-as-doctors-spot-gene-therapy
779,Gilead's Yescarta matches BMS' Breyanzi with a 2L lymphoma win, https://www.fiercepharma.com/pharma/gilead-s-kite-matches-bristol-myers-yescarta-car-t-win-earlier-lymphoma
780,Biopharma M&A on track for a strong second half: analysts, https://www.fiercepharma.com/pharma/biopharma-m-a-track-for-a-strong-second-half-despite-political-noise-analysts
781,"BMS-Eisai, China price cuts, AZ-Hutchmedâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-bms-eisai-adc-deal-china-s-generics-price-cut-az-hutchmed-lung
782,Fierce 15 winner Senti is picking up a factory all its own, https://www.fiercepharma.com/manufacturing/fierce-15-winner-senti-bio-hot-off-645m-spark-pact-tees-up-house-manufacturing-for
783,"Awaiting FDA drug approval, Legend plots new cell therapy plant", https://www.fiercepharma.com/manufacturing/j-j-cell-therapy-partner-legend-biotech-carves-out-manufacturing-foothold-belgium-as
784,"Novartis touts Zolgensma data as Biogen, Roche rivalries heat up", https://www.fiercepharma.com/pharma/novartis-touts-latest-zolgensma-data-as-sma-competition-against-biogen-roche-heats-up
785,What cost watchdog ICER needs to bless gene and cell therapies, https://www.fiercepharma.com/pharma/cost-watchdog-icer-will-bless-some-high-priced-gene-and-cell-therapies-but-only-solid-proof
786,Dendreon reinvents itself as cell therapy contract manufacturer, https://www.fiercepharma.com/manufacturing/dendreon-still-alive-and-well-shifts-focus-to-contract-manufacturing-for-cell-therapy
787,Danaher strikes $9.6B buyout for contract manufacturer Aldevron, https://www.fiercepharma.com/manufacturing/danaher-strikes-9-6b-buyout-for-next-gen-contract-manufacturing-player-aldevron
788,$71M site will make French CDMO Yposkesi a viral vector force, https://www.fiercepharma.com/manufacturing/71m-investment-french-cdmo-yposkesi-set-to-double-capacity-and-become-major-viral
789,Vibalogics spending $50M on viral vector capacity in Germany, https://www.fiercepharma.com/manufacturing/cdmo-vibalogics-speeding-toward-u-s-commercial-plant-pumps-50m-into-viral-vector
790,The cell and gene therapy surge is straining viral vector supply, https://www.fiercepharma.com/manufacturing/vexed-by-vectors-how-covid-19-vaccine-and-cell-and-gene-players-are-meeting-viral
791,"BMS eyes virtual training, automation at new cell therapy plants", https://www.fiercepharma.com/manufacturing/bristol-myers-sees-automation-and-virtual-reality-horizon-at-its-dual-cell-therapy
792,"Gilead, Merck, BeiGene, Astellas and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-gilead-merck-helps-india-covid-beigene-s-btk-win-astellas-gene
793,Gene therapy 'development engine' nabs $120M to amp up CDMO work, https://www.fiercepharma.com/manufacturing/forge-biologics-charts-120m-series-b-to-accelerate-viral-vector-manufacturing-build
794,Bayer eyes 2023 start for upcoming Berkeley cell therapy plant, https://www.fiercepharma.com/manufacturing/bayer-plots-200-million-cell-therapy-plant-at-overhauled-berkeley-campus-report
795,BMS's cell therapy manufacturing push makes its way to Europe, https://www.fiercepharma.com/manufacturing/bristol-myers-flush-double-car-t-approvals-blueprints-first-cell-therapy-factory
796,Bluebird lays off staffers in EU amid Zynteglo rollout hiccup, https://www.fiercepharma.com/marketing/bluebird-bio-lays-off-staffers-europe-as-zynteglo-rollout-hits-a-snag-from-start
797,Resilience snaps up Ology in biomanufacturing expansion spree, https://www.fiercepharma.com/manufacturing/national-resilience-keeps-expansion-spree-rolling-buyout-biologics-maker-ology
798,"GSK, Takeda, Celltrion and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-gsk-india-zantac-plant-sale-takeda-bridgene-drug-discovery-pact
799,TCR2's commercial cell therapy production network takes shape, https://www.fiercepharma.com/manufacturing/tcr2-snags-maryland-manufacturing-plant-to-bring-cell-therapy-cancer-treatments-to
800,"BMS, bluebird's Abecma label could hand J&J's CAR-T an advantage", https://www.fiercepharma.com/marketing/bristol-myers-bluebird-bio-have-their-bcma-car-t-nod-but-latecomer-j-j-could-have
801,"Novartis is closing Colorado production site, cutting 400 jobs", https://www.fiercepharma.com/manufacturing/after-overestimating-demand-novartis-shutting-down-colorado-plant
802,BMS is beefing up its cell therapy production network, https://www.fiercepharma.com/manufacturing/breyanzi-nod-hand-bristol-myers-sets-sights-cell-therapy-expansion-faster
803,Novartis' Â£1.79M gene therapy Zolgensma scores NICE backing, https://www.fiercepharma.com/pharma/novartis-ps1-79m-gene-therapy-zolgensma-scores-nice-backing-threatening-biogen-s-spinraza
804,"Manufacturing roundup: Moderna, Baxter, AGC and WuXi AppTec", https://www.fiercepharma.com/manufacturing/manufacturing-news-note-agc-wuxi-apptec-tap-into-end-to-end-cell-and-gene-therapy
805,"AstraZeneca-Junshi, Takeda and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-astrazeneca-junshi-pd-1-deal-takeda-s-1-2b-diabetes-selloff-ovid
806,Biogen to lay manufacturing groundwork for gene therapies, https://www.fiercepharma.com/manufacturing/biogen-blueprints-200m-gene-therapy-factory-at-north-carolina-s-research-triangle
807,Celonic is moving into Novartis' cell therapy production site, https://www.fiercepharma.com/manufacturing/cdmo-celonic-to-beef-up-cell-and-gene-therapy-at-swiss-novartis-hub
808,AbbVie plant buy fuels Pharmaron's cell and gene therapy hopes, https://www.fiercepharma.com/manufacturing/abbvie-offloading-allergan-biomanufacturing-plant-to-pharmaron-for-188m
809,Catalent is set to acquire cell and gene therapy CDMO Delphi, https://www.fiercepharma.com/manufacturing/catalent-continues-belgian-manufacturing-push-as-it-moves-to-snap-up-another-cell-and
810,BMS looks to beef up cell therapy production with new facility, https://www.fiercepharma.com/manufacturing/bristol-myers-hot-off-breyanzi-nod-plots-new-cell-therapy-factory-massachusetts
811,MilliporeSigma is pumping $47M into two New England plants, https://www.fiercepharma.com/manufacturing/merck-kgaa-s-milliporesigma-lays-out-47m-upgrade-for-new-england-sites-tapped
812,ShapeTX claims breakthrough in tissue-specific gene therapies, https://www.fiercepharma.com/drug-delivery/shapetx-claims-breakthrough-tissue-specific-gene-therapies
813,Researchers spotlight a safer method for CRISPR delivery, https://www.fiercepharma.com/drug-delivery/unsw-team-taps-light-activated-liposomes-for-safer-crispr-delivery
814,Germany's Vibalogics lays out $150M for Boston viral vector site, https://www.fiercepharma.com/manufacturing/new-ceo-board-germany-s-vibalogics-lays-out-150m-for-boston-viral-vector-site
815,Bluebird tanks with FDA delay of LentiGlobin in sickle cell, https://www.fiercepharma.com/pharma/bluebird-tanks-as-fda-demands-for-lentiglobin-gene-therapy-sickle-cell-delay-filing-to-late
816,"Minaris invests in new German, Japanese manufacturing facilities", https://www.fiercepharma.com/manufacturing/showa-denko-s-minaris-plots-64-5m-manufacturing-expansion-europe-and-asia
817,Orchard gene therapy Strimvelis linked to a leukemia case, https://www.fiercepharma.com/pharma/orchard-s-rare-disease-gene-therapy-strimvelis-linked-to-a-leukemia-case
818,Novartis adds Japanese site to Kymriah manufacturing network, https://www.fiercepharma.com/manufacturing/novartis-looks-to-hurdle-manufacturing-crunch-for-car-t-therapy-kymriah-first-asian
819,Catalent adds Belgian site to cell and gene therapy portfolio, https://www.fiercepharma.com/manufacturing/catalent-continues-big-push-into-cell-and-gene-therapies-belgian-facility-buyout
820,Novartis Gene Therapies president talks Zolgensma, https://www.fiercepharma.com/pharma/novartis-gene-therapies-president-talks-zolgensma-competition-path-forward-for-new
821,DNA maker Touchlight adds Lonza veteran to head manufacturing, https://www.fiercepharma.com/manufacturing/dna-maker-touchlight-adds-lonza-vet-to-head-manufacturing-swing-at-covid-19-vaccine
822,Sixfold to test targeted gene therapy delivery system, https://www.fiercepharma.com/drug-delivery/sixfold-bioscience-snares-uk-grant-to-test-cancer-fighting-sirna-delivery-system
823,Novartis unveils new SMA gene therapy data in EU, https://www.fiercepharma.com/pharma/novartis-cites-transformative-data-zolgensma-as-it-rolls-out-sma-gene-therapy-europe
824,Pfizer fleshes out 'build-buy-partner' strategy in gene therapy, https://www.fiercepharma.com/manufacturing/pfizer-leans-into-gene-therapy-manufacturing-build-buy-partner-strategy
825,Novartis hits FDA roadblock in Zolgensma expansion bid, https://www.fiercepharma.com/marketing/relief-for-biogen-and-roche-novartis-plan-for-zolgensma-older-patients-hits-setback-fda
826,Vibalogics taps Lonza veteran as CEO to head U.S. expansion, https://www.fiercepharma.com/manufacturing/viral-vector-manufacturer-vibalogics-adds-ceo-to-lead-expansion-covid-19-response
827,J&J partner Legend's CEO under 'residential surveillance', https://www.fiercepharma.com/pharma-asia/chinese-customs-raids-j-j-car-t-partner-legend-s-office-puts-new-ceo-under-residential
828,"Takeda, Celltrion, BMS-Dr. Reddy's and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-takeda-s-cell-therapy-center-celltrion-s-covid-antibody-dr-reddy-s
829,Takeda opens R&D cell therapy manufacturing center in Boston, https://www.fiercepharma.com/manufacturing/takeda-unveils-new-boston-r-d-manufacturing-center-for-cell-therapy-pipeline-push
830,Merck KGaA plots new facility for next-gen oncology meds, https://www.fiercepharma.com/manufacturing/merck-kgaa-s-miiliporesigma-pumps-65m-into-antibody-drug-conjugate-scale-up
831,Emergent plots $75M plant expansion to produce viral vectors, https://www.fiercepharma.com/manufacturing/emergent-plots-75m-expansion-to-produce-viral-vectors-for-expanding-gene-therapy
832,Gilead scores long-awaited EU approval for Dutch CAR-T facility, https://www.fiercepharma.com/manufacturing/gilead-sees-better-days-ahead-for-car-t-therapy-yescarta-after-eu-nod-for-amsterdam
833,WuXi AppTec names Celgene veteran to CAR-T manufacturing lead, https://www.fiercepharma.com/manufacturing/wuxi-apptec-welcomes-veteran-celgene-s-troubled-cell-therapy-program-to-car-t
834,WuXi upgrades CAR-T offerings with new manufacturing platform, https://www.fiercepharma.com/manufacturing/wuxi-upgrades-car-t-offerings-new-manufacturing-platform
835,Novartis eyes new Zolgensma growth with EU nod, https://www.fiercepharma.com/marketing/new-zolgensma-inflection-point-here-as-novartis-snags-eu-nod-for-sma-gene-therapy
836,"BMS, bluebird bio scramble after FDA rebuffs CAR-T submission", https://www.fiercepharma.com/pharma/bristol-myers-squibb-hot-water-after-fda-rebuffs-car-t-therapy-manufacturing-concerns
837,Merck KGaA earmarks $110M for viral vector expansion, https://www.fiercepharma.com/manufacturing/merk-kgaa-invests-110m-expanding-california-viral-vector-facility
838,"Takeda-CSL, Qiming, Fujifilm's Avigan and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-takeda-csl-coronavirus-tie-up-qiming-s-1b-vc-fund-fujifilm-s-avigan
839,"Fujifilm's Avigan, Aurobindo-Sandoz and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-fujifilm-s-avigan-for-covid-19-aurobindo-novartis-deal-end-china-s-api
840,Zolgensma delay is bad for Novartis but good for Biogen: analyst, https://www.fiercepharma.com/pharma/another-zolgensma-delay-bad-for-novartis-sma-but-good-for-biogen-s-spinraza-analyst
841,Daiichi inks $200M licensing deal with gene therapy manufacturer, https://www.fiercepharma.com/manufacturing/daiichi-sankyo-inks-200m-licensing-deal-ultragenyx-to-boost-gene-therapy
842,FDA lets Novartis off the hook in Zolgensma data manipulation, https://www.fiercepharma.com/pharma/fda-lets-novartis-off-hook-zolgensma-data-manipulation
843,Coronavirus disrupts Bluebird's Zynteglo plans, https://www.fiercepharma.com/marketing/coronavirus-delays-bluebird-bio-gene-therapy-zynteglo-s-eu-launch-u-s-filing
844,Univercells' CDMO Exothera targets COVID-19 vaccine partners, https://www.fiercepharma.com/manufacturing/univercells-launches-cell-and-gene-therapy-cdmo-exothera
845,New CEO takes over as Fujifilm Diosynth Biotechnologies expands , https://www.fiercepharma.com/manufacturing/new-ceo-takes-over-as-fujifilm-diosynth-biotechnologies-expands
846,"Coronavirus, AZ, vadadustat and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-coronavirus-s-impact-astrazeneca-global-drug-supply-vadadustat-prv
847,Bluebird aims to dose first Zynteglo patients in H1, https://www.fiercepharma.com/pharma/now-cleared-for-launch-bluebird-aims-to-dose-first-zynteglo-patients-first-half
848,Audentes investing $109M in gene therapy manufacturing facility, https://www.fiercepharma.com/manufacturing/audentes-investing-109m-gene-therapy-manufacturing-facility-200-jobs
849,Here are 2020's 11 blockbuster drug launches, https://www.fiercepharma.com/marketing/from-novartis-and-bristol-s-ms-meds-to-new-adcs-here-are-2020-s-blockbuster-drug-launches
850,Catalent laying out $315M to snatch another gene therapy CDMO, https://www.fiercepharma.com/manufacturing/catalent-laying-out-315m-to-snatch-another-gene-therapy-cdmo
851,AGC Biologics expands plasmid DNA capacity, https://www.fiercepharma.com/manufacturing/agc-biologics-expands-plasmid-dna-capacity-as-biotechs-develop-gene-therapies
852,"Behind Astellas' $3B Audentes buyout, whispers and a bidding war", https://www.fiercepharma.com/pharma/behind-astellas-3b-buyout-audentes-furtive-whispers-and-a-bidding-war
853,Roche wraps up Spark deal after antitrust ordeal ends with FTC, https://www.fiercepharma.com/pharma/roche-to-wrap-up-4-3b-spark-deal-after-antitrust-ordeal-ends-ftc-thumbs-up
854,Roche-Spark's U.K. antitrust nod tees up similar FTC ruling, https://www.fiercepharma.com/pharma/u-k-antitrust-watchdog-clears-roche-s-4-3b-spark-deal-indicating-similar-move-by-ftc
855,Is Roche finally near a Spark deal antitrust decision?, https://www.fiercepharma.com/pharma/roche-extends-spark-deal-offer-for-shorter-period-are-antitrust-decisions-finally-near
856,Keytruda's bladder cancer gene therapy rival wins in phase 3, https://www.fiercepharma.com/marketing/watch-out-keytruda-ferring-s-bladder-cancer-gene-therapy-rival-has-new-data-and-they-look
857,"Astellas, China's NRDL, Hanmi and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-astellas-3b-gene-therapy-bet-china-s-pd-1-coverage-hanmi-rapt-i-o-deal
858,Can Merck's Keytruda rival gene therapy in bladder cancer?, https://www.fiercepharma.com/marketing/keytruda-nabs-fda-quick-review-for-new-bladder-cancer-use-a-gene-therapy-breathing-down
859,"Vertex plans major expansion for gene, cell therapies", https://www.fiercepharma.com/pharma/vertex-plans-major-boston-expansion-as-gene-and-cell-therapies-ambition-takes-form
860,Cell and viral vector manufacturing facility backed by Harvard, https://www.fiercepharma.com/manufacturing/50m-cell-and-viral-vector-manufacturing-operation-backed-by-harvard
861,Manufacturers get clarity and value with a distribution partner, https://www.fiercepharma.com/pharma/clarity-and-value-distribution-partners-beyond-pick-pack-and-ship
862,Lonza leader Marc Funk quits after just 9 months as CEO, https://www.fiercepharma.com/manufacturing/lonza-leader-marc-funk-quits-after-just-nine-months-as-ceo
863,Pfizer 'brainstorming' with payers on gene therapy payment: exec, https://www.fiercepharma.com/pharma/gene-therapies-development-pfizer-brainstorming-payers-about-new-payment-models-bloomberg
864,AveXis knew of Zolgensma's latest safety flag since March, https://www.fiercepharma.com/pharma/another-zolgensma-woe-another-delay-data-reporting-at-novartis-avexis
865,Zolgensma safety scare hits again with FDA clinical hold, https://www.fiercepharma.com/marketing/zolgensma-safety-scare-hits-novartis-again-as-fda-halts-spinal-injection-trial
866,Bio-Techne investing up to $50M recombinant protein production, https://www.fiercepharma.com/manufacturing/bio-techne-investing-up-to-50m-new-plant-for-recombinant-proteins
867,Roche-Spark sees hope as FTC staff gives thumbs-up: report, https://www.fiercepharma.com/pharma/roche-s-4-3b-spark-antitrust-agony-sees-glimmer-hope-as-ftc-staff-gives-thumbs-up-report
868,Bluebird to launch Zynteglo as EU OKs 'refined' manufacturing, https://www.fiercepharma.com/manufacturing/bluebird-bio-readies-zynteglo-launch-as-eu-approves-refined-manufacturing
869,Novartis' Zolgensma faces stepped-up manufacturing scrutiny, https://www.fiercepharma.com/manufacturing/novartis-zolgensma-faces-eu-japan-approval-delays-after-regulators-raise
870,Novartis' Zolgensma smashes sales estimates, https://www.fiercepharma.com/pharma/novartis-zolgensma-beats-data-woe-payer-resistance-strong-and-high-interest-ceo
871,Pfizer adds $500M to gene therapy manufacturing plant, https://www.fiercepharma.com/manufacturing/pfizer-adds-500m-to-gene-therapy-manufacturing-plant-where-it-will-hire-300-workers
872,Novartis' Zolgensma data rigging draws Senators' ire, https://www.fiercepharma.com/pharma/sanders-warren-join-team-senators-blasting-novartis-zolgensma-data-rig
873,'We did the best we could' in Zolgensma data probe: Novartis CEO, https://www.fiercepharma.com/pharma/novartis-ceo-we-did-best-we-could-zolgensma-data-manipulation-probe
874,PTC grabs Bristol-Myers facility to gear up gene therapies, https://www.fiercepharma.com/manufacturing/ptc-inks-long-term-lease-deal-bms-expanding-its-new-jersey-footprint
875,FDA weighs punishment for falsified Zolgensma data, https://www.fiercepharma.com/pharma/fda-weighs-civil-and-criminal-penalties-over-manipulated-data-novartis-zolgensma-application
876,Brammer Bio seeking TIF for manufacturing site in Massachusetts, https://www.fiercepharma.com/manufacturing/brammer-bio-seeking-tif-for-proposed-new-manufacturing-site-massachusetts
877,Could FTC scrutiny of Roche-Spark merger scuttle future pharma deals?, https://www.fiercepharma.com/pharma/could-ftc-scrutiny-roche-spark-merger-scuttle-future-pharma-deals-analysts-are-fretting
878,"Roche extends $4.3B Spark bid yet again, this time to September", https://www.fiercepharma.com/pharma/roche-extends-4-3b-spark-tender-offer-again-now-targeting-september
879,Lonza expanding ADC production as pharma business thrives , https://www.fiercepharma.com/manufacturing/lonza-expanding-adc-production-as-pharma-business-thrives
880,Manufacturing News of Noteâ€”AveXis goes deeper on Zolgensma manufacturing, https://www.fiercepharma.com/manufacturing/manufacturing-news-note-avexis-goes-deeper-zolgensma-manufacturing-76-billion-opioid
881,Biotech building facility to make off-the-shelf CAR-T therapies, https://www.fiercepharma.com/manufacturing/biotech-building-facility-to-make-genome-edited-off-shelf-car-t-therapies
882,Zolgensma launch 'in line' with expectations: Novartis CEO, https://www.fiercepharma.com/pharma/zolgensma-launch-track-and-fully-line-expectation-says-novartis-ceo
883,Manufacturing News of Noteâ€”New cell therapy facility in China, https://www.fiercepharma.com/manufacturing/manufacturing-news-note-new-cell-therapy-facility-china
884,Gilead's Kite to build viral vector manufacturing in California, https://www.fiercepharma.com/manufacturing/gilead-s-kite-builds-cell-therapy-manufacturing-quickly-even-as-yescarta-sales-grow
885,Insurers push back on Novartisâ€™ $2.1M SMA gene therapy: report, https://www.fiercepharma.com/pharma/insurer-response-to-novartis-2-1m-sma-gene-therapy-reflects-material-resistance-report
886,Thermo Fisher and Catalent to manufacture Amicus' gene therapies, https://www.fiercepharma.com/manufacturing/thermo-fisher-to-manufacture-gene-therapies-being-developed-by-amicus
887,Catalent snaps up Novavax production sites and 100 employees, https://www.fiercepharma.com/manufacturing/catalent-snaps-up-novavax-production-sites-and-100-employees-18m-deal
888,The top 10 drug launches of 2019, https://www.fiercepharma.com/special-report/top-10-drug-launches-2019
889,Bluebird Bio's gene therapy launch impeded by manufacturing, https://www.fiercepharma.com/manufacturing/bluebird-bio-s-delays-zynteglo-launch-as-manufacturing-trips-up-another-gene-therapy
890,Bluebird prices gene therapy at â‚¬1.575M over 5 years in Europe, https://www.fiercepharma.com/pharma/bluebird-prices-gene-therapy-zynteglo-at-eu1-575m-europe-to-be-paid-over-5-years
891,Novartis CEO calls for new drug payment model, https://www.fiercepharma.com/pharma/novartis-ceo-narasimhan-preps-zolgensma-launch-call-for-new-drug-payment-model
892,'Cornucopia' of innovation blurs drug launch forecasts: analyst, https://www.fiercepharma.com/marketing/cornucopia-biopharma-innovation-blurs-drug-launch-value-clarity-analyst-laments
893,Biogen's Spinraza wins NICE backing as competitors loom, https://www.fiercepharma.com/pharma/biogen-s-spinraza-wins-nice-recommendation-helping-its-case-sma-as-competitors-loom
894,Bluebird plots conservative EU launch for its first gene therapy, https://www.fiercepharma.com/pharma/bluebird-details-conservative-eu-rollout-plan-for-tdt-gene-therapy
895,Novartis ready to meet even 'unprecedented' demand for Zolgensma, https://www.fiercepharma.com/manufacturing/novartis-ready-to-meet-even-unprecedented-demand-for-zolgensma
896,Novartis touts latest data from Zolgensma studies at AAN, https://www.fiercepharma.com/pharma/awaiting-fda-nod-novartis-touts-latest-data-from-3-zolgensma-studies
897,"New Gilead chief plots Kite CEO hire, pipeline M&A", https://www.fiercepharma.com/pharma/new-gilead-chief-plots-kite-ceo-hire-pipeline-m-a-and-organizational-tweaks
898,Can Bluebird chief turn $23M in 2018 equity awards into cash?, https://www.fiercepharma.com/pharma/bluebird-bio-chief-nick-leschly-pulled-down-24m-2018-but-can-he-make-it-pay-off
899,Novartis investigates infant death in European Zolgensma trial, https://www.fiercepharma.com/pharma/infant-s-death-eu-zolgensma-trial-launches-novartis-internal-probe
900,Novartis touts new Zolgensma data as FDA verdict comes into view, https://www.fiercepharma.com/pharma/novartis-releases-positive-sma-gene-therapy-data-as-fda-verdict-comes-into-view
901,Ajinomoto Bio-Pharma Services takes control of GeneDesign, https://www.fiercepharma.com/manufacturing/japan-s-ajinomoto-bio-pharma-services-adds-gene-services-genedesign-deal
902,Catalent pulls off $1.2B deal for gene therapy CDMO Paragon, https://www.fiercepharma.com/manufacturing/catalent-pulls-off-1-2b-deal-for-gene-therapy-cdmo-paragon
903,Post-Alcon Novartis eyes M&A in ophthalmic digital therapeutics, https://www.fiercepharma.com/pharma/post-alcon-novartis-eyes-new-amd-drug-digital-therapeutics-and-gene-therapies
904,Novartis' SMA gene therapy should cost no more than $1.5M: ICER, https://www.fiercepharma.com/pharma/novartis-sma-gene-therapy-would-not-be-cost-effective-if-priced-over-1-5m-icer
905,Reluctant Spark investors force Roche to extend $4.3B offer, https://www.fiercepharma.com/pharma/roche-s-spark-tender-offer-delayed-as-investors-sue-over-4-3b-merger
906,Novartis' AveXis buys AstraZeneca site in Colorado, https://www.fiercepharma.com/manufacturing/novartis-aveaxis-buys-astrazeneca-site-colorado-as-it-anticipates-gene-therapy-launch
907,Europe tees up Bluebird's first gene therapy approval, https://www.fiercepharma.com/pharma/europe-sets-up-first-bluebird-gene-therapy-approval-thumbs-up-thalassemia-treatment
908,Masthercell adds to global gene and cell manufacturing frenzy, https://www.fiercepharma.com/manufacturing/masthercell-adds-to-global-gene-and-cell-manufacturing-frenzy-eu-facility
909,Bluebird gene therapy manufacturing facility up and running, https://www.fiercepharma.com/manufacturing/bluebird-completes-cell-and-gene-therapy-manufacturing-facility
910,Thermo Fisher buying viral vector producer Brammer Bio for $1.7B, https://www.fiercepharma.com/manufacturing/thermo-fisher-shoulders-into-gene-therapy-manufacturing-1-7b-deal-for-brammer
911,Biotech tied to GSK to build cell production facility in U.S., https://www.fiercepharma.com/manufacturing/biotech-bought-gsk-s-bubble-boy-drug-to-build-stem-cell-manufacturing-facility-u-s
912,Novartis looks ahead to China with Kymriah manufacturing pact, https://www.fiercepharma.com/pharma/novartis-looks-ahead-to-china-kymriah-manufacturing-pact
913,"CHMP endorses Lilly's CGRP Emgality, Spark's Luxturna and more", https://www.fiercepharma.com/pharma/lilly-s-cgrp-emgality-and-spark-s-luxturna-win-chmp-nod-as-sarepta-s-exondys-misses
914,"Opdivo, Novartis Korea, GSK and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-opdivo-s-chinese-price-new-novartis-korea-chief-gsk-indian-consumer
915,Korean biotech buys GMP-ready production facility in California, https://www.fiercepharma.com/manufacturing/korean-biotech-buys-gmp-ready-production-facility-california
916,Gileadâ€™s Kite taps Eisai vet to helm CAR-T commercial strategy, https://www.fiercepharma.com/pharma/gilead-s-kite-taps-eisai-oncology-vet-amoroso-to-helm-car-t-commercial-strategy
917,Cancer drugmaker Spectrum looks at potential sale: report, https://www.fiercepharma.com/hematology-and-oncology-drugmaker-spectrum-looks-at-potential-sale-bloomberg
918,"Sarepta, CDMO Brammer Bio ink deal to expand manufacturing", https://www.fiercepharma.com/manufacturing/sarepta-thereapeutics-cdmo-brammer-bio-ink-deal-to-expand-manufacturing-footprint
919,Abeona Therapeutics opens gene therapy manufacturing facility, https://www.fiercepharma.com/manufacturing/abeona-therapeutics-opens-gene-therapy-manufacturing-and-starts-phase-two
920,BioMarin scores long-sought FDA nod for PKU drug, https://www.fiercepharma.com/pharma/biomarin-scores-long-sought-fda-nod-for-rare-disease-drug-but-can-it-hit-blockbuster-status
921,"Novartis' new gene therapy biotech to build $55M plant, hire 200", https://www.fiercepharma.com/manufacturing/novartis-brand-new-gene-therapy-player-avexis-will-build-55m-plant-hire-200
922,CTG Catapult opens cell and gene therapy plant in the U.K., https://www.fiercepharma.com/manufacturing/ctg-catapult-opens-its-new-unique-cell-and-gene-therapy-plant-u-k
923,"Cosentyx woes, generics weakness cast cloud on Novartis earnings", https://www.fiercepharma.com/financials/cosentyx-woes-generics-weakness-cast-cloud-otherwise-solid-q1-for-novartis
924,Gene therapy cures might not deliver sustainable sales: analyst, https://www.fiercepharma.com/financials/car-t-and-other-gene-therapies-may-not-be-sustainable-businesses-for-pharma-analyst
925,"Lonza moves cell work, cuts jobs at plant hit by warning letter", https://www.fiercepharma.com/manufacturing/lonza-cuts-125-jobs-as-it-moves-cell-work-from-u-s-plant-hit-warning-letter
926,"FiercePharmaAsiaâ€”Astellas, Celltrion, Korea's digital health plan", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-astellas-acquisition-teva-s-celltrion-problem-korea-s-digital-health
927,"Spark, Novartis tie up in gene therapy licensing deal", https://www.fiercepharma.com/pharma/spark-novartis-tie-up-gene-therapy-licensing-deal-worth-up-to-170m
928,Payers see Sparkâ€™s gene therapy pricing as new model, https://www.fiercepharma.com/financials/payers-point-to-spark-s-gene-therapy-as-a-model-for-innovative-pricing-plans
929,Cost watchdogs back Glaxo's $714K gene therapy, https://www.fiercepharma.com/pharma/u-k-cost-watchdogs-endorse-gsk-s-gene-therapy-strimvelis-at-714-000
930,Spark prices gene therapy Luxturna at $850K, https://www.fiercepharma.com/pharma/spark-prices-gene-therapy-luxturna-at-850k-grabbing-top-spot-pharma-s-costliest-drugs
931,"GSK sees Â£7B in HIV sales by 2026, updates next-gen timelines", https://www.fiercepharma.com/pharma/gsk-dials-hiv-sales-projection-ps7b-2026-updates-next-generation-regimen-timeline
932,"Government-backed manufacturer AktiVax shuts down, lays off 70", https://www.fiercepharma.com/pharma/government-backed-autoinjector-specialist-aktivax-shutters-substantially-all-its-operations
933,Apellis homes in on possible source of rare Syfovre side effect, https://www.fiercepharma.com/pharma/apellis-flags-needle-problems-hunt-syfovre-side-effect-source
934,Kindeva captures Â£33M UK grant to boost inhaler production, https://www.fiercepharma.com/manufacturing/kindiva-captures-ps33m-grant-uk-inhaler-production
935,GSK's ViiV explores novel pathway to expand long-acting HIV drug, https://www.fiercepharma.com/pharma/gsks-viiv-explores-novel-pathway-bring-long-acting-hiv-drug-cabenuva-tough-populations
936,FDA shoots down Amneal's Parkinson's med, https://www.fiercepharma.com/pharma/amneals-hopes-dashed-after-fda-rebuffs-extended-release-parkinsons-prospect-could-net-500m
937,Eyenovia nabs FDA approval for pupil dilation spray Mydcombi, https://www.fiercepharma.com/marketing/no-more-eye-drops-eyenovia-nabs-fda-approval-pupil-dilation-spray-mydcombi
938,BMS plots interstellar manufacturing move aboard ISS, https://www.fiercepharma.com/manufacturing/bristol-myers-shoots-stars-next-leg-international-space-station-biomanufacturing
939,Orexo seeks approval of nasal high-dose opioid rescue medicine, https://www.fiercepharma.com/pharma/orexo-leveraging-drug-delivery-tech-seeks-fda-approval-nasal-high-dose-opioid-rescue
940,Recurv raises $24M to take nano-emulsion taxane to clinical POC, https://www.fiercepharma.com/pharma/lilly-backed-fund-commits-24m-recurvs-push-clinical-proof-concept-nano-emulsion-taxane
941,"Investors kibosh Midatech merger, triggering scramble for cash", https://www.fiercepharma.com/pharma/investors-kybosh-midatech-merger-triggering-scramble-cash
942,Loading mRNA into extracellular vesicles limits wrinkles in mice, https://www.fiercepharma.com/pharma/loading-mrna-extracellular-vesicles-reduces-wrinkles-mice
943,Biogen bets $10M on implant to improve delivery of Spinraza, https://www.fiercepharma.com/pharma/biogen-scrapping-sma-market-share-bets-10m-implant-improve-delivery-spinraza
944,"Mayo, InSitu pen prolonged-release cancer co-development pact", https://www.fiercepharma.com/pharma/mayo-spreads-support-insitu-prolonged-release-cancer-drug-co-development-pact
945,Midatech plots pivot beyond delivery tech with Bioasis buyout, https://www.fiercepharma.com/pharma/teetering-edge-midatech-plots-pivot-beyond-drug-delivery-platform-bioasis-buyout
946,"Recovering from rejection, Eyenovia gets eye spray decision date", https://www.fiercepharma.com/pharma/recovering-rejection-eyenovia-lands-may-fda-decision-date-eye-spray
947,LTS Lohmann leads investment in needle-free delivery specialist, https://www.fiercepharma.com/pharma/lts-lohmann-leads-investment-needle-free-delivery-specialist
948,Genentech starts phase 2 trial to optimize cell therapy delivery, https://www.fiercepharma.com/pharma/genentech-starts-phase-2-trial-optimize-delivery-eye-disease-cell-therapy
949,ScPharmaceuticals raises $50M for launch of on-body infusor, https://www.fiercepharma.com/pharma/scpharmaceuticals-prices-50m-offering-fund-commercialization-body-infusor
950,Erytech pivots to drug delivery after lead candidate collapses, https://www.fiercepharma.com/pharma/erytech-pivots-extracellular-vesicle-drug-delivery-after-lead-candidate-collapses
951,"SpaceX, ISS partner to test delivery tech on orbiting laboratory", https://www.fiercepharma.com/pharma/spacex-iss-partner-test-remote-control-drug-delivery-technology-orbiting-laboratory
952,"Kindeva, former Pfizer unit merge to form drug-device CDMO", https://www.fiercepharma.com/manufacturing/kindeva-ties-knot-former-pfizer-unit-named-epipen-pricing-manufacturing-entanglements
953,Fulgent inks $100M deal to reunite with drug delivery sibling, https://www.fiercepharma.com/pharma/plotting-fulgent-future-diagnostic-business-inks-100m-deal-reunite-drug-delivery-sibling
954,Lilly pumps $50M into Purdue drug delivery pact, https://www.fiercepharma.com/pharma/lilly-pumps-50m-purdue-pact-study-intrathecal-and-nanoparticle-drug-delivery
955,Nanoparticles maximize cancer drug's STING in preclinical tests, https://www.fiercepharma.com/pharma/nanoparticles-maximize-cancer-drugs-sting-preclinical-tests
956,Roche has run into a problem with its new eye med Susvimo, https://www.fiercepharma.com/manufacturing/roche-recalls-susvimo-implant-lucentis-leakage-fears-return-market-expected-within
957,Surge raises $26M to take anti-cancer hydrogel into the clinic, https://www.fiercepharma.com/pharma/surge-raises-26m-take-anticancer-extended-release-hydrogel-clinic
958,Bankrupt Zosano sells intradermal delivery tech to Emergex, https://www.fiercepharma.com/pharma/bankrupt-zosano-sells-intradermal-delivery-tech-emergex-vaccines
959,"BeiGene, Bayer-Hua, Novavax-Fujifilm and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/beigene-btk-win-bayer-hua-diabetes-nod-novavax-fujifilm-covid-deal-abortion
960,Eisai cuts the ribbon on $69M injectable drug delivery facility, https://www.fiercepharma.com/pharma/eisai-cuts-ribbon-69m-injectable-drug-delivery-facility
961,Merck bags chance to test ADCs based on Starpharma delivery tech, https://www.fiercepharma.com/pharma/merck-bags-chance-test-adcs-based-starpharma-delivery-tech
962,Mice data show promise of checkpoint inhibitor delivery depots, https://www.fiercepharma.com/pharma/act-local-mice-data-point-potential-delivering-checkpoint-inhibitor-depots-direct-tumors
963,Cure Pharmaceutical sells drug delivery patents in $20M deal, https://www.fiercepharma.com/pharma/cure-pharmaceutical-sells-drug-delivery-patents-20m-deal
964,Lilly taps Triastek to use 3D printing for targeted gut delivery, https://www.fiercepharma.com/pharma/lilly-taps-triastek-use-3d-printing-gut-targeted-drug-delivery
965,Phase 2 flop causes Endo's frozen shoulder plan to come unstuck, https://www.fiercepharma.com/pharma/endos-frozen-shoulder-plan-comes-unstuck-phase-2-flop-driving-strategy-reevaluation
966,Pending inspection scuppers Acer's UCD approval hopes for now, https://www.fiercepharma.com/manufacturing/fda-rebuffs-acer-and-reliefs-urea-cycle-disorder-prospect-over-pending-contract
967,Stanford develops amphibious millirobot for fantastic voyage, https://www.fiercepharma.com/pharma/roll-flip-spin-stanford-develops-amphibious-millirobot-fantastic-voyage
968,Bacteria-triggered drug release system clears preclinical tests, https://www.fiercepharma.com/pharma/bacteria-triggered-drug-release-system-clears-preclinical-tests
969,"With Alzheimer's in its sights, Alnylam discusses siRNA delivery", https://www.fiercepharma.com/pharma/alzheimers-its-sights-alnylam-shares-data-getting-sirna-targets-beyond-liver
970,"Takeda, Biogen-Samsung, Astellas and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma/takeda-ceo-drug-pricing-biogen-samsungs-us-biosimilar-launch-astellas-antibody-pact
971,"After $500M IPO, HK inno.N enters exosome drug delivery", https://www.fiercepharma.com/pharma/after-500m-ipo-hk-innon-enters-exosome-drug-delivery-ilias-pact
972,PharmaTher grows ketamine portfolio with on-body injector deal, https://www.fiercepharma.com/pharma/pharmather-fleshes-out-ketamine-delivery-portfolio-deal-body-injector
973,Zealand pumps up its prospects with late-phase rare disease hit, https://www.fiercepharma.com/pharma/zealand-pumps-its-prospects-late-phase-rare-disease-hit
974,BD inks deal for syringe material at glass-plastic sweet spot, https://www.fiercepharma.com/pharma/bd-inks-deal-work-syringe-material-sweet-spot-between-glass-and-plastic
975,Drug delivery problems have prompted a new Teva recall, https://www.fiercepharma.com/manufacturing/teva-recalls-one-lot-blood-disorder-med-after-testing-flags-capsule-woes
976,RDT inks deals to push oral film tech to COVID-19 vaccine firms, https://www.fiercepharma.com/pharma/rdt-inks-deals-push-oral-film-tech-covid-19-vaccine-firms
977,West and Corning team up for injectable drug delivery project, https://www.fiercepharma.com/drug-delivery/west-and-corning-team-up-for-injectable-drug-delivery-project
978,Stevanato doubles down on pen injector technology, https://www.fiercepharma.com/drug-delivery/stevanato-doubles-down-pen-injector-technology-expanding-into-indications-beyond
979,BDSI readies to launch game-changing liquid migraine medicine, https://www.fiercepharma.com/marketing/bdsi-readies-to-launch-game-changing-liquid-migraine-medicine
980,"Chasing Pfizer, Antares advances rescue med into pivotal trial", https://www.fiercepharma.com/drug-delivery/chasing-pfizer-antares-advances-rescue-med-into-pivotal-trial
981,Stanford spinout forms drug delivery JV with Chinese biotech, https://www.fiercepharma.com/drug-delivery/stanford-spinout-forms-drug-delivery-joint-venture-chinese-biotech
982,Selecta taps Ginkgo to improve gene therapy delivery , https://www.fiercepharma.com/drug-delivery/selecta-taps-ginkgo-to-create-better-capsids-for-gene-therapy-delivery
983,Aerami is jumping on the SPAC bandwagon in bid to go public, https://www.fiercepharma.com/drug-delivery/aerami-therapeutics-eager-to-breeze-into-smart-inhaler-market-unveils-250m-spac-deal
984,Sixfold bags VC funding to expand RNA delivery beyond the liver, https://www.fiercepharma.com/drug-delivery/sixfold-bags-vc-funding-to-expand-rna-delivery-beyond-liver
985,Moderna suffered a blow in its patent feud with Arbutus, https://www.fiercepharma.com/pharma/moderna-loses-bid-to-invalidate-vaccine-delivery-patents-teeing-up-potential-lawsuit
986,"AbbVie re-ups cancer pact, extending alliance out to 2025", https://www.fiercepharma.com/drug-delivery/abbvie-re-ups-university-chicago-cancer-pact-extending-alliance-out-to-2025-after
987,Improving immunotherapy delivery by ordering tumor blood vessels, https://www.fiercepharma.com/drug-delivery/improving-immunotherapy-delivery-by-bringing-order-to-tumor-blood-vessels
988,"Sanofi, Roche team up to drive adoption of smart insulin pen", https://www.fiercepharma.com/drug-delivery/sanofi-roche-team-up-to-drive-adoption-smart-insulin-pen
989,Halozyme eyes role for drug delivery tech in cell therapies, https://www.fiercepharma.com/drug-delivery/subcut-darzalex-driving-growth-halozyme-eyes-role-for-drug-delivery-tech-cell
990,"AmMax, targeting a Daiichi market, posts data on rare tumor drug", https://www.fiercepharma.com/drug-delivery/ammax-targeting-a-daiichi-market-posts-data-delivery-rare-tumor-drug
991,FDA approves Genentech's eye implant for macular degeneration, https://www.fiercepharma.com/pharma/fda-green-lights-genentech-s-eye-implants-for-macular-degeneration-will-it-be-a-tough-sell
992,SynAgile takes on debt to study drug delivery dental retainer, https://www.fiercepharma.com/drug-delivery/synagile-takes-debt-to-wrap-up-midphase-trial-drug-delivery-dental-retainer
993,Virpax raises $40M to use delivery systems to improve pain drugs, https://www.fiercepharma.com/drug-delivery/virpax-raises-40m-to-use-delivery-systems-to-improve-pain-drugs
994,Investor snaps up Swiss drug delivery specialist Acino, https://www.fiercepharma.com/drug-delivery/investor-snaps-up-drug-delivery-specialist-acino-bid-to-build-regional-pharma-hub
995,FDA starts pilot after J&J makes case for delivery excipients, https://www.fiercepharma.com/drug-delivery/fda-starts-pilot-after-astrazeneca-j-j-make-case-for-novel-drug-delivery-excipients
996,Citius pays Dr. Reddy's $40M for Ontak replacement, https://www.fiercepharma.com/drug-delivery/citius-buys-out-license-to-ontak-replacement-from-dr-reddy-s-for-40m
997,Ascendis' long-acting growth hormone wins FDA blessing, https://www.fiercepharma.com/pharma/ascendis-crosses-fda-finish-line-once-weekly-growth-hormone-but-pfizer-hot-its-trail
998,CRISPR pioneer helps create gene-editing delivery system, https://www.fiercepharma.com/drug-delivery/crispr-pioneer-helps-create-gene-editing-delivery-system
999,Aptar inks deal to target Chinese injectable drug delivery field, https://www.fiercepharma.com/drug-delivery/aptar-inks-deal-to-target-chinese-injectable-drug-delivery-field
1000,"Stevanato IPO raises $672M to fund biologics, vaccine delivery", https://www.fiercepharma.com/drug-delivery/stevanato-ipo-raises-672m-to-fund-biologics-vaccine-delivery
1001,Junshi commits $31M to pact with mRNA delivery specialist, https://www.fiercepharma.com/drug-delivery/junshi-commits-31m-to-pact-mrna-delivery-specialist
1002,Vectura has a new bidder in Marlboro maker Philip Morris, https://www.fiercepharma.com/pharma/marlboro-maker-philip-morris-strikes-1-2b-deal-for-vectura-just-months-after-cdmo
1003,GSK puts long-acting injectables at heart of HIV growth plans, https://www.fiercepharma.com/drug-delivery/gsk-puts-long-acting-injectables-at-heart-hiv-growth-plans-downplays-threat-oral
1004,"Stevanato seeks $100M to invest in biologics, vaccine delivery", https://www.fiercepharma.com/drug-delivery/boosted-by-covid-19-stevanato-seeks-100m-ipo-to-invest-biologics-and-vaccine-delivery
1005,Novo's $1.8B Emisphere buyout hit with investor lawsuit, https://www.fiercepharma.com/pharma/former-stockholders-take-novo-nordisk-s-1-8b-buyout-delivery-specialist-emisphere-to-court
1006,"With expiration near, FDA extends J&J COVID shot shelf life", https://www.fiercepharma.com/pharma/j-j-s-covid-19-vaccine-cleared-by-fda-for-more-time-shelf-just-as-millions-doses-were-set-to
1007,"Biogen to ship first Aduhelm doses in 2 weeks, execs say", https://www.fiercepharma.com/pharma/faced-historic-drug-launch-biogen-says-it-will-ship-alzheimer-s-drug-two-weeks-hundreds
1008,BD aims to employ 600 at new Spanish factory by 2030, https://www.fiercepharma.com/manufacturing/bd-unveils-plans-for-200m-delivery-device-plant-spain-set-to-add-600-jobs-by-2030
1009,Progenity gets IBD Ventures Fund support for drug delivery tech, https://www.fiercepharma.com/drug-delivery/progenity-gets-ibd-ventures-fund-support-for-drug-delivery-tech
1010,OliX allies with PCI to develop dermatological RNAi therapies, https://www.fiercepharma.com/drug-delivery/olix-allies-pci-to-develop-dermatological-rnai-therapies
1011,Pharma putting digital drug delivery at heart of plans: survey, https://www.fiercepharma.com/drug-delivery/pharma-putting-digital-drug-delivery-at-heart-plans-survey
1012,Private equity firm buys PTS to expand nanoparticle delivery, https://www.fiercepharma.com/drug-delivery/private-equity-firm-buys-pts-to-seize-covid-19-fueled-transformation-nanoparticle
1013,"Takeda, Anima, Daiichi Sankyo and moreâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-anima-mrna-translation-pact-china-digital-health-incubator
1014,Eisai plans drug delivery center to support biologics expansion, https://www.fiercepharma.com/drug-delivery/eisai-plans-drug-delivery-center-to-support-biologics-expansion
1015,AstraZeneca extends drug delivery pact with Aptamer, https://www.fiercepharma.com/drug-delivery/astrazeneca-extends-oligonucleotide-conjugate-drug-delivery-pact-aptamer
1016,FDA approves first liquid-filled aspirin capsule, https://www.fiercepharma.com/drug-delivery/fda-approves-first-liquid-filled-aspirin-capsule
1017,Grace offers $570M for Albemarle's fine chemical services unit, https://www.fiercepharma.com/manufacturing/w-r-grace-lays-out-half-a-billion-for-albemarle-unit-to-bolster-pharma-portfolio-api
1018,"Takeda, Merck-Eisai, Daewoong-Evolusâ€”Fierce Pharma Asia", https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-cmv-drug-win-merck-eisai-kidney-cancer-data-botox-rival
1019,ACT bags cash to trial local iontophoresis chemotherapy delivery, https://www.fiercepharma.com/drug-delivery/act-bags-cash-to-trial-local-iontophoresis-chemotherapy-delivery
1020,Multilayer microcapsules enable PET-guided theranostic approach, https://www.fiercepharma.com/drug-delivery/multilayer-microcapsules-enable-pet-guided-theranostic-approach
1021,Amneal lands drug delivery platforms in $70M buyout, https://www.fiercepharma.com/drug-delivery/amneal-lands-drug-delivery-platforms-70m-kashiv-specialty-buyout
1022,BD shelling out $1.2B to boost prefilled syringe capacity, https://www.fiercepharma.com/manufacturing/bd-plots-1-2b-investment-pre-filled-syringe-capacity-new-euro-manufacturing-facility
1023,Sedor eyes swift seizure treatment with temp-stable drug formula, https://www.fiercepharma.com/drug-delivery/sedor-pharma-bags-nod-for-room-temp-stable-form-seizure-med-sesquient
1024,J&J's new Invega formulation could cut dosing to twice a year, https://www.fiercepharma.com/drug-delivery/johnson-johnson-aims-to-beef-up-invega-schizophrenia-offerings-application-for-new
1025,Xeris steps on FDA fast track with its injectable seizure drug, https://www.fiercepharma.com/drug-delivery/xeris-pharmaceuticals-injectable-diazepam-nets-fast-track-designation-to-treat
1026,Nanoform to test nanoformed drug in humans before year is out, https://www.fiercepharma.com/drug-delivery/recently-launched-nanoform-finland-plots-early-start-for-first-human-trial-nanoformed
1027,"Alexion's new, quicker-infusing Ultomiris formula snares FDA nod", https://www.fiercepharma.com/drug-delivery/alexion-snares-approval-for-new-ultomiris-formulation-teeing-up-speedy-infusions-and
1028,Nano-carrier hopeful deploys drugs on contact with cancer cells, https://www.fiercepharma.com/drug-delivery/scientists-unlock-targeted-cancer-drug-delivery-potential-early-stage-nano-carrier
1029,"Scientists create one-dose, temperature-stable ear infection gel", https://www.fiercepharma.com/drug-delivery/scientists-look-to-ease-ear-drop-dosing-headaches-one-time-temp-stable-hydrogel-for
1030,Stada buys Lobsor for its pump-based Parkinson's treatment, https://www.fiercepharma.com/drug-delivery/stada-arzneimittel-picks-up-sweden-s-lobsor-eyeing-pan-european-approvals-for-late
1031,Antares snares license to Ferring's sublingual nocturia tablet, https://www.fiercepharma.com/drug-delivery/antares-pharma-snares-ferring-license-for-first-approved-sublingual-tablet-to-treat
1032,Sixfold to test targeted gene therapy delivery system, https://www.fiercepharma.com/drug-delivery/sixfold-bioscience-snares-uk-grant-to-test-cancer-fighting-sirna-delivery-system
1033,"Takeda, Celltrion, BMS-Dr. Reddy's and moreâ€”FiercePharmaAsia", https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-takeda-s-cell-therapy-center-celltrion-s-covid-antibody-dr-reddy-s
1034,Starpharma pairs nano tech with Veklury for less-frequent dosing, https://www.fiercepharma.com/drug-delivery/starpharma-eyes-long-lasting-subq-veklury-doses-nanoparticle-formulation-gilead-s
1035,UroGen undeterred after RTGel-Botox combo misses in phase 2, https://www.fiercepharma.com/drug-delivery/urogen-s-rtgel-hopes-remain-high-after-botox-pairing-stumbles-overactive-bladder
1036,"Union, TFF team up to fight COVID-19 with inhaled tapeworm med", https://www.fiercepharma.com/drug-delivery/tff-pharmaceuticals-snares-210m-licensing-pact-union-for-covid-fighting-niclosamide-0
1037,Robotic jaws could replace humans in medicated gum trials, https://www.fiercepharma.com/drug-delivery/robot-jaws-snap-into-future-medicated-chewing-gum-trials
1038,Gilead may struggle to expand remdesivir's COVID market: analyst, https://www.fiercepharma.com/pharma/gilead-may-struggle-to-expand-remdesivir-s-market-to-moderately-ill-covid-19-patients
1039,Lundbeck aims to grow Vyepti in busy migraine prevention field, https://www.fiercepharma.com/pharma/vyepti-launch-lundbeck-aims-to-overcome-challenges-crowded-migraine-field-exec
1040,Fujifilm liposome plant ready to deliver  , https://www.fiercepharma.com/manufacturing/fujifilm-liposome-plant-nearly-ready-to-go
1041,Cost watchdogs take issue with J&J's Spravato price, https://www.fiercepharma.com/pharma/icer-takes-issue-johnson-johnson-s-spravato-price-questions-breadth-data
1042,"Roche, Novartis to debut new version of aging blockbuster Xolair", https://www.fiercepharma.com/marketing/roche-novartis-grab-fda-ok-for-new-version-aging-blockbuster-xolair
1043,New delivery of an old antibiotic nabs first-of-its-kind FDA nod, https://www.fiercepharma.com/pharma/novel-delivery-old-antibiotic-nabs-first-ever-fda-nod-under-new-pathway
1044,Fujifilm building a plant in Japan to produce liposomes, https://www.fiercepharma.com/manufacturing/fujifilm-building-a-plant-japan-to-produce-liposomes
1045,Pain-free patch could boost flu vaccine rates, https://www.fiercepharma.com/vaccines/new-pain-free-microneedle-patch-could-help-boost-vaccination-rate
1046,Nanoparticles alone form 'wave of destruction' against cancer cells, https://www.fiercepharma.com/drug-delivery/nanoparticles-alone-form-wave-destruction-against-cancer-cells
1047,Bayer partners with DelSiTech in ophthalmology drug delivery technology, https://www.fiercepharma.com/drug-delivery/bayer-partners-delsitech-ophthalmology-drug-delivery-technology
1048,Could EpiPen's plastic cap be Mylan's secret weapon?, https://www.fiercepharma.com/drug-delivery/could-a-plastic-cap-epipen-have-given-mylan-its-market-dominance
1049,Carnegie Mellon researchers looking at edible batteries as the next drug delivery system, https://www.fiercepharma.com/drug-delivery/carnegie-mellon-researchers-looking-at-edible-batteries-as-next-drug-delivery-system
1050,Intrexon recruits two startups with drug delivery applications, https://www.fiercepharma.com/drug-delivery/intrexon-recruits-two-startups-drug-delivery-applications
1051,Recipharm inks $205M deal with Indiaâ€™s Kemwell to expand reach, https://www.fiercepharma.com/drug-delivery/recipharm-inks-205m-deal-india-s-kemwell-to-expand-reach
1052,Lonza's potential Catalent buy remains under wraps, https://www.fiercepharma.com/drug-delivery/lonza-s-potential-catalent-buy-remains-under-wraps
1053,"Lilly suffers another FDA snub, this time for lebrikizumab", https://www.fiercepharma.com/pharma/eli-lilly-slapped-third-fda-rejection-2023-time-eczema-treatment-lebrikizumab
1054,Lilly moves to settle whistleblower lawsuit, https://www.fiercepharma.com/pharma/eli-lilly-moves-settle-whistleblower-lawsuit-alleging-trulicity-manufacturing-shortfalls
1055,Hermes earmarks â‚¬25M to expand oral drug production capacity, https://www.fiercepharma.com/manufacturing/hermes-pharma-earmarks-25m-euros-expand-oral-dosage-production-capacity
1056,WuXi plots hundreds of hires at first standalone vaccine plant, https://www.fiercepharma.com/pharma/wuxi-unveils-standalone-vaccines-cdmo-site-china-where-it-plans-employ-more-500
1057,MilliporeSigma christens â‚¬28M pair of mRNA production plants, https://www.fiercepharma.com/pharma/merck-kgaas-milliporesigma-pumps-eu28m-2-new-mrna-production-plants
1058,Pfizer resumes production at tornado-hit plant in North Carolina, https://www.fiercepharma.com/pharma/pfizer-restarts-production-early-tornado-hit-nc-plant-supply-squeezes-are-expected-persist
1059,Ten23 health expands former swissfillon facility in Switzerland, https://www.fiercepharma.com/manufacturing/ten23-health-expands-former-swissfillon-facility-visp-switzerland
1060,Sobi to trim staff as Pfizer contract for hemophilia drug ends, https://www.fiercepharma.com/manufacturing/sobi-trim-staff-pfizer-contract-hemophilia-drug-refacto-ends-early
1061,"Takeda hit with CRL, extending struggles for Natpara", https://www.fiercepharma.com/executives/takeda-hit-fda-complete-response-letter-extending-struggles-its-rare-disease-med-natpara
1062,"Wockhardt, Serum Institute of India to build new UK facility", https://www.fiercepharma.com/manufacturing/wockhardt-serum-institute-india-build-uk-fill-finish-plant-wales
1063,"Macleods recalls drugs to treat high blood pressure, schizophren", https://www.fiercepharma.com/manufacturing/macleods-recalls-drugs-treat-high-blood-pressure-schizophrenia
1064,Catalent finishes $30M expansion project at French site, https://www.fiercepharma.com/manufacturing/catalent-completes-30m-construction-project-french-site
1065,"Indian pharma, US doctor ink deal to build $50M plant in Africa", https://www.fiercepharma.com/manufacturing/indian-pharma-us-plastic-surgeon-reach-deal-build-50m-drug-plant-africa-report
1066,I Peace expansion triples capacity to manufacture iPSC cells, https://www.fiercepharma.com/manufacturing/cdmo-i-peace-expansion-triples-capacity-manufacture-ipsc-cells
1067,Italian vials maker Stevanato acquires plant in China, https://www.fiercepharma.com/manufacturing/more-growth-stevanato-italian-vials-maker-buys-plant-china
1068,Curia inks deal with US agencies to supply injectables, https://www.fiercepharma.com/manufacturing/curia-inks-deal-us-agencies-supply-injectables
1069,"Cytiva opens Welsh production plant, part of $1.5B expansion", https://www.fiercepharma.com/manufacturing/cytiva-opens-welsh-production-plant-part-15b-expansion-plans
1070,Gilead is looking to beef up its manufacturing in California, https://www.fiercepharma.com/pharma/gilead-boost-west-coast-production-after-new-jersey-layoff-round
1071,Lonza completes lab expansion at Chinese API production plant, https://www.fiercepharma.com/manufacturing/lonza-completes-lab-expansion-chinese-api-production-plant
1072,Biopharmas tapping the Tar Heel State's 'limitless' potential, https://www.fiercepharma.com/pharma/eli-lilly-just-latest-tap-tar-heel-state-north-carolina-sees-biopharma-manufacturing-spread
1073,Moderna taps Kenya as site for $500M mRNA manufacturing facility, https://www.fiercepharma.com/manufacturing/moderna-taps-kenya-site-500m-mrna-manufacturing-facility
1074,"Novartis hands over the keys to factories in Canada, Ireland", https://www.fiercepharma.com/pharma/novartis-sells-pair-manufacturing-plants-sandoz-strategic-review-rolls
1075,FDA delays GC Pharma approval of its blood derivative, https://www.fiercepharma.com/manufacturing/fda-upends-gc-pharma-approval-blood-derivative-due-inspection-delay
1076,"With facility upgrades ongoing, Emergent drops guidance by $100M", https://www.fiercepharma.com/manufacturing/emergent-drops-2022-guidance-100-million-says-bayview-maintenance-underway-and
1077,GAO shares recommendations to fix the FDA's oversight abroad, https://www.fiercepharma.com/pharma/fda-must-solidify-plan-for-unannounced-foreign-inspections-rev-up-hiring-overseas
1078,Roche's Genentech cleared for massive HQ expansion, https://www.fiercepharma.com/pharma/roche-s-genentech-cleared-for-massive-headquarters-expansion-to-add-up-to-4-3m-square-feet]
